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1. INTRODUCTION
1.1. A GLANCE TO THE MICROBIAL ECOLOGY HISTORY
Microbial  ecology  is  a  research field  in  microbiology  that  focuses  on the  role  of  microbes  in  the  environment  and their
interactions. It is a significant area of study since prokaryotes are the most abundant form of life on the planet, and has a main
impact in the entire biosphere (Moya et al. 2008, Whitman et al. 1998). 
Anton van Leeuwenhoek, a Dutch tradesman and scientist, was the first observing microorganisms after scraping his
own teeth in 1683, initiating one of the widest fields of biology: microbiology. The Golden Era of microbiology began 200 years
later, mainly by the contributions of Louis Pasteur, Ferdinand Cohn and Robert Koch. The later scientist, known as the father of
modern bacteriology, confirmed through studies in tuberculosis, anthrax and cholera, that microorganisms are causative agents
of disease. He also set the standards for medical microbiology, with his famous postulates that link a specific microorganism
with a specific disease, being essential the isolation and pure culture of the agent. 
A few years later, Martinus Beijerinck, a Dutch microbiologist and botanist, introduced the enriched culture, a medium
with  specific  properties  which allows  the  growth of  particular  microorganisms isolated from the  environment. Beijerinck
together with the Russian microbiologist Sergei Winogradsky, were the pioneers in the study of microorganisms in a physiologic
and ecological point of view. Winogradsky is well-known for discovering the chemosynthesis, the process by which organisms
derive energy through the oxidation of inorganic compounds. 
Later, a main discovery came from the microbial ecologist Robert Edward Hungate when developed the first techniques
for  the  culturing  of  anaerobic  microbes  during  his  studies  on  the  bovine  rumen. From  the  mid-  to  late  20th  century,
enrichment culture of  microorganisms, microscopy and biochemical tests enabled great advances in the study of  microbial
communities. Despite the great contributions derived from culture techniques, an important limitation of these techniques is
the large number of bacteria from several environments that are unable to grow in culture media, a phenomenon known as "the
great plate anomaly" (Staley & Konopka 1985). In fact, it has been estimated that more than 99% of bacteria remain uncultured
(Amann et al. 1995, Eilers et al. 2000).
A breakthrough came by 1980 when the American microbiologist and biophysicist Carl Woese and colleagues proposed
to classify  the life  in three domains (bacteria, archaea and eukarya) using the  small  ribosomal subunit  for a phylogenetic
reconstruction of  the tree of  life  (Woese & Fox 1977). Since then, the 16S rRNA gene (SSU) has been widely used for the
taxonomic affiliation of bacteria (Fox et al. 1980). The develop of polymerase chain reaction (PCR) facilitated the cloning and
sequencing  of  the  rRNA encoding genes  allowing to  describe  the  composition of  mixed communities  without  cultivation
(Giovannoni et al. 1990). In parallel, other methods to explore microbial populations based on the SSU rRNA genes such as
different types of  in situ hybridization and fingerprinting techniques were also developed (Amann et al. 1990, Liu et al. 1997,
Muyzer 1999). 
In  1998, Handelsman  and  collaborators  defined,  for  the  first  time,  metagenomics  as  the  analysis  of  the  collective
genomes (total DNA) that are present in a specific environment (Handelsman et al. 1998). This culture-independent method
opened the doors to describe not only the composition but also the genetic potential and ecological interactions of  whole
microbial ecosystems. 
The usage of  these culture-independent techniques (rRNA-based approaches and metagenomics) has been improved
since the development of new sequencing technologies, which have increased the sequencing depth by orders of magnitude. To
gain more insights, not only in the potential functions but also in activity biomarkers, other meta-"omics" approaches such as
metatranscriptomic  (messenger  RNA), metaproteomic  (proteins)  or  metametabolomic  (metabolites)  were  later  developed
(Zoetendal et al. 2008).
In 2006, the first microbial ecology studies based on pyrosequencing (454 platform) were reported and since then, a
variety of  microbial communities have been explored such as  those living in marine water, soils, the bovine rumen or the
human gut (Brulc et al. 2009, Qin et al. 2010, Roesch et al. 2007, Sogin et al. 2006). Nowadays, several projects to study the
ecology of microbial communities are ongoing. As a consequence, a lot of information is being generated and the scientific
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community is currently investing much effort in the development of bioinformatics tools for the ecological analyses. Several
programs, databases and websites are now involved in dealing with the huge amount of data that microbial ecologists produce
from their research (Robinson et al. 2010).
1.2. OVERVIEW OF THE HUMAN MICROBIOTA
Bacteria have inhabited Earth from at least 2.5 billion years and are the most abundant organisms on the biosphere (Brocks et
al. 1999, Whitman et al. 1998). Thus, our predecessors adapted to live in a microbial world. Indeed, it has been described that
animals  have carried  resident microorganisms since  at  least  the  emergence of  sponges  (Hoffmeister  & Martin  2003). The
vertebrate-associated bacterial communities have a diversity pattern very different of the free-living communities from marine,
terrestrial  or  freshwater environments. This  suggests  that  co-evolution over hundred millions years  has  selected a  specific
community of microbes adapted to the stable environment which is the human body (Ley et al. 2008b).
The human body harbours complex microbial communities (defined as microbiota) with ~ 10 14 microbial symbionts,
outnumbering the human cells by at least 10-fold (Savage 1977). The collective genomes of our indigenous microbes is defined
as the microbiome and their total number of genes also exceeds those of the human genome. The majority of microorganisms
and the largest diversity is found in the intestinal tract, which contains in average 10 12 cells per gram of faeces and around 100-
fold more genes than the human genome (Hooper & Gordon 2001, Savage 1977, Yang et al. 2009). Moreover, the microbiome
variability between individuals is huge compared to the human genome variation. The human genome is about 99.9% similar
among individuals, but can be 80-90% different in terms of the microbiome (values obtained from gut and skin studies) (Ursell
et al. 2012). 
The traditional idea that all microorganisms are parasitic, causing disease, has changed to a non-pathogenic vision of
microbe-host interactions, being most of the relationships described as commensals (one partner is benefited and the other
remains  unharmed)  or  mutualists  (both  partners  benefit)  (Dethlefsen  et  al.  2007).  The  human-associated  microbial
communities benefit the host in different ways, being the best known those performed by the gut microbiota. Our intestinal
symbionts participate in food digestion, energy metabolism, development and maintenance of the immune system, synthesis of
vitamins, renewal of  gut epithelial cells or pathogen resistance, among others  (Backhed et al. 2004, Hattori & Taylor 2009,
Hooper 2004, Leser & Molbak 2009, Montalto et al. 2009). On the other hand, the intestinal microbial residents benefit from
stable growth conditions and constant source of nutrients (Savage 1977). 
Microbes associated with the human body include mainly bacteria which comprise the bulk of biomass, but archaea,
viruses, and eukaryotes are also present (Breitbart et al. 2008, Eckburg et al. 2005, Marchesi 2010). The bacterial diversity of the
human body  shows  a  limited  number  of  phyla  but  a  high  richness  at  strain  and  species  levels.  In  free-living  microbial
communities of environments such as soil or water, it has been found more than 50 bacterial phyla, but only 4 are dominant in
the human microbiota: Firmicutes, Bacteroidetes, Actinobacteria and Proteobacteria (Aas et al. 2005, Eckburg et al. 2005, Gao et
al. 2007, Ley et al. 2008b, Pei et al. 2004). Thus, the diversity pattern of the human microbiota is the result of strong selective
forces along the co-evolution time of the microbial communities and the host and each individual presents at species and strain
levels a unique microbiota (Blaser & Falkow 2009, Dethlefsen et al. 2007, Eckburg et al. 2005, Ley et al. 2008b) (Figure 1.1).
Microbial habitats are found mainly in the skin surfaces, the eyes, the respiratory, the urinary and the reproductive
systems, the oral cavity, and the gastrointestinal tract (GIT), being the most diverse the mouth and the gut (Wilson 2008). Each
site has its own physicochemical and biologic features and thus, it presents a specialized set of microorganisms (Dethlefsen et al.
2007). In this regard, it has been described that the differences along time within a specific habitat are smaller than between
habitats and that also stable inter-individual differences are found between body sites  (Caporaso et al. 2011, Costello et al.
2009). 
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Figure 1.1. Patterns of diversity of human-associated microbial
communities. a. Lineage-by-distance analysis of 16S rRNA gene
sequences  from  human  microbial  communities  in  specific
habitats. b. 16S rRNA gene-based patterns of microbial diversity
displayed  as  dendograms.  In  soil  and  aquatic  environments,
they generally resemble the tree shape on the left,   with new
branches arising at all distances from the root. In invertebrate-
associated communities, they resemble  the tree shape on the
right,  with  few branches  arising  close  to  the  root  and  many
branches  arising  close  to  the  branch  tips  (Adapted  from
Dethlefsen et al. 2007).
1.2.1. THE SKIN
The  human skin  harbours  a  complex  microbial  ecosystem, which  is  affected  by  environmental  factors  such as  humidity,
temperature or light exposure and host factors as immune status, gender, genotype, hygiene habits, or cosmetic use (Fredricks
2001, Roth & James 1988). The microbial communities of the skin live in a wide range of physiologically and topographically
niches and protect against the invasion of harmful organisms  (Grice & Segre 2011). The first molecular study based on 16S
rRNA gene analysis  was performed by Gao and colleagues, being Actinobacteria, Firmicutes and Proteobacteria  the major
observed phyla (Gao et al. 2007). They found no differences between regions of the body with the same properties, while large
variations  over  time  and  between  individuals  were  observed.  A  more  recent  study  of  20  skin  sites  also  showed  that
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physiologically comparable sites harbour similar bacterial communities and that the diversity and stability are dependent on
specific characteristics of the site (sebaceous, moist or dry). It was also described that the stability of the skin microbiota over
time is site-dependent. In general, the most abundant species of the skin belonged to Corynebacterium and Propionibacterium
genera (Actinobacteria phylum), followed by Staphylococcus (Firmicutes phylum) (Findley et al. 2013, Grice et al. 2009). 
Little is known about the functional potential of our skin microbiome. Until now, metagenomic studies of human skin
have not been reported, mainly by the critical amount of  starting material, host  DNA contamination, or lack of  reference
genomes for skin isolates  (Grice & Segre 2011). The development of new methods to solve some of these issues will allow a
functional characterization of our skin microbiota and its role in health and disease.
1.2.2. THE EYE
The ocular surface is continually exposed to the environment and, as a consequence, to several types of microbes throughout
life. Several studies based on cultivation techniques have shown that the most common bacteria isolated from the conjunctiva,
lids  or  tears  belong to  the  genera  Staphylococcus (Firmicutes),  Propionibacterium and  Corynebacterium (Actinobacteria)
(Willcox 2013). 
The first non-cultivable molecular studies of the ocular surface have identified other taxa in addition to those obtained
by  cultivation,  mainly  Bacillus,  Streptococcus (both  Firmicutes),  Rhodococcus (Actinobacteria),  Bradyrhizobium,
Acinetobacter,  Brevundimonas,  Aquabacterium,  Sphingomonas,  Pseudomonas and  Klebsiella (Proteobacteria)  (Dong et  al.
2011a, Graham et al. 2007). 
Moreover,  the  composition  of  the  eye  microbiota  seems  to  be  extremely  variable  between  individuals,  with  some
individuals colonized by diverse types of microbes and others by a narrow spectrum of them (Lee et al. 2012). 
Since the eye-associated microbiota has been poorly studied, little is known about their possible role in human health.
The human tears contain a diverse range of  antimicrobial components and molecules of  the innate and adaptive immune
system (McDermott 2013). Thus, it is possible that the role of eye microbial communities could be related to protection against
pathogens by stimulating human defense systems (Willcox 2013). 
In addition, the ocular microbiota composition is affected by external factors as the use of contact lenses and its effect
may vary depending on the length of lens wear, the type of polymer of which they are made or the frequency of use (Fleiszig &
Efron 1992, Iskeleli et al. 2005, Larkin & Leeming 1991, Willcox 2013). 
Further research would clarify the existence of a normal ocular surface microbiota, its acquisition mode or its changes
associated to pathologies as pathogen invasions associated to the use of contact lenses (Stapleton et al. 1995).
1.2.3. THE RESPIRATORY SYSTEM
The respiratory system supplies oxygen and removes carbon dioxide from the blood. It consists of the respiratory tract for air
conduction, a respiratory membrane for gaseous exchange and a ventilator mechanism for delivering gases to and from the
respiratory membrane. The respiratory tract is divided into the upper (nose and pharynx) and the lower tract (larynx, trachea,
bronchi,  bronchioles,  alveolar  ducts,  alveolar  sacs  and  alveoli),  being  the  upper  tract  the  main  area  populated  by
microorganisms (Wilson 2008). Given that bacteria present in the respiratory tract cannot be cultivated, it was supossed that
airways were sterile. Recently, several works have shown not only the presence of bacteria in the airways, but also an association
of specific bacterial load and composition with health and disease status (Marsland et al. 2013). 
Charlson  and  colleagues,  by  means  of  molecular  analyses  (16S  rRNA  quantitative  PCR  and  pyrosequencing),
characterized multiple sites along the respiratory tract, showing a microbiota that decreases in biomass from the upper to the
lower  tract,  but  with  a  similar  phylogenetic  composition  (Charlson  et  al.  2011).  The  predominant  families  of  the
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nasopharyngeal niche are Staphylococcaceae (Firmicutes), Propionibacteriaceae and Corynebacteriaceae (both Actinobacteria),
being  similar  to  the  skin  composition, while  the  oropharynx showed a composition closer  to  that  of  the  gastrointestinal
microbiota (Firmicutes, Proteobacteria and Bacteroidetes phyla) (Charlson et al. 2011, Lemon et al. 2010). 
Cigarette smoke is the main factor for chronic obstructive pulmonary disease, which is one of the major chronic airway
diseases. Smokers  present  greater  variation in the  type  and relative abundance of  bacteria  for both sites, oropharynx and
nasopharynx, than non-smokers. The altered microbiota associated to cigarette smoking may facilitate pathogen colonization of
the upper respiratory tract (Charlson et al. 2011). Generally, a greater diversity has been associated with health conditions of the
respiratory system (Blainey et al. 2012, Erb-Downward et al. 2011, Hilty et al. 2010).
Sampling the upper respiratory tract is by far easier compared to the lower respiratory tract. It remains to be proven if
the microbes detected on the lower respiratory tract are resident or transient that were inhaled from the upper tract, a possible
contamination from the oropharynx in the collection of samples, or individuals incorrectly categorized as healthy  (Huang &
Lynch 2011).
Recent studies suggest that shifts in airway microbiome could be associated with chronic airway diseases such as allergy,
asthma, chronic obstructive pulmonary disease or cystic fibrosis. It is still unknown if the changes are the main cause of disease
or a consequence of inflammation, but the association suggests a microbe-host cross talk whose functional consequences need
to be addressed (Marsland et al. 2013). 
Pioneer studies in mice suggest a positive role of the airway microbiota in differentiation, maturation and regulation of
immune system cells, antiviral immunity, and inflammatory responses (Abt et al. 2012, Herbst et al. 2011, Larsen et al. 2012,
Olszak  et  al.  2012). Since  this  field  is  quite  recent, future  research  will  help  to  address  the  establishment  of  the  airway
microbiota, as well as its role in health and disease. 
1.2.4. THE URINARY SYSTEM
The  urinary  system is  responsible  for  the  removal  of waste  products  of  metabolism  and  the  regulation  of  the  chemical
composition, volume and pressure of body fluids. The system consists of two kidneys, two ureters, a bladder and a urethra.
Historically, urine has been considered sterile, nevertheless urine (representing the bladder microbiota) contains several bacteria
which are not cultivated but that have been described by 16S rRNA gene sequencing (Nelson et al. 2010, Siddiqui et al. 2011). 
The microbiota of urinary system is mainly dominated by Firmicutes, but there are also large differences between sexes
regarding the presence and abundance of many of the genera. For instance, male show a lack of members from Actinobacteria
and Bacteroidetes that are present in females (Lewis et al. 2013, Nelson et al. 2010, Siddiqui et al. 2011). 
The female microbiota of the urinary system shares some bacterial members with the vaginal microbiota and with the
male urogenital tract (Dong et al. 2011b, Ling et al. 2010). The most abundant genera are Lactobacillus (Firmicutes), Prevotella
(Bacteroidetes) and  Gardnerella (Actinobacteria), but a  high inter-individual  variation in the community structure is  also
present  (Siddiqui  et  al. 2011). In general,  the  urine microbiota from males  and females  overlaps in composition to other
microbial  communities  found  in  the  superficial  skin,  colon  or  vagina,  being  the  predominant  genera:  Lactobacillus
(Firmicutes), Corynebacterium (Actinobacteria), Streptococcus (Firmicutes) and  Sneathia spp. (Fusobacteria)  (Eckburg et al.
2005, Gao et al. 2007, Ling et al. 2010). There is a substantial inter-individual variation in the urine microbiome of males even at
the phylum level and greater that in female (Nelson et al. 2010). 
1.2.5. THE REPRODUCTIVE SYSTEM
The female reproductive system consists of the ovaries, fallopian tubes, uterus, cervix vagina and the vulva. The cervix, vagina
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and vulva are those organs colonized by microbial communities, being the vaginal ecosystem the most extensively studied. 
The indigenous  microbiota  of  the  vagina  plays  a  role  in  protecting  against  colonization  by  pathogenic  organisms,
including those related to symptomatic bacterial vaginosis, sexually transmitted infections and urinary tract infections (Gupta
et al. 1998, Hillier et al. 1992, Wijgert et al. 2000). 
The genus  Lactobacillus has been considered as a keystone of  the vaginal microbial community in reproductive-age
women and prevents colonization by potentially harmful microorganisms, through the lactic acid production which results in a
low protective pH (Boskey et al. 1999). Also, some Lactobacillus species has an antimicrobial action including the production of
target-specific bacteriocins and broad-spectrum peroxidases, which also contribute to fight pathogen invasion (Eschenbach et
al. 1989). Its importance is emphasized by the fact that disruption of the equilibrium of the normal vaginal microbiota can
trigger a bacterial vaginosis which is a highly prevalent disorder in reproductive age women (Ravel et al. 2013, Srinivasan et al.
2012). Species of  the  Lactobacillus genus are dominant in the majority  of  healthy women, but a diverse group of  strictly
anaerobic microorganisms has also been found in high abundance in some women (Ma et al. 2012, Ravel et al. 2011).
The microbial communities of the vagina show different behaviour among women by changing markedly on some of
them over short  periods of  time, while  on others  are relatively  stable  along time  (Ma et  al. 2012). Moreover, the  vaginal
microbiota changes continuously along woman life, from childhood to puberty, during the reproductive years and menopause
with several factors influencing the composition and stability of the ecosystem, mainly the menstrual cycle and sexual activity.
Thus, this ecosystem is a result of adaptive co-evolutionary processes integrating host physiology and sexual hormone levels
with the composition and functions of the microbial community. 
The genital microbiota of male is present in the lower male genital tract, mostly in the urethra and coronal sulcus. The
microbial composition of the urogenital tract has been characterized in the previous epigraph (1.2.4. The urinary system). The
upper genital tract (including prostate tissue and vas deferens) is generally germ-free except in case of infections, as prostatitis
(Mändar 2013). 
 The male genital microbiota has an impact on the microbiota of the reproductive system of females, promoting an
increase  of  vaginosis  probability,  although  contradictory  results  have  been  found  (Mändar  2013).  Future  studies  will  be
required to study the interaction between the male and female genital  microbiota and its  relationship to diseases  such as
vaginosis that represents a high cost for public health.
1.2.6. THE ORAL CAVITY
The oral cavity is the entrance to the GIT and consists of a complex system of tissues and organs mainly involved in selecting
and processing the food into a suitable form for passage into the rest of the GIT (Wilson 2008).
After the gut, the oral cavity constitutes the second most complex habitat of the human body with around 1000 species
of bacteria present (Dewhirst et al. 2010, Human Microbiome Project Consortium 2012). Based on the taxonomic composition,
three distinct bacterial communities have been identified in different areas of the oral cavity: the buccal mucosa, gingivae and
hard palate (first group), saliva, tongue, tonsils and throat (second group) and supra- and sub-gingival plaque (third group)
(Segata et al. 2012). 
The bacterial  community of  the mouth is  dominated by Firmicutes, Bacteroidetes, Proteobacteria, Spirochaetes and
Fusobacteria  (Dewhirst  et  al.  2010).  At  genus  level,  Actinomyces  (Actinobacteria),  Streptococcus (Firmicutes),  Neisseria
(Proteobacteria),  Veillonella (Firmicutes),  Porphyromonas (Bacteroidetes),  Granulicatella (Firmicutes),  Corynebacterium
(Actinobacteria),  Rothia (Actinobacteria) and  Fusobacterium (Fusobacteria) are predominant in a healthy oral  microbiota
(Zarco et al. 2012). It has been proposed that one of the most important roles of the oral microbiota is to avoid infections by
opportunistic  pathogens such as  Staphylococcus aureus  or Candida  species, mainly by competing for binding to host  cell
receptors (Jenkinson & Douglas 2002).
Poor oral hygiene is greatly responsible for accumulating plaque will lead to overgrowth of  some bacteria that may
become pathogenic, reducing the  biodiversity  of  the oral  cavity, and ultimately  causing two of  the  most common human
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pathologies: the dental caries and the periodontal diseases  (Wade 2013, Zaura et al. 2009). The microbiota of  dental caries
shows a taxonomic and functional composition that differs to the normal microbiota with a lower microbial diversity and a
lower presence of some protective functions as antimicrobial peptide production or quorum sensing, among other differences
(Belda-Ferre et al. 2012).
1.3. THE GUT MICROBIAL ECOSYSTEM
The digestive system consists in the GIT and the accessory digestive organs (teeth, tongue, salivary glands, liver, gallbladder and
pancreas). Its  main function is  to process the food by breaking down the dietary compounds in small  molecules that are
absorbed and distributed throughout the body (Wilson 1998). The human gut is anatomically divided in different sections: the
oral cavity, esophagus, stomach, small intestine (divided in duodenum, jejunum, and ileum), cecum, colon or distal gut (divided
in ascending, transverse and descending colon) and rectum. 
1.3.1. COMPOSITION, DIVERSITY AND SOURCES OF VARIATION OF THE GUT MICROBIAL COMMUNITIES
The GIT is colonized by a wide variety of microorganisms and each section harbours a specific microbial community according
to the properties of the compartment. The number of microorganisms and the complexity increase from the stomach to the
rectum, being the colon the most densely populated region with up to 1012  bacteria per gram of luminal material  (Leser &
Molbak 2009, Marchesi 2011, Whitman et al. 1998) (Figure 1.2). 
The digestion process starts in the mouth with the mechanical and enzymatic digestion. The microbial communities of the oral
cavity share high levels of diversity as well as phyla composition (Actinobacteria, Bacteroidetes, Firmicutes, Proteobacteria) with
other compartments of the GIT (Marchesi 2010) (detailed description of the oral cavity in the epigraph 1.2.6). 
Moving down the gut we found the throat and esophagus, whose microbial communities have been less explored than
those from other areas of the human body. The few conducted studies have shown Firmicutes, Bacteroidetes, Actinobacteria,
Proteobacteria, Fusobacteria and candidate division TM7 as the most abundant phyla. The throat harbours a stable microbial
ecosystem with a high similarity between individuals and a low diversity (at phylotype level) compared to other regions of the
GIT. The dominant genera for both, esophagus and throat, are Streptococcus (Firmicutes) and Prevotella (Bacteroidetes), but
Actinomyces  (Actinobacteria),  Gemella  (Firmicutes),  Rothia  (Actinobacteria),  Granulicatella  (Firmicutes),  Haemophilus
(Proteobacteria) and Veillonella (Firmicutes) are also present (Andersson et al. 2008, Pei et al. 2004). 
The food passes from the esophagus to the stomach where it is performed the next part of digestion after chewing: the release of
gastric acid and proteases. This organ is a markedly different habitat to the oral cavity or the intestine, with a strong selective
pressure due its low pH (1-2 in adult humans) and other antimicrobial factors. Used to be thought that due these extreme
conditions, a very low (or any) significant microbiota inhabits the stomach, except the opportunistic pathogen  Helicobacter
pylori. However, Bik and collaborators (2006) reported the presence of a microbiota mainly distributed over the most abundant
phyla  of  the  GIT:  Proteobacteria,  Firmicutes,  Bacteroidetes,  Actinobacteria,  and  Fusobacteria  (in  decreasing  order  of
abundance), although the biomass and microbial diversity is lower than in highly populated regions of the GIT as the oral
cavity or the lower intestine. The most common genera described on the human stomach are  Caulobacter (Proteobacteria),
Actinobacillus (Proteobacteria), Corynebacterium (Actinobacteria), Rothia (Actinobacteria) and Gemella (Firmicutes).
The composition of the stomach microbiota is highly variable between individuals, even for the most abundant taxa.
This variability could be due to the acid in the stomach that kills many microbes derived from the esophagus and from the
ingested food, frequently reshaping the resident and transient microbial populations there present. 
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Figure 1.2. Overview of the gastrointestinal tract, main bacterial phyla and their abundance in each
region (Adapted from Marchesi, 2011). 
Moreover, the infection by  H. pylori, which is well known as the agent causing of gastritis, has been associated to an
extremely low diversity of the stomach microbial ecosystem, since during infection the pathogen can constitute the 93%-97% of
the total community (Andersson et al. 2008, Bik et al. 2006).
Most of the digestion and absorption of food take place in the small intestine which comprises duodenum, jejunum and
ileum. The small intestine presents a large absorptive surface area of epithelium due to the villi (finger-like projections from the
epithelial lining) and the microvilli (microscopic cellular membrane protrusions). The epithelium is covered by mucus layers
which act as a mechanical barrier that separates the luminal bacteria from the epithelium. 
The food passes from the stomach to the duodenum where is blended with bile, bicarbonate and digestive enzymes. In
healthy  humans  the  intestinal  content  (chyme)  passes  from the  duodenum  to  the  ileum  in  1-4  hours  and  the  bacterial
populations increase from 104 to 108 bacteria per ml of intestinal content (Laux et al., 2005). In the small intestine the bacteria
deconjugate bile and produce vitamins and amino acids for the host (Conly & Stein, Tannock et al. 1994, Torrallardona et al.
2003). 
The bacterial community in duodenum and jejunum are strikingly different from that in distal ileum, with a lower
diversity and a dominance of  Streptococcus species which are acid-tolerant bacteria. For its part, the ileum is dominated by
Bacteroidetes and Clostridium clusters XIVa and IV (Firmicutes) and the composition is more similar to that of  the large
intestine (Wang et al. 2005). Moreover, biopsies from different regions have revealed that the mucosal microbiota of the small
intestine  is  dominated  by  the  phyla  Bacteroidetes,  Firmicutes,  Proteobacteria,  Actinobacteria,  Fusobacteria  and
Verrucomicrobia  and  the  most  common genera  are  Streptococcus (Firmicutes),  Veillonella (Firmicutes)  and  Clostridium
(Firmicutes) (Marchesi 2010, Wang et al. 2003, 2005).
The transit time in the large intestine (cecum, colon and rectum) is the largest of the digestion process, ranging from 10
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hours to various days. The dietary compounds that are not degraded in the upper GIT reach the large intestine supporting the
microbiota with nutrients and energy for longer time, which explains why it is the most heavily colonized area of the GIT. Even
the great biomass of bacteria in the large intestine, only seven phyla (common to other regions of the GIT) have been found
(Bacteroidetes,  Firmicutes,  Proteobacteria,  Actinobacteria,  Fusobacteria,  Verrucomicrobia  and  Cyanobacteria),  being
Bacteroidetes and Firmicutes the great majority (more than 95% of the total bacteria) (Eckburg et al. 2005). However, a large
diversity has been found at lower phylogenetic levels, with more than 1000 species (Claesson et al. 2009, Rajili -Stojanovi  et al.ć ć
2009). The bacterial composition in the mucosal community is very similar along the large intestine. On the other hand, there is
a high inter-individual and a low intra-individual variation in the bacterial community structure of the gut (Ahmed et al. 2007,
Eckburg et al. 2005, Green et al. 2006). 
Some  of  the  most  prevalent  and  abundant  genera  in  human  gut  are  Faecalibacterium,  Roseburia, Ruminococcus,
Eubacterium,  Dorea, Blautia, Coprococcus (Firmicutes),  Bacteroides, Alistipes, Parabacteroides  (Bacteroidetes)  and
Bifidobacterium (Actinobacteria) (Arumugam et al. 2011, Tap et al. 2009). It has been attempted to identify a species core in the
adult microbiota, being important Faecalibacterium prausnitzii, Roseburia intestinalis or Bacteroides uniformis, but even these,
can be in relative abundances lower than 0.5% in some individuals  (Lozupone et al. 2012, Qin et al. 2010, Turnbaugh et al.
2009). Thus, the inter-subject variation has not allowed to properly defining a core microbiota, except the fact that Bacteroidetes
and Firmicutes are the main phyla  (Lozupone et al. 2012, Marchesi 2011). However, a large metagenomic study (33 faecal
samples) determined three clusters of the human gut composition, designated as enterotypes, based on phylogenetic profile
similarities. The enterotypes are mainly driven by groups of co-occurring species with a high representation of  Bacteroides
(enterotype 1),  Prevotella (enterotype 2) and  Ruminococcus (enterotype 3) genera  (Arumugam et al. 2011). Similar clusters
have been found in other two data sets (16S rRNA data from 154 individuals from the United States and metagenomes from 85
individuals from Denmark), but other three data sets failed to show the same pattern (98 adults from the United States, 531
individuals from Malawi, Venezuela and Unites States and 250 adults from the United States)  (Qin et al. 2010, The Human
Microbiome Project  Consortium, 2012 Turnbaugh et  al.  2009, Wu et  al. 2011, Yatsunenko et  al. 2012) . Nevertheless, the
variation of these last populations (in the adults) was associated to a trade-off between Bacteroides and Prevotella that seems
important for the microbiota equilibrium (Lozupone et al. 2012). Therefore, the enormous variation of the microbiota between
individuals, introduced by genotype, age, diet, health status and geographic locations, makes difficult the classification into a
limited number of types and it is something to be considered for human gut studies.
Along the GIT two mucus layers have been identified: one firmly attached to the epithelium (known as the inner layer)
and other  less  adherent  facing  the  intestinal  lumen (known as  the  outer  layer). However, the  bacteria  are  not  uniformly
distributed in the layers, being the outer densely populated, while bacteria are absent in the inner layer  (Atuma et al. 2001,
Johansson et al. 2010). The major component for both layers is the highly glycosylated Muc2 mucin, which is secreted by goblet
cells of the epithelium and forms a net-like polymer. The inner mucus is dense, thus protecting epithelial cells from bacterial
invasion.  For  its  part,  the  O-glycans  of  the  outer  layer  serve  as  nutrients  and  attachment  sites  for  commensal  bacteria
(Johansson et al. 2011). Bacteria use the energy obtained from mucin degradation for their own use, but as a result produce
short-chain  fatty  acids  (SCFA)  that  are  used  by  colonocytes  as  a  source  of  energy,  maintaining  a  balance  between
microorganisms and host (Louis et al. 2007). 
Faeces are the waste product of the digestion process and are expelled through the anus. Most of the studies of the gut
microbiota are based on faecal material since its collection is a simple and non-invasive method, but bacteria from the stool
(human faeces) are not entirely representative of the mucosal microbiota. In fact, some studies have shown that the microbiota
attached to the mucosa is significantly different to that of the faeces, since the mucosal-associated bacteria are between 4-6
orders of magnitude more abundant than the luminal bacteria, which constitute the major fraction of bacteria carried on the
faeces. Thus, a lower diversity and the absence of some bacterial groups are typical of faeces respect to biopsies (Durbán et al.
2011, Eckburg et al. 2005). Therefore, even though the stool is a good approximation to study the gut microbiota, it is important
to be cautious when extrapolating what is observed in faeces to what is occurring in the gut.
Most of the studies about microbial communities of the human gut are limited to bacteria due to they constitute the
great  majority. The domain Archaea has  been identified in the  human microbiota, being  Methanobrevibacter  smithii and
Methanosphaera  stadtmanae  the  most  common  species  in  the  distal  gut,  both  from  the  Methanobacteriaceae  family
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(Euryarchaeota phylum)  (Dridi et al. 2011, Eckburg et al. 2005, Scanlan & Marchesi 2008). These microorganisms through
methane  production  play  a  role  in  removing  the  H2 produced  from  the  polysaccharides  fermentation.  Otherwise,  H2
accumulation would reduce the efficiency of processing the dietary carbohydrates (Gill et al. 2006).
Much of the work undertaken on the eukaryotic communities has been based on culture-based approaches and found as
the most abundant the fungi  Candida and  Saccharomyces spp. (both Ascomycota). On the other hand, culture-independent
approaches based on 18S rRNA genes show that  Blastocystis spp. is one of  the main eukaryotes of  the human gut. Like in
bacteria where a reduced diversity is found at deep phylogenetic levels (phylum), a few dominant lineages of eukaryotes (fungi
and Blastocystis) are adapted to the gut environment. The eukaryotic communities are also stable across time and unique to
individuals (Parfrey et al. 2011, Scanlan & Marchesi 2008). 
The viral component of the gut habitat has received little attention, however its number is at least an order of magnitude
higher than bacterial number in the distal gut. The first culture-independent studies showed the Siphophage group of viruses as
the majority (Breitbart et al. 2003, 2008). Latest, Reyes and colleagues characterized the total virus-like particles isolated from
human faecal samples and they found that around 25% of viral genomes were phages and prophages, most of them of double-
strand-DNA type  and members  of  Caudovirales  order. The intra-individual  variation along the  time of  the  viromes  was
minimal,  in  contrast  to  the  inter-individual  that  was  extremely  high  (Minot  et  al.  2011,  Reyes  et  al.  2010).  This  high
interpersonal variability of human gut viruses may be derived of two sources: the persistence of small portion of the virome
over time and the rapid evolution of specific long-term viral residents within the gut (Minot et al. 2013). A substantial portion
of the phages in human gut seem to be temperate, so that the genes within phage may alter phenotype of the bacterial host by
lysogenic conversion, which may be significant in the functioning of the whole ecosystem (Minot et al. 2011). Recently, the most
abundant bacteriophage of human faeces, named crAssphage, has been described, and a Bacteroides host was predicted for it
(Dutilh et  al. 2014). Viruses are critical  components of  the gut ecosystems, helping in controlling the  growth of  bacterial
populations and protecting mucosal surfaces (Barr et al. 2013). 
Further investigation will be necessary to clarify the role of this less known fraction (eukaryotes, archaea, viruses) in
the gut ecosystem, as well as, their interactions with other members of the microbiota and with the host. 
Then,  the  gut  microbiota  of  adult  human  individuals  is  unique  and  stable  along  the  time  (in  the  absence  of
disturbances), and the composition is influenced by several deterministic factors such as host genetics, diet or health status and
also by stochastic events (Durbán et al. 2012a, Zoetendal et al. 1998).
1.3.1.1. HOST GENOTYPE
The host genotype contributes to explain the inter-individual variation observed on the human gut microbial composition.
Research based on dependent and independent cultivation techniques have shown that in humans there is a positive correlation
between the genetic grade of individual’s relatedness and the similarity of the microbial composition, being maximum in the
case of monozygotic twins (Merwe et al. 1983, Stewart et al. 2005, Turnbaugh et al. 2010). The issue is that in human microbiota
investigations, several environmental factors as diet, age, or health status make difficult to evaluate the exact contribution of the
host genotype to the microbial variation among individuals. The closest approximation so far is based on mouse studies under
controlled environmental conditions, where it  has been shown that host genotype effects are distributed across all  the gut
dominant taxa, and that genomic traits can influence the abundance of specific microbial groups and have pleiotropic effects on
different taxa (Benson et al. 2010). 
Regarding  specific  genetic  effects  on  the  gut  microbiota,  studies  on  mouse  model  have  revealed  that  the  faecal
composition is mainly affected by polymorphisms of  immune system genes  (Toivanen et al. 2001). Besides the impact of
immune system, differences on genes involved in the epithelial barrier function (availability of attachment sites) also influence
the community structure (Dethlefsen et al. 2006, McKnite et al. 2012). 
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1.3.1.2. HOST AGE
After birth, a bacterial succession starts that lasts until the establishment of an adult microbiota within the first two years of life
(Koenig et al. 2011, Palmer et al. 2007, Vallès et al. 2014). Newborns acquire their microbiota initially from the mother and from
the environment they are exposed. The composition of  meconium samples suggests that the mother is the first important
microbial source of the fetus gut during the intrauterine life (Gosalbes et al. 2013). The colonization of the gut microbiota in
early years is influenced by several factors, as maternal microbiota, diet (breast or formula fed), mode of delivery (normal vs.
cesarean), gestation (full or preterm) or antibiotic intake (Biasucci et al. 2010, Dominguez-Bello et al. 2010, Favier et al. 2003,
Morowitz et al. 2011, Palmer et al. 2007). All these factors contribute to explain the uniqueness of the gut microbiota of early
years and also to determine the adult microbiota. The first days of life are characterized by a microbiota dominated by one or
two taxonomic groups, but the diversity is increasing as time progresses and the ecosystem structure converges to an assembly
characteristic of  adults  (Favier  et  al. 2002, Palmer et  al. 2007, Vallès et  al. 2014). The adult  gut community shows limited
variations over extended periods in the absence of disturbances, except by fluctuations of minor bacterial groups (Durbán et al.
2012a, Robinson et al. 2010). In old age, the microbiota undergoes extreme changes and the structure is substantially different
from that of younger people, with a higher variability among individuals and unusual proportions of the main phyla (Claesson
et al. 2011). 
1.3.1.3. DIET
Diet is one of the main determinants of the gut microbiota composition since birth. In fact, the faecal microbiota of infants is
strongly affected by the transitions between breast milk, formula and solid food (Favier et al. 2002, Harmsen et al. 2000, Vallès et
al. 2014). The gut microbial  composition depends on different dietary habits. For instance, children from a rural  African
population with a diet enriched in fiber presented a gut microbiota that had co-evolved with the host to maximize energy intake
from plant polysaccharides producing SCFAs that also protect them from inflammation. On the other hand, a less diverse
microbiota with a lower presence of beneficial members was found in European children as a consequence of a diet enriched in
fat, protein and sugars. The consumption of these type of food are rapidly limiting the adaptive potential of our gut microbiota,
thus contributing to explain the great increase in the incidence of intestinal diseases in developed countries (Filippo et al. 2010).
A study on adult humans under different controlled diets has shown that  diet-driven changes occurred rapidly, being
detectable  within  3–4  days  (Walker  et  al.  2011).  Also,  the  short-term  consumption  of  diets  with  different  nutritional
composition alters microbial community structure in dependence on the components of the diet. Animal-based diets increase
the abundance of bile-tolerant microorganisms (as  Alistipes,  Bilophila and  Bacteroides), while plant-based diets increase the
levels  of  Firmicutes  that  metabolize  plant  polysaccharides  (as  Roseburia,  Eubacterium rectale and  Ruminococcus  bromii)
(David et al. 2013). Moreover, the gut microbiota of adults has the ability to return to its original composition after short-term
dietary changes (Durbán et al. 2013). 
A large study of mammals and their gut microbiota shows that phylogeny and host diet have influenced significantly the
structure of the gut microbiota along their co-evolution time. A same type of diet (herbivore, omnivore or carnivore) has leaded
to a microbial assembly with common features between different phylogenetic groups (Ley et al. 2008a). 
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1.3.1.4. MICROBIAL INTERACTIONS
Microbial interactions are important determinants of intestinal niche's ecology and contribute to increase the diversity and the
variability between individuals  (Day et al. 2003, Freter 1983, Savage 1977). For example, the interspecific cooperation that
occurs during metabolism of dietary fiber and the subsequent fermentation of the monosaccharides involve diverse bacterial
groups that are metabolically connected in a complex way, contributing to determine the assembly of the intestinal microbiota
of  individuals.  Also,  microbial  competition  through  different  mechanisms  as  the  production  of  toxic  metabolites  or
antimicrobial compounds (as bacteriocins), induces complex population dynamics that generate different patterns of diversity
between  individuals  (Dethlefsen  et  al.  2006,  Flint  2004,  Fons  et  al.,  2000).  Moreover,  interactions  (as  cooperation  or
competence) between microorganisms in the gut ecosystem can complicate the responses to external factors as dietary changes
or medication, leading to greater inter-individual variability. 
1.3.1.5. STOCHASTIC EVENTS
The gut microbiota of  healthy adults is claimed to be stable in the absence of  disturbances, mainly because the temporal
variability  is  smaller  than  the  inter-individual  differences,  but  stochastic  processes  as  colonization  history,  bacteriocin
production or phage dynamics, may explain the differential dynamics of some bacterial groups among individuals (Dethlefsen
et al. 2006). 
The  order  of  colonization  and  establishment  of  the  gut  after  birth  is  a  probabilistic  process  that  depends  on  the
environmental origin of the microbial sources, as well as the retention in the colon via attachment to mucus, or to particles in
the lumen (Freter et al. 1983, Sonnenburg et al. 2004). Since there is a wide repertoire of bacteria adapted to live in the gut
environment and a high functional redundancy, different assemblies are possible to persist over time (Dethlefsen et al. 2006). 
An  important  source  of  variability  along  life  are  bacteriocins  and  phages,  that  can  cause  rapid  shifts  by  depleting  well-
established members of the community, changing temporarily the dynamic of the gut ecosystem or even leading to evolutionary
changes in the gut microbial populations (Brüssow & Kutter 2005, Czárán et al. 2002). 
1.3.2. BIOLOGICAL FUNCTIONS OF THE HUMAN GUT MICROBIOTA
The genetic potential of the human gut microbiota has been deeply examined in recent years through "omics" approaches as
metagenomics, metatranscriptomics or metaproteomics (Arumugam et al. 2011, Gill et al. 2006, Gosalbes et al. 2011, Kolmeder
et al. 2012, Kurokawa et al. 2007, Qin et al. 2010, Turnbaugh et al. 2010, Verberkmoes et al. 2009). 
As we previously  mentioned, a  great  variation in  bacterial  composition calls  into  question the  existence  of  a  core
microbiota, but a great number of shared genes between individuals allow to identify a core microbiome, which implies that a
high functional redundancy is a property of the human gut microbial community (Lozupone et al. 2012, Qin et al. 2010, The
Human Microbiome Project Consortium 2012, Turnbaugh et al. 2010). 
In the study of Qin and colleagues, a total of 3.3 million of non-redundant microbial genes on human faeces, 99% of
them from bacteria, were found. The authors identified a set of functions necessary for living in a gut context (minimal gut
genome)  and  genes  involved  in  the  homoeostasis  of  the  whole  ecosystem  encoded  across  different  phylogenetic  groups
(minimal gut metagenome). The first  group includes the house-keeping genes of  main metabolic pathways, as amino acid
biosynthesis, nucleic acid processing, or central carbon metabolism, and also specific genes for inhabit the gut environment as
those  involved in adhesion to  the  host  proteins, or  in catabolism of  globoseries  glycolipids. In addition, the  minimal  gut
metagenome group comprises genes involved in the biodegradation of dietary complex sugars and glycans that are indigestible
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for the host, as well as synthesis of some essential amino acids and vitamins, or detoxification of xenobiotics. These functions
are important for the maintenance of the equilibrium on the gut microbial ecosystem and for host-bacterial interactions, being
most of them not only present, but also enriched in our gut microbiome  (Gill et al. 2006, Kurokawa et al. 2007, Qin et al.
2010) (Figure 1.3). 
Figure 1.3. KEGG pathways reveal metabolic function enriched or underrepresented in the human gut microbiome.
The samples were compared with all sequenced bacterial genomes in KEGG (blue), the human genome (red), and
all sequenced archaeal genomes in KEGG (yellow). Asterisks indicate significant enrichment (odds ratio  > 1) or
underrepresentation (odds ratio < 1) (Adapted from Gill et al. 2006).
Metatranscriptomic  and metaproteomic  studies  confirmed  that  some of  the  potential  functions  identified  on human gut
metagenomes are actually being expressed in the gut ecosystem, highlighting carbohydrates metabolism, energy production and
vitamin synthesis (Gosalbes et al. 2011, Kolmeder et al. 2012, Verberkmoes et al. 2009). 
Other  reservoir  of  functions  are  encoded  on  genetic  elements  related  to  gene  transfer, such  as  phage, plasmids,
transposons, and others mobile genetic elements. These elements of the human microbiota constitute the mobile microbiome
or mobilome. Since molecular techniques to isolate and handle with these type of genetic elements are so far complicated and
can give biased results, little is known about its nature and roles in the human gut (Marchesi 2011). Some studies have found a
mobilome core in the gut with certain roles that benefit the host, as butyrate production or bile salt deconjugation, but also
with large proportion of genes of unknown function (Jones 2010). Nevertheless, the develop of new approaches as the in silico
plasmid identification from metagenomic data will allow a great increase in the knowledge of those mobile genetic elements
and their putative function in a short period of time (Jørgensen et al. 2014).
1.3.2.1. METABOLIC FUNCTIONS
The gut microbiota plays an important role in obtaining energy from the food. In fact, germ-free mice (born and raised under
sterile conditions) require 30% more energy in their diet to survive (Wostmann 1981). 
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One of  the main constituents of  human diet  are carbohydrates, which essentially  are plant derived polysaccharides
(cellulose, hemicellulose, and pectin), starches and sugars. Human cells are able to hydrolyze some disaccharides and absorb
monosaccharides as glucose or galactose, but they cannot break down most of the polysaccharides, which as a consequence pass
to the distal gut. 
In contrast, many colonic living bacteria contain a large repertoire of enzymes for the digestion of fiber of which the human
cells lack (Gill et al. 2006, Hooper et al. 2002, Qin et al. 2010). Thus, some bacterial groups are specialized in degrading a wide
range of dietary carbohydrates undigested by the human. For example, species of the Bacteroides genus are very successful in
the gut because they are able of degrade and ferment many types of polysaccharides (Bäckhed et al. 2005, Cho & Salyers 2001,
Kurokawa et al. 2007, Xu et al. 2003, Zocco et al. 2007). 
Members of the gut microbiota have evolved the capacity to degrade not only dietary carbohydrates, but also a variety of
host-derived glycoconjugates (glycans), including chondroitin sulfate, mucin, hyaluronate and heparin  (Bäckhed et al. 2005,
Hooper et al. 2002, Kurokawa et al. 2007, Mahowald et al. 2009). 
The microbial fermentation of all these compounds generates SCFAs (mainly acetate, propionate and butyrate) that are
absorbed by the host and provide around the 10% of calories extracted by the daily diet (Leser & Molbak 2009, Turroni et al.
2008). Butyrate is considered the preferred source of the colon epithelial cells and 70% of  their energy is derived from the
oxidation of these acids (Bik 2009, Fitch & Fleming 1999, Leser & Molbak 2009, Montalto et al. 2009). 
Acetate is taken by peripheral tissues as skeletal and cardiac muscle and is also utilized by adipocytes for lipogenesis
(Bergman 1990, Cummings & Macfarlane 1977). The SCFAs  have  others  beneficial  effects  on the  gut  physiology  such as
stimulate intestinal blood flow, participating in absorption of water and ions due its anionic nature, stimulating the human
immune system and participating in the inflammatory response  (Hooper et al. 2002, Lawley & Walker 2013, Montalto et al.
2009, Mortensen et al., Russell et al. 2013). 
In addition to its role in caloric uptake through polysaccharides fermentation, the gut microbiota regulates fat storage in
the host if there is no regular access to food. It has been demonstrated that the introduction of gut microbiota into germ-free
mice is associated with increased hepatic lipogenesis and fat storage (Bäckhed et al. 2004, 2005, Vrieze et al. 2010). 
The intestinal microbiota also contributes to the host health with the synthesis of vitamins, mainly K and B12, biotin,
folic acid and pantothenate (Montalto et al. 2009, Nelson 2011, Sumi et al. 1977, Wostmann 1981). Also essential amino acids
are provided by the gut microbiota. Indeed, from 1% to 20% of circulating plasma lysine and threonine in adults is derived
from intestinal  bacteria  metabolism  (Metges  2000, Nelson 2011).  Other role carried by the gut microbiota is  the bile  salt
transformation, allowing its  re-absorption across  the colonic  epithelium  (Ridlon et  al. 2006). Otherwise, its  accumulation
would trigger health issues, as it has been associated with the pathogenesis of colon cancer and other GIT diseases (McGarr et
al.  2005,  Montalto  et  al.  2009,  Nagengast  et  al.,  Nelson  2011). Finally,  the  gut  microbiota  is  also  involved  in  xenobiotic
detoxification and its relation with the efficiency of drug metabolism (Björkholm et al. 2009, Russell et al. 2013). 
1.3.2.2. GUT EPITHELIAL PROLIFERATION, DIFFERENTIATION AND HOMEOSTASIS
Germ-free animals have been used to study how the microbiota affects different processes of host physiology. Regarding the
intestinal epithelium, it has been found that cell turnover is twice faster in conventional animals that in those germ-free, as well
as the number of secretory goblets and enteroendocrine cells is increased in conventional animals (Bates et al. 2006, Savage et al.
1981). This is due to the gut microbial action in cell proliferation and differentiation. Beneficial members of the gut microbiota
such as Bacteroides thetaiotaomicron are involved in regulating the mucosal barrier function, as well as in the maintenance of
the epithelial barrier integrity (Hooper & Gordon 2001, Schiffrin & Blum 2002). Also, the interactions between microbiota and
immune cells stimulate the renewal of epithelium, being even able of repairing damaged mucosal barriers (Pull et al. 2005). 
SCFAs are not only important energy sources for the colonic epithelium, but they also regulate the epithelial cell growth
and differentiation (Fung et al. 2012, Matsuki et al. 2013, O’Keefe 2008, Wong et al. 2006). Besides its role in cell differentiation,
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butyrate  participates  in  prevention  of  colonic  cancer  by  terminating  cell  cycle  progression  and  promoting  apoptosis  of
transformed colonocytes (Comalada et al. 2006, Fung et al. 2012, Yu et al. 2012). 
1.3.2.3. DEVELOPMENT AND HOMEOSTASIS OF THE IMMUNE SYSTEM
Bacterial colonization of the gut is essential for the development of innate and adaptive immune responses of the host, being
the gut microbiota one of the most important factors driving the process of immune education (Atarashi et al. 2011, Chow &
Mazmanian 2010, Clarke et al. 2010, Clemente et al. 2012, Kelly et al. 2004, 2007; Mazmanian et al. 2005, Tourneur & Chassin
2013). Thus, a healthy mucosal defense system protects against pathogens, but tolerates the indigenous microbiota (Cebula et al.
2013, Edwards 2009). This acquired tolerance to several microbial antigens reduces allergies and inflammatory processes over
life (Cebra 1999, Montalto et al. 2009, Nicholson et al. 2005).
Strong regulation of the innate and adaptive immune system operates through intercellular signalling between lymphoid
cell types that occur within germinal centers and secondary lymphoid follicles associated with the gut-associated lymphoid
tissues (GALT). The development of the GALT, which is one of the main components of the immune system, is largely due to
their interactions with the gut microbiota (Bauer et al. 2006, Fagarasan et al. 2010, Kelly et al. 2007). 
The  microbiota  induces  the  host  mucosal  immune  system  to  produce  immunoglobulin  A  (IgA),  as  well  as  some
antimicrobial compounds, two protective mechanisms that limit colonization and penetration of harmful bacteria through the
epithelial layer (Kunisawa & Kiyono 2013, Macpherson et al. 2005, Müller et al. 2005, Satoh-Takayama et al. 2008, Suzuki et al.
2010, Zelante et al. 2013). Moreover, commensal members of  the gut community stimulates the mucin secretion, which is
component of the mechanical mucosal barrier that also protects against pathogen invasion  (Burger-van Paassen et al. 2009,
Leser & Molbak 2009, Szentkuti et al. 1990). Some SCFAs produced by the microbiota as acetate and butyrate also play a role in
controlling inflammation and also in the protection against pathogens by stimulating the immune system (Fukuda et al. 2011,
Fung et al. 2012, Kamada & Núñez 2014, Maslowski et al. 2009). 
1.3.2.4. PROTECTION AGAINST PATHOGENS
The  gut  microbiota  is  able  of  blocking  pathogen  colonization  and  the  consequent  infection  from  the  beginning.  The
mechanism whereby the gut microbiota protects against harmful microorganisms infection is called colonization resistance
(Servin 2004). 
Regarding the colonization resistance capacity of  the gut microbiota, multiple levels of  defence have been proposed
(Figure 1.4). It works through direct interactions between microorganisms, and also via indirect mechanisms by stimulating the
host  immune system (known as immune-mediated colonization resistance)  (Buffie  & Pamer 2013, Lawley & Walker 2013,
Stecher & Hardt 2011). 
In vivo and  in vitro studies have demonstrated that  interactions between microorganisms are a key component of
colonization resistance. These microbe-microbe interactions inhibit pathogen colonization by different ways. First, the resident
microbiota competes with invaders for niches (as the intestinal mucosa) or available nutrients  (Freter et al. 1983, Juge 2012,
Lawley & Walker 2013, Wilson & Perini 1988). Thus, the direct competition limits the required densities of pathogens within
the lumen to invade the epithelial surface and deeper tissues (Falkow 1997, Lawley & Walker 2013).
A second mechanism of colonization resistance is the metabolic exclusion. Specific products of the metabolism of the
indigenous microbiota such as SCFAs create conditions that inhibit growth and virulence of pathogens  (Duncan et al. 2009,
Gantois et al. 2006, Shin et al. 2002, Veiga et al. 2010). Also, the metabolic activity of the gut microbiota reduces free oxygen,
thus slowing the growth rate and virulence of intestinal pathogens, as for example, some members of the Enterobacteriaceae
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that are facultative anaerobes (Altier 2005, Marteyn et al. 2011). 
The third system is based on directly attack the harmful microorganisms by releasing different types of antimicrobial
compounds, highlighting the bacteriocins that are peptides with narrow or broad-spectrum bactericidal activity (Dobson et al.
2012, Gong et al. 2010, Rea et al. 2010).
                                                       
Figure  1.4.  Three  mechanisms  of  intestinal  microbiota-mediated  colonization
resistance  against  enteric  pathogens.  (1)  Direct  inhibition  of  the  pathogen  by
antimicrobial  molecules (bacteriocins, metabolic by-products). (2) Competition for
nutrients  establishes  colonization  resistance  by  shutting  down  all  potentially
available nutrient niches for the pathogen. (3) Indirect inhibition by stimulating the
host  defence  system.  The  microbiota  releases  microbial  patterns  (LPS,
peptidoglycan)  which  are  sensed  by  the  host's  epithelial  cells,  triggering
antibacterial mechanisms such as release of epithelial-derived defensins, mucin
secreted by goblet cells, and secretory IgA produced by lamina propria plasma B-
cells (Adapted from Stecher and Hardt, 2011).
On the other hand, host-commensal interactions promote resistance to pathogen infections. Toll-like receptors (TLRs) and
nucleotide-binding  oligomerization  domain-like  receptors  (NODs)  are  key  in  recognizing  pathogens  and  trigger  the  host
defense and inflammation. The interactions between the TLRs with the commensal microbiota are required to maintain the
intestinal homeostasis and regulation of this system (Buffie & Pamer 2013, Kawai & Akira 2009, Rakoff-Nahoum et al. 2004,
Vaishnava et al. 2008). Besides this, the microbiota is involved in the regulation of the activity of T cells (lymphocytes involved
in immunity) in the intestine, which is important for fighting pathogen invasion, as well as for protecting against exuberant
inflammation and mucosal injury (Barnes & Powrie 2009, Buffie & Pamer 2013, Lawley & Walker 2013, Round & Mazmanian
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2010, Sokol et al. 2008). Moreover, SCFAs produced by beneficial bacteria of  the gut play a role in colonization resistance,
because they participate in lowering inflammation, by counteracting the damaging effects of neutrophils  (Kamada & Núñez
2014, Maslowski et al. 2009, Vinolo et al. 2011).
1.4. ANTIBIOTICS AND GUT MICROBIOTA
Disturbance  has  been  defined  as  an  event  or  process  (physical  or  biological)  that  causes  drastic  structural  changes  to
community composition. In fact, it is the main source of spatial and temporal heterogeneity in natural communities  (Sousa,
1984). The type of disturbance and its characteristics (intensity, frequency, and duration) determine which specific organisms
and properties of a community are selected over time, as well as the specific features of adaptation that they possess (Relman
2012). Properties of the ecosystems as resistance, resilience or functional redundancy, also contribute to define the response to
perturbations (Allison & Martiny 2008) (Figure 1.5). 
Aspects  of  modern  lifestyles  such  as  medications  (mainly  antibiotics),  dietary  changes  or  topical  use  of  detergents,  are
interfering in the co-evolved human-microbiota interactions. Many of these human activities occur at a frequency and intensity
higher than those at the microbial ecosystem are able to adapt, thus increasing the incidence of some diseases associated to an
altered microbiota (Relman 2012). 
Figure 1.5.  A schematic of the states and possible responses of
microbial  communities during disturbance (resistance, resilience,
functional redundancy) (Adapted from Allison & Martiny, 2008).
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Antibiotics are probably one of the most important discoveries in the history of medicine. Since their introduction into clinical
practice in the 1940s, the majority of infectious diseases that plagued human history for many centuries have been successfully
treated. Antibiotics are now one of the most common disturbance in human associated communities since on any given day
approximately 1 to 3% of people in the developed world are exposed to antibiotics (Goossens et al. 2005). 
Although some antibiotics target  specific pathogenic populations, most of  the administered antibiotics have broad-
spectrum activity and are used to treat many infections (Nathan 2004). Thus, not only the specific pathogens, but also related
members of the human microbiota are affected by antibiotic therapies. 
Moreover, as microorganisms establish a complex network of co-dependence for the provision of nutrients, secondary
metabolites or removal of toxic waste products, antibiotics also affect the microorganisms that are functionally connected to
them (Figure 1.6) (Belenguer et al. 2006, Samuel & Gordon 2006, Willing et al. 2011). For example, this "chain reaction" effect
was found in a study of mice treated with vancomycin, after which some Gram-negative bacteria were depleted, despite the
antimicrobial activity of this agent is restricted to Gram-positive microorganisms (Robinson & Young 2010). 
             
            
Figure 1.6. Direct and indirect effects of antibiotics on the gut microbiota. (a) Mutualism exists between gut symbionts and the host
in the absence of antibiotics.  Co-dependence among symbionts is exemplified in the figure.  (b)  When antibiotics are introduced,
mutualistic traits of the symbionts that are directly targeted (solid crosses) by the antibiotic are eliminated, and the microorganisms
participating in those mutualistic associations are indirectly affected (dashed crosses). IEC,, intestinal epithelial cell (Adapted from
Willing et al. 2011).
Besides  the  spectrum  of  the  agent, other  features  such as  dosage  and  duration  of  treatment, route  of  administration  or
pharmacokinetic and pharmacodynamic properties influence the microbial community antibiotic-associated changes (Jernberg
et al. 2010, Looft et al. 2012). 
Alterations of the gut microbiota affect the beneficial functions they performed, leading to negative effects on several
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aspects of the host health, such as immune system homeostasis, energy metabolism or colonization resistance  (Brandl et al.
2008, Buffie et al. 2012, Dessein et al. 2009, Donskey 2006, Ng et al. 2013, Romick-Rosendale et al. 2009, Willing et al. 2011, Yap
et  al. 2008). Moreover, antibiotic  use  also  promotes  the  increase  of  antibiotic-resistant  strains, turning  the  intestine  in  a
reservoir for resistance genes (Jernberg et al. 2010, Löfmark et al. 2006, Modi et al. 2013, Sommer et al. 2009). 
1.4.1.  ANTIBIOTIC  EFFECTS  ON  THE  MICROBIAL  DIVERSITY  AND  COMPOSITION  OF  THE  GUT
MICROBIOTA
Due to its importance for public health most of the research about the detrimental effect of antibiotics has been focused on the
emergence and spread of  resistant strains. Recent studies have addressed the impact of  antibiotics on the structure of  the
intestinal  microbiota,  mainly  through  DNA  sequencing-based  approaches  (Antonopoulos  et  al.  2009,  Buffie  et  al.  2012,
Dethlefsen & Relman 2010, Dethlefsen et al. 2008, Jakobsson et al. 2010, Jernberg et al. 2007, O’Sullivan et al. 2013, Panda et al.
2014). 
Most of the studies on human and animal models have found an association of antibiotics with a reduced microbial
diversity (Antonopoulos et al. 2009, Dethlefsen & Relman 2010, Dethlefsen et al. 2008, Jernberg et al. 2007, Panda et al. 2014) .
However, a reduction of the total biomass seems to depend on the type and doses of the antibiotic (Panda et al. 2014). In fact,
antibiotic-associated  changes  are  more  related  to  altered taxon abundance  than to  the  gain  or  loss  of  bacterial  members
(Dethlefsen & Relman 2011). 
Studies of  the effect of  antibiotics on the gut community have covered different types of  them as fluoroquinolones,
lincosamides, beta-lactams, oxazolidinones, among others. In most of them, shifts in relative proportions of certain populations
are observed since human-associated microbial communities exhibit low resistance to antibiotic perturbations (Jernberg et al.
2010, Panda et al. 2014, Robinson & Young 2010). 
Several antibiotics are especially active against anaerobic bacteria that are dominant in the human gut microbiota. One
example is clindamycin that has been shown to have a large negative effect on the anaerobic fraction of the gut microbiota
(Löfmark  et  al.  2006, Nyberg  et  al.  2007). Also,  amoxicillin  treatment  has  a  strong  effect  on  specific  groups  of  the  gut
environment, among aerobic and anaerobic species, leading a decrease in  Clostridium and  Eubacterium and an increase in
Enterobacteriaceae, Bacteroides and Prevotella taxa (Barc et al. 2004, Sullivan et al. 2001). The commonly used treatment for H.
pylori  gastritis,  which  is  a  triple  therapy  with  clarithromycin,  metronidazole  and  omeprazole,  perturbs  dramatically  the
composition of the gut microbiota, decreasing mainly beneficial members of Clostridia and Bifidobacteria classes (Jakobsson et
al. 2007, 2010). 
The gut microbiota, as a whole, is considered relatively resilient to antibiotic challenge and after short-term therapy it
returns to the pre-treatment state (De La Cochetière et al. 2005). However, it is clear that antibiotic therapies have long-term
effects in the community structure, with a lower abundance of specific bacterial groups after the therapy, as well as an increase
in the risk of antibiotic resistance genes and its transference to pathogens (Dethlefsen & Relman 2011, Dethlefsen et al. 2008,
Francino 2013, Jakobsson et al. 2010, Jernberg et al. 2007). 
For instance, a treatment with clindamycin resulted in lower diversity of  the  Bacteroides genus, in an enrichment of
resistant Bacteroides clones, and also in an increase in the abundance of the resistant erm-genes up to two years after treatment
(Jernberg et al. 2007, Löfmark et al. 2006). 
Long-term effects of metronidazole and clarithromycin on the faecal human microbiota up to four years after treatment
have been also described, with increased persistence of the macrolide resistance gene ermB (Jakobsson et al. 2010).
The two longer follow-up studies about antibiotic effects on human gut diversity and composition so far, were carried
out by Dethlefsen and colleagues. They studied the effects of the commonly used antibiotic oral ciprofloxacin, on the faecal
microbiota of different individuals by sampling their microbiota before, during and after the antimicrobial therapy (Dethlefsen
& Relman 2011, Dethlefsen et al. 2008). For both studies, ciprofloxacin administration correlated with a reduction of taxon
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richness, diversity and evenness and the individuals showed different responses and recovery periods. Interesting, in one of the
studies, individuals were treated with a second round of ciprofloxacin and responded differently respect to the first course. This
phenomenon is likely, since repeated perturbations are "recorded" by the microbiota, even when the community seems to have
recovered from the initial perturbation (Dethlefsen & Relman 2011).
On the other hand, the absence of clinical symptoms on the individuals of the study could be explained by the functional
redundancy  of  the  gut  inhabitants, at  least  in some functions related to  diet  processing  as  the  carbohydrate  metabolism.
However, other functions as colonization resistance to pathogens or regulation of host immunity, may be restricted to a subset
of the community. Therefore, every antibiotic course could contribute to displace a mutualist with a strain that may provide or
not the same benefit, having an accumulative detrimental effect on the beneficial functions of the gut microbiota (Dethlefsen &
Relman 2011).
1.4.2. ANTIBIOTIC EFFECTS ON THE FUNCTIONAL PROFILE OF THE GUT MICROBIOTA
The  effect  of  antibiotics  on the  functions  carried  by  the  human gut  microbiota  has  been poorly  addressed. Most  of  the
knowledge about the antibiotic-related changes of the biological functions of the gut microbiota have been carried on animal
models.  For  instance,  a  metagenomic  study  of  antibiotic-associated  shifts  on  the  functional  potential  of  the  swine  gut
microbiota showed that genes encoding virulence, gene-transfer and energy production and conversion are positively selected
by the antibiotics. Due to their roles, those genes could promote the stability and spread of antibiotic resistance genes in the gut
ecosystem (Looft et al. 2012).
The metabolic profiles have been studied in mice under different antibiotic regimens and a common feature with treated
humans is the reduced production of SCFAs (Willing et al. 2011, Woodmansey et al. 2004). Some mice studies have also shown
that the microbial fermentation of carbohydrates is disrupted by the antibiotics, since high concentrations of oligosaccharide
and low concentrations of amino acids and SCFAs were observed in treated mice. Interesting, as for the microbial diversity, the
levels of some metabolites were not recovered weeks after the therapy (Yap et al. 2008). Antibiotic treatments have a profound
impact on the mice intestinal metabolome affecting the levels of more than the 87% of all the metabolites, being decreased
pathways critical for host health as bile acid, eicosanoid and steroid hormone synthesis (Antunes et al. 2011).
In a culture-based study of metabolic activities of the gut microbiota in young adults and in elderly subjects (treated and
non-treated  with  antibiotics),  Woodmansey  and  colleagues  showed  that  antibiotic-treated  individuals  presented  a  high
proteolytic  species  diversity  (fusobacteria, clostridia  and  propionibacteria)  (Woodmansey  et  al.  2004).  Increased  levels  of
protein break-down and amino acid fermentation result in the formation of toxic bacterial metabolites (Macfarlane et al. 1989).
Also, the presence of  bacterial fermentation products that are essential for host health, specifically SCFAs (mainly butyrate,
propionate, acetate) was lower in antibiotic-treated elderly.
Recently, a chemostat model consisting of a defined consortium model (14 species) of the most common cultivable and
saccharolytic and amino acid fermenting bacteria of the gut was used to study the effects of two broad spectrum antibiotics
(metronidazole and ampicillin) on the bacterial composition and metabolic activities (Newton et al. 2013). The two antibiotics
showed great differences on their effect on the microbiota model, but for both agents, the production of SCFAs decreased, while
the production of some hydrolytic enzymes was dependent of the antibiotic-resistant populations that survived.
1.4.3. ANTIBIOTIC THERAPY AND RESISTANCE GENES IN THE GUT ENVIRONMENT.
The antibiotic usage is the major risk factor for the spread of resistant bacteria and resistance genes in the human intestinal
ecosystem. Other factors include the capacity of resistant strains to colonize the gut, their relative fitness, mutation rates and
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efficiency of horizontal gene transfer (Jernberg et al. 2010). 
The gut environment has good conditions for efficient transmission of resistance genes, since it comprises high numbers
of  bacteria  and a  stable  diverse  ecosystem (rich in  nutrients  and with relatively  constant  chemical  parameters). After  the
resistance  selection  process  by  the  antibiotic  therapy, the  resistance  genes  can be  transferred  to  other  bacteria, including
pathogens. For instance, the transfer of a plasmid carrying a beta-lactamase gene from a resistant Escherichia coli strain to a
susceptible one was demonstrated in an ampicillin-treated child  (Karami et al. 2007). Thus, antibiotics not only select  for
resistance bacteria but also increase the chance of transfer events from the increased resistant microorganisms.
 Recently, it has been postulated that when the selective pressure of antibiotics is no longer present, the resistant strains
could  have  a  lower  fitness  compared  with  the  non-resistant  ones,  but  there  are  mechanisms  such  as  the  acquisition  of
compensatory  mutations,  by  which  these  resistant  bacteria  can  reduce  the  fitness  costs  (Andersson  &  Hughes  2011,
Chewapreecha 2014, Snitkin et al. 2013). 
Some studies have shown the impact of antibiotic therapy on long-term persistence of antibiotic resistance genes. In a
study about the effect of clyndamicin in the faecal microbiota it was found a significant increase in erm resistance genes (ermF,
ermG and  ermB) ,that could be still detected two years after the antibiotic course  (Jernberg et al. 2007). Two other studies
investigated the effect of clarithromycin, showing the presence of highly resistant enterococci that carried the ermB gene, one
year after the antibiotic administration, as well as the presence of the macrolide-resistant Staphylococcus epidermis up to four
years after therapy (Sjölund et al. 2003, 2005).
Sommer and colleagues characterized the antibiotic resistance reservoir in the human microbiota of individuals who had
not been exposed to antibiotics for at least one year, finding an immense diversity of  resistance genes in their microbiome
(Sommer et al. 2009). Most than half of the resistance genes harboured by the gut microbiota were distantly related to resistance
genes detected in pathogenic isolates. This could imply that the resistance genes of our gut are difficult to access or infrequently
exchanged with human pathogens. However, the resistance genes identified were functional in E. coli, suggesting that if there is
a  barrier  between  commensal  bacteria  and  pathogens  for  gene  transfer,  it  must  due  to  processes  different  of  functional
compatibility. On the other hand, nearly half  of resistance genes of cultured aerobic gut isolates were identical to resistance
genes from human pathogens. Some examples are the genes encoding for tetracycline efflux pumps (TetA), two classes of
aminoglycoside-modifying enzymes (AAC(3)-II and AAC(6)-Ib) and three classes of beta-lactam-inactivating enzymes (TEM,
AmpC and  CTX-M). Besides  this,  in  a  metagenomic  study  of  antibiotic  resistance  genes  of  a  large  human cohort  (162
individuals)  more  than  1000  resistance  genes  were  identified,  being  highly  abundant  those  conferring  resistance  against
tetracycline. In addition, the levels of antibiotic resistance genes were significantly higher in the gut microbiome on average
(0.266%) compared with environmental data sets (0.008-0.171%) (Hu et al. 2013). Moreover, a study of antibiotic effects on the
swine gut microbiome showed that antibiotics use causes a significant increase in the abundance of diverse resistance genes,
including genes that do not confer resistance against the administered antibiotic, which suggests an indirect mechanism of
selection, as co-occurrence on mobile elements, to explain this event (Looft & Allen 2012).
Interestingly, a recent study of the phageoma (total resident phages) of the murine gut under antibiotic pressure has
shown that they are enriched in a wide range of antibiotic resistances after drug perturbation. This observed cross-resistance
can be mediated by drug-specific inactivators as well as multidrug-resistance exporters (Modi et al. 2013). 
On the other hand, some bacteria that originate from ingested food are only transient inhabitants of the intestine during
digestion, even so they can play a role in the transfer of resistance genes during their passage through the intestine (Andremont
2003, Finley et  al. 2013, Salyers  et  al. 2004). Therefore, the  use  of  antibiotics  in agriculture might  be contributing to  the
emerging resistance problem in clinical environment, since cultivated soils are large global resistance reservoirs (Aubry-Damon
et al. 2004, Lipsitch et al. 2002). In fact, it has been described in soils resistance cassettes against five classes of antibiotics (beta-
lactams,  aminoglycosides,  amphenicols,  sulfonamides  and  tetracyclines)  that  are  identical  to  genes  from  diverse  human
pathogens, demonstrating the exchange (horizontal gene transfer) of resistance genes of soil bacteria with human pathogens
(Forsberg et al. 2012). 
Resistance genes, resistant bacteria and antibiotics flow between different areas of use (human, animal, soil, water etc...)
promote the emerging, enrichment and spread of resistant bacteria between hosts and environments. Figure 1.7 represents the
resistant bacteria and antibiotics flows between different areas of  use and environments  (Andersson & Hughes 2011). The
37
antibiotic therapies are often administered in humans, animals and agriculture at high concentrations. Thus, about half of all
antibiotics are excreted in an active form in humans and animals urine into the environment (waste water, manure) where they
finally reach aquatic environments (lakes, rivers) and soils (Bryskier 2005). 
It is difficult to assess the relative contributions of  environments and selection to the spread of  resistances and it is
commonly assumed that hospitals are a significant source because of the high use of antibiotics (strong local selection) and the
large host population that promote the spread of resistant bacteria (Andersson & Hughes 2011). However, it is noteworthy that
weaker  selective  pressures  as  a  whole  (lakes, rivers, soils)  are  equally  important  for  the  emerging  of  resistances  (Baquero
2001a,b). 
Figure 1.7.  Schematic representation of ows of resistant bacteria (blue) and antibiotics (red) between differentﬂ
environments and areas of use (Andersson & Hughes, 2012).
1.4.4. RELATION OF ANTIBIOTIC USE AND HUMAN PATHOLOGIES.
As stated before, the commensal gut microbiota plays a major role in the homeostasis of the human host. Hence, disruption of
the gut microbiota by antibiotics increase the chance of disease and have long-term consequences for host health. A dysbiotic
microbiota  is  defined as  one that  contains  an imbalance  in  structure  and function compared with  that  found in  healthy
individuals and it has strong effects on host physiology and disease processes. Additionally, a dysbiotic microbiota can harbour
bacteria  that  exacerbate  intestinal  inflammation or  manifest  systemic  disease  (Pham & Lawley  2014).  In  fact,  a  dysbiotic
microbiota has been associated to several intra and extra-intestinal conditions as inflammatory bowel disease, irritable bowel
syndrome, antibiotic-associated diarrhea, obesity, cancer and pathogen infection, HIV infection, among others ( Figure 1.8)
(Francino 2013, Kassinen et al. 2007, Macfarlane 2014, Macfarlane et al. 2009, McGarr et al. 2005, Morgan et al. 2012, Mutlu et
al. 2014, Turnbaugh et al. 2008, Vázquez-Castellanos et al. 2014, Willing et al. 2011). 
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Figure 1.8. Oral antibiotics have been associated with changes in numerous intra-
and extra-intestinal diseases. CDAD, Clostridium difficile- associated diarrhoea; EAE,
experimental  autoimmune  encephalopathy;  T1D,  type  1  diabetes;  T2D,  type  2
diabetes; VRE, vancomycin-resistant Enterococcus (Willing et al. 2011).
A common side effect of antibiotic treatment is the appearance of diarrhea (antibiotic-associated diarrhea or AAD). It is
not necessary an etiologic agent for AAD as the drugs cause the dysfunction per se. For instance, if the bacteria responsible for
breaking down diet fiber in the colon are eliminated by the antibiotic, an osmotic diarrhea may appear. This is because the
normal digestion of  these  compounds prevent  this  type of  diahrrea  (Young & Schmidt  2004). On the  other hand, some
opportunistic  pathogens  can cause  disease  during  therapy, including  Salmonella spp.,  Clostridium perfringens,  Klebsiella
oxytoca, Candida albicans or Clostridium difficile, being this last the most common cause of pathogen-associated AAD (15%-
25%) (Walk & Young 2008).
As we previously explained, the gut microbiota has an important role in the colonization resistance against pathogens.
Thus, the disruption of the microbiota by antimicrobial therapies results in increased susceptibility to infection by pathogens.
For example, the vancomycin-resistant  Enterococcus (VRE), which can cause serious systemic infections, is a strain able to
colonize effectively those mice treated with antibiotics. It has been proposed that the colonization of this pathogen is possible
due to a reduced production of the antimicrobial peptide REG3  as a consequence of microbial signals loss γ (Brandl et al. 2008).
Moreover, in a study of  patients undergoing allogeneic hematopoietic stem cell  transplantation, which received antibiotics
during their hospitalization, it was found an intestinal domination (>97%) by VRE previous to bloodstream infection (Ubeda
et  al.  2010). Recently, Ubeda  and  colleagues  found that  intestinal  colonization  with  commensal  anaerobic  bacteria  from
Barnesiella genus confers resistance against an overgrowth in the intestine and bloodstream infection with VRE (Ubeda et al.
2013). 
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Using a mouse-model, Buffie and colleagues showed that even a single dose of oral clindamycin promotes the infection
and persistence of C. difficile, whose overgrowth leads to a high risk for pseudomembranous colitis (Bartlett 2002, Buffie et al.
2012). Also in a mouse-based study it was found that some antibiotics as clindamycin and piperacillin-tazobactam increase the
abundance of carbapenemase-producing Klebsiella pneumoniae (KPC), which produces principally pneumonia, and decrease
the presence of  some anaerobic bacteria, suggesting the importance of  anaerobes for protection against KPC colonization
(Perez et al. 2011). 
Germ-free  mice  have  not  only  intestinal  but  also  extra-intestinal  problems  indicating  that  the  host-microbiota
interactions  have  systemic  implications. Over  recent  years  there  has  been  an increase  in  the  presence  of  immunological
disorders in the developed world, supporting what it is called the "hygiene hypothesis" (Guarner et al. 2006, Wills-Karp et al.
2001). This hypothesis proposes that insufficient exposure to microorganisms, parasites and infectious agents alters the normal
immune development, increasing the susceptibility to allergic diseases (Willing et al. 2011). An extension of this hypothesis is
the "microflora hypothesis" since epidemiological studies have associated early antibiotic use with an increase in the risk of
atopic diseases. Thus, the overuse of antibiotics during childhood alters the microbiota and inhibits the normal maturation of
the immune system, fuelling some diseases as allergies and asthma (Blaser 2011, Francino 2013). 
1.5. CLOSTRIDIUM DIFFICILE INFECTION.
The recent increase in the incidence and virulence of C. difficile infection (CDI), its association with antibiotic administration
and the present interest  in the role of  the  human microbiome in health and disease  have led to a renewed attraction to
investigate the relation between C. difficile and the human gut microbiota. 
1.5.1. CLINICAL FEATURES ABOUT C. DIFFICILE INFECTION.
C. difficile is a Gram-positive, spore-forming anaerobic bacillus that is commonly found in the gut of mammals and is the agent
that causes CDI (Bartlett 1994). The first confirmed case of CDI was reported in 1977 and its incidence has continued rising
since then, and at present is the most frequent cause of nosocomial diarrhea worldwide (Kuijper et al. 2007). The symptoms of
CDI range from mild diarrhea to severe pseudomembranous colitis and often occur after broad-spectrum antibiotic therapies
(Dawson  et  al.  2009).  Other  common  clinical  symptoms  are  abdominal  pain  and  cramping,  fever  and  leucocytosis.
Pseudomembranous colitis  in the distal  colon and rectum is fatal in 6%-30% of  cases  (Kuijper et  al. 2007). However, the
infection with C. difficile could remain asymptomatic probably due to different factors as the microorganism level of virulence,
the degree of disruption of the normal microbiota, or the host immune response  (Gerding 2012). Several routine laboratory
tests  are  applied for  CDI diagnosis  such as  enzyme immunoassays  to detect  toxins  A and B, real-time PCR to detect  the
toxigenic genes, anaerobic culture for toxigenic C. difficile strains, culture cytotoxicity assay and enzyme-linked immunosorbent
assay (ELISA) of the toxins A and B (Hookman & Barkin 2009). 
The major risk factor for CDI is antibiotic exposure, particularly the broad-spectrum antibiotics with activity against
anaerobes (Denève et al. 2009). Other factors are hospitalization, immunocompromised status and old age (>65 years). In fact,
old debilitated patients in hospitals are highly vulnerable to CDI with a reported colonization rate of 73% (Barbut et al. 1996).
Other risk factors are treatments with proton-pump inhibitors, H2 antagonists and methotrexate, as well as the presence of
some gastrointestinal diseases as inflammatory bowel diseases (Dial et al. 2005). 
The pathogenesis of C. difficile starts generally with the antimicrobial therapy which disrupts the normal gut microbiota,
thus reducing the colonization resistance capacity. Then, pathogen spores of endogenous or exogenous origin germinate and the
vegetative forms multiply. Then, C. difficile penetrates the mucus layer with the aid of flagella and proteases and adheres to the
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enterocytes  through multiple  adhesins. These  steps  belong to the  first  phase  of  the  pathogenic process, "the  colonization"
(Denève et al. 2009) (Figure 1.9).
The second phase of the pathogenesis is the production of toxins A and B encoded by the genes tcdA and tcdB. Those
genes are located in the pathogenicity locus PaLoc with the tcdE gene encoding a putative holin and the genes tcdR and tcdC
encoding regulatory proteins (Dupuy et al. 2008, Tan et al. 2001). The toxins TcdA and TcdB modify the actin cytoskeleton of
epithelial cells via the covalent glucosylation of  Rho, Rac and Cdc42 proteins, which regulate actin, leading to cytoskeleton
disorganization, inhibition of cell division and membrane trafficking, resulting in the destruction of the intestinal epithelial cells
(Jaffe & Hall 2005, Just et al. 1995a,b; Ridley 2001) (Figure 1.9). 
 Figure 1.9. Pathogenesis of Clostridium dif cile ﬁ (Dèneve et al. 2009).
 Few strains (6% of C. difficile isolates) present a binary toxin called CDT (encoded by CdtA and CdtB in the Cdt locus) which
consists of a binding and enzymatic component with actin-specific ADP ribosyl transferase activity that leads to cytoskeleton
disorganization (Perelle et al. 1997). This toxin is considered as an additional virulence factor since it potentiates the toxicity of
TcdA and TcdB, causing a more severe disease  (Barbut et al. 2005). In the last years the epidemiology of  CDI has changed
radically with a five-fold increase in its incidence in the population of North America, eight-fold increase in the elderly, as well
as an increase in its incidence in European countries but associated with specific outbreaks  (Kuijper et al. 2007, Pépin et al.
2004). In Spain, the incidence is similar to the surrounding European countries but with a trend to increase due to the high
frequency of  prescription of  antibiotics  (Asensio & Monge 2012). Other recent epidemiological  changes are an increase in
severity of the disease associated with septic shock, toxic megacolon, intestinal perforation, mortality, treatment failure plus
several relapses and spread to low-risk populations (McFarland 2008, Musher et al. 2005, Pépin et al. 2005). These changes in
the pattern of the pathology of CDI worldwide have been associated with the emergence of a hypervirulent strain named C.
difficile NAP1/027/BI strain. This epidemic strain produces higher levels of the TcdA (16-fold) and TcdB (23-fold) toxins due
to a truncated and inactive TcdC protein which is a negative regulator of toxin genes (Dupuy et al. 2008, Warny et al. 2005).
Besides, C. difficile NAP1/027/BI strain possesses the locus Cdt encoding the binary toxin CDT which potentiates the toxicity of
the TcdA and TcdB toxins. 
The most effective initial treatments for CDI are oral antibiotic therapies, mainly vancomycin and metronidazole (Miller
2007). However, a high number of patients (between 20-35%) develop recurrent illness several days to weeks after the initial
"success" of the antibiotic therapy (McFarland et al. 2002, Wilcox 1998).
An alternative method for the maintenance and restoration of the gut microbiota after antibiotic therapies involves the
use of prebiotics and probiotics. Probiotics as bifidobacteria and lactobacilli seem to counteract AAD and relapsing CDI, but
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some studies  on probiotics  to treat  CDI have  shown conflicting results  (Hookman & Barkin 2009, Macfarlane 2014). For
instance, a study of probiotic treatment with three types of probiotics (Saccharomyces boulardii, Lactobacillus rhamnosus GG,
and probiotic mixture) showed that only S. boulardii  was effective in treating the recurrent disease  (McFarland 2006). Other
alternative therapies are the use of a novel neutralizing monoclonal antibody against  C. difficile toxins, anion-binding resins
that neutralize clostridial toxins, vaccination against the pathogen and its toxins, or immunoglobulin based therapies, but most
of  these  treatments  are  in  early  stage  of  development  (Jank  et  al.  2008, McPherson  et  al.  2006, Peterfreund  et  al.  2012,
Sougioultzis et al. 2005, Taylor et al. 2008). A promising approach for patients with recurrent CDI involves the transplantation
of  defined  microbial  communities  or  the  entire  faecal  microbiota  from  healthy  individuals  (bacteriotherapy).  The  faecal
microbiota transplantation has been effective against recurrent CDI and restoring the intestinal microbial diversity in up to
95% of patients (Bakken et al. 2011, Borody et al. 2004, Gough et al. 2011, Khoruts et al., Lawley et al. 2012, Petrof et al. 2013) .
Further studies will be required to understand how the implantation of these microbial communities are able to suppress the
CDI and other consequences that they may have on human health (Britton & Young 2014).
1.5.2.  INFLUENCE OF ANTIBIOTICS IN THE GUT MICROBIOTA AND ITS  RELATION WITH  C.  DIFFICILE
INFECTION.
As we previously mentioned, the main risk for developing CDI is antibiotic use, mainly clindamycin, cephalosporins, penicillins
and more recently fluoroquinolones (Bartlett 2010, Britton & Young 2012). Also, several antibiotic exposures over time increase
the  risk  of  developing  disease,  since  an  accumulative  detrimental  effect  shifts  the  normal  gut  microbiota  that  loses  its
colonization resistance capacity (Stevens et al. 2011). Besides this, it has been demonstrated that antibiotic use and the exchange
of mobile elements between intestinal bacteria lead to a rapid evolution of the epidemic C. difficile strain (ribotype 027) (He et
al. 2013).
The development of animal models for studying CDI in the basis of microbial ecology has led to advance in the relation
between the microbiota and the development of the infection and its complications. Several studies in animals and humans
have shown that antibiotics have strong and long-lasting effects on the community structure of the microbiota, affecting the
biomass, composition and functions, thus reducing resistance to CDI (Britton & Young 2014) (Figure 1.10).
In mice, a variety of antibiotics have been associated to the loss of resistance to  C. difficile colonization  (Buffie et al.
2012, Chen et al. 2008, Reeves et al. 2011, Theriot et al. 2011). For example, a study showed that a single dose of clindamycin
markedly  reduced  the  diversity  of  the  intestinal  microbiota  and  the  inoculation  of  C.  difficile to  these  mice  resulted  in
development of diarrhea, colitis and a high mortality rate (40-50%) (Buffie et al. 2012). 
A similar study on  C. difficile  colonization of  antibiotic treated mice described a high abundance of  Proteobacteria
(mainly Enterobacteriaceae) and a low abundance of normal members of the microbiota as Lachnospiraceae (Firmicutes) in the
ill animals compared with the healthy controls (Reeves et al. 2011). The same group investigated, also in mice, the role of strains
of  both groups (Enterobacteriaceae and Lachnospiraceae) in colonization resistance against  C. difficile (Reeves et al. 2012).
They  found  that  only  the  Lachnospiraceae  strain  was  able  to  partially  restore  the  colonization  resistance  because
Lachnospiraceae-inoculated mice  presented decreased  C. difficile colonization, lower  intestinal  cytotoxin  levels, less  severe
clinical  signs and colonic histopathology. Moreover, a recent study showed that six phylogenetically  diverse species of  gut
normal bacteria administered together were able to restore colonization resistance and prevented the chronic carriage of  C.
difficile in mice (Lawley et al. 2012). 
Microbiome-based studies of  patients with CDI have provided data that correlated with some findings from animal
studies, specifically a decrease in biodiversity and a differential abundance of  some beneficial microbial groups, as a lower
abundance of some Clostridiales members (mainly Lachnospiraceae and Ruminococcaceae) compared with healthy individuals
(Antharam et al. 2013, Chang et al. 2008, Hopkins & Macfarlane 2002, Vincent et al. 2013). 
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Figure 1.10. Cycle of CDI. Antibiotic administration alters the indigenous intestinal microbiota, producing an
environment that permits germination of C. dif cileﬁ  spores and expansion of the pathogen. C. dif cileﬁ  produces
toxins  that  cause  colitis  and  resulting  symptoms.  Returning  the  microbiota  to  a  state  of  colonization
resistance cures CDI. However, if the microbiota is unable to restore resistance to colonization by C dif cileﬁ ,
then patients have recurring CDI.  In certain cases,  repeat courses of  anti-C.  dif cileﬁ  antibiotic therapy can
eradicate the pathogen. In other cases, therapeutic restoration of a diverse microbiota via faecal microbiota
transplantation is required to overcome CDI (Britton & Young, 2014).
Also, Chang and colleagues profiled the gut microbiota of patients with antibiotic-associated diarrhea due to C. difficile
in both, initial and recurrent episodes using 16S rRNA-encoding gene clone libraries. They found a highly variable bacterial
composition and a very low diversity in the recurrent patients. Patients with initial infections showed an intermediate diversity
pattern between recurrent cases and controls (Chang et al. 2008). 
A different  study examined the  microbiota  associated to  CDI in  elderly  by  pyrosequencing  of  the  16S rRNA gene
amplicons, finding a marked reduction in microbial diversity at genus level in infected patients compared with non-infected
(Rea et  al. 2011). The infected patients  showed a  higher abundance of  Lactobacillaceae  and Enterococcaceae  and a lower
abundance of Bacteroides, Prevotella and Bifidobacteria. 
A lower diversity prior to episodes of  CDI was observed in a similar comparative study of  patients under antibiotic
therapy. Bacteria from Bacteroidaceae and Clostridiales were depleted in patients compared with controls, whereas patients
were enriched in Enterococcaceae family  (Vincent et al. 2013). The higher abundance of Enterococcaceae members could be
explained by its opportunistic nature that, similar to C. difficile, could take advantage of a low bacterial diversity to overgrow.
A recent research compared the structure of the microbiota (based on 16S rRNA gene pyrosequencing) of three groups
of individuals: C. difficile infected (CDI) subjects with diarrhea, C. difficile-negative nosocomial diarrhea (CDN) and healthy
controls. Significant alterations in the microbiota were associated to CDI and CDN compared with controls. Bacteria producing
butyrate  and other  SCFAs  mainly  from Ruminococcaceae  and  Lachnospiraceae  families  were  depleted  in  CDI and CDN,
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suggesting a main role of these bacteria in colonization resistance against the pathogen and in the maintenance of the ecosystem
equilibrium (Antharam et al. 2013).
1.6. METHODS FOR STUDYING THE HUMAN MICROBIOTA.
The gut microbiota is an ecosystem of great interest because of its essential role for the host health. For a long time, the research
on the gut microbial community has been based on isolation and culture of the microorganisms in the laboratory. Over the last
years,  the  development  of  new  molecular  techniques  and  high-throughput  sequencing  technologies  have  promoted  an
exponential increase of the amount of data related to the intestinal microbiota.
1.6.1. CULTURE TECHNIQUES FOR INTESTINAL MICROBIOTA CHARACTERIZATION
The first insights into the gut microbiota composition have been obtained from isolating organisms from faecal or intestinal
samples by culturing them. The majority of the cultivated representatives of the gut were discovered after the introduction of
anaerobic cultivation technologies that are now standard tools (Arank et al. 1969). Bacteria that have been cultivated from the
gut include a variety of butyrate-producing bacteria from Firmicutes phylum and other abundant bacteria from Bacteroidetes
(Bakir et al. 2006, Barcenilla et al. 2000, Hayashi et al. 2007, Pryde et al. 2002, Sakamoto et al. 2007) . Also, the use of alternative
carbon sources has allowed the discovery of species of minority phyla such as Verrucomicrobia or Lentisphaerae (Derrien et al.
2004, Zoetendal et al. 2003). Nevertheless, a great number of microorganisms will remain under-represented among cultured
bacteria, due to they have developed an intimate and highly dependent relation with the host and with other members of the
community along evolution, being almost impossible to grow into pure culture (Zoetendal et al. 2008). Despite its limitations,
microbial cultivation is still essential to define bacteria-bacteria and bacteria-host interactions (Walker et al. 2014). 
1.6.2. CULTURE-INDEPENDENT METHODS TO STUDY THE GUT MICROBIOTA
It is well known that the major part of gut bacteria has not been described by cultivation techniques. This fact, together with the
development  of  high-throughput  sequencing  technologies,  have  promoted  the  implementation  of  culture-independent
methods,  such  as  sequencing  of  the  16S  small  subunit  (SSU)  rRNA  gene  and  meta-"omics"  approaches,  to  expand  our
knowledge about the structure, functions and ecology of the human gut microbiota. 
1.6.2.1. 16S rRNA BASED APPROACHES TO EXPLORE THE DIVERSITY OF THE GUT ECOSYSTEM.
The use of the ribosomal 16S rRNA gene for phylogenetic classification focused on the sequence diversity of this gene to study
the diversity of microbial communities  (Woese 1987, Woese et al. 1990). In fact, 16S rDNA sequencing has become the gold
standard for microbial communities characterization, and around 75% of microbes described in the gut has been detected only
through 16S rRNA sequencing (Petrosino et al. 2010, Zoetendal et al. 2008).
The first studies of SSU rRNA sequencing of GIT were performed by cloning 16S rRNA gene amplicons and sequencing
them with Sanger technology. The application of this method allowed to describe a significant fraction of the bacteria so far
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unknown from different regions of GIT such as colon, ileum, oral cavity or human faeces (Eckburg et al. 2005, Hold et al. 2002,
Paster et al. 2001, Suau et al. 1999, Wang et al. 2003, Zoetendal et al. 1998). Sanger sequencing projects of 16S rDNA amplicons
showed the predominance of two phyla, Bacteroidetes and Firmicutes in the gut ecosystem, as well as the presence of other less
abundant  phyla  as  Actinobacteria, Proteobacteria, Verrucomicrobia  or  Fusobacteria  (Bäckhed et  al. 2005, Ley  et  al. 2006,
Zoetendal et al. 2006). 
The high-throughput sequencing technology revolutionized the microbial ecology since it allows to deep sequencing the
total 16S rRNA genes of an environment, thus revealing low-abundance species (named the rare biosphere) and giving a more
complete picture of the whole community (Huse et al. 2008, Marchesi 2010, Sogin et al. 2006). The high-throughput 16S rRNA
gene sequencing has become the most widely used method to characterize the structure of the human gut microbiota under
different conditions, as well as the influence of  internal and external factors in its composition and diversity. For instance,
Andersson and colleagues used 454-pyrosequencing of a hyper-variable region of the 16S rRNA gene to compare microbial
communities of the human throat, stomach and faeces (Andersson et al. 2008). This approach has been applied to examine the
human gut microbiota under several illness conditions as CDI , inflammatory bowel diseases, irritable bowel syndrome or
Crohn's disease. The gut microbial differences associated to factors as age, diet, or antibiotic usage have been also addressed in
this manner (Antharam et al. 2013, Claesson et al. 2011, Dethlefsen & Relman 2011, Durbán et al. 2012b, Filippo et al. 2010, Li
et al. 2012, Rea et al. 2011, Walker et al. 2011, Willing et al. 2011).
Issues  of  16S  rRNA  gene  sequencing  are  the  biases  introduced  by  the  nucleic  acid  isolation  (different  molecular
methods)  or PCR (number of  cycles, gene region to amplify) that  makes difficult  to compare data from different studies
(Youssef et al. 2009, Zoetendal et al. 2004). Other problem associated to PCR-based surveys is the underestimation of the low-
proportion taxa of the microbial communities and that its detection depends on the sequencing effort (Gonzalez et al. 2012). 
Despite  these  limitations,  some  advancements  including  a  higher  sequencing  resolution  at  lower  cost  and  the
development of analytical tools for multiple related samples (temporal and spatial series) have contributed to maintain a central
role for 16S rRNA in microbial ecology (Tringe & Hugenholtz 2008).
A group of techniques that have been successfully performed to monitor the dynamics of microbial communities are
those based on fingerprinting of the 16S rRNA gene. The fingerprinting techniques are based on 16S rRNA gene PCR and their
results  represent  profiles  of  sequence  diversity  of  ecosystems, but  the  principles  and procedures  vary  between  them. For
example, Denaturing Gradient Gel Electrophoresis (DGGE), Temperature Gradient Gel Electrophoresis (TGGE) and Temporal
Temperature Gradient Gel  Electrophoresis  (TTGE) are based on sequence specific  melting behaviour of  amplicons, Single
Strand  Conformation  Polymorphism  (SSCP)  on  the  secondary  structure  of  single  strand  DNA and  Terminal-Restriction
Fragment Length Polymorphism (T-RFLP) on specific target sites for restriction enzymes (Zoetendal et al. 2004). DGGE, TGGE
and TTGE have been the most widely applied to monitor and characterize the GIT microbial communities and have resulted in
knowledge about  factors  that  affect  the  microbiota such as  perturbations, physiological  states  or differences  between GIT
locations (La Cochetière et al. 2008, Lepage et al. 2005, Zoetendal et al. 2001). 
The disadvantages of these approaches are that they do not provide quantitative information and that they are not able
to identify lower abundance bacterial groups. However, other methods also based on the 16S rRNA gene have been applied to
obtain quantitative information such as the real-time PCR approach that is nowadays one of the most used to quantify the
bacterial load of GIT on humans and animal studies (Buffie et al. 2012, Matsuki et al. 2004). 
A different quantitative method to analyze environmental samples is the fluorescent in situ hybridization (FISH) using
16S rRNA targeted oligonucleotide probes (Amann et al. 1995). It combines the probe hybridization with microscopy or flow
cytometry  for detection and quantification of  individual  cells. The major disadvantage of  FISH is  that  it  depends on the
availability of probes and that only a few probes can be used simultaneously per analysis (Zoetendal et al. 2004). 
Other probe based method that has been used to study the microbial diversity of the gut is the DNA microarrays that
can be hybridized with DNA or RNA. The DNA microarrays have been applied in several ecological studies in which not only
SSU rRNA genes but also others genes, as antibiotics resistance genes, have been used as targets (Call et al. 2003, Peplies et al.
2003). The limitation  of  this  method  is  also  the  bias  introduced by  the  nucleic  acids  isolation and  the  subsequent  PCR
(Zoetendal et al. 2008). 
The flow-cytometry is a powerful approach since it is possible to sort uncultured bacteria and study specific bacterial
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groups (Wallner et al. 1997). It has been used to describe the diversity of active microbial fractions compared with the whole
community from human faecal samples (Peris-Bondia et al. 2011).
Since growing bacteria have greater amounts of  rRNA, targeting 16S rRNA rather than 16S rDNA allows to identify
bacteria that are metabolically more active (Itoh et al. 2013, Kemp et al. 1993, Lee et al. 2008, Moeseneder et al. 2005, O'Sullivan
2000). This approach is based on retrotranscription of the total RNA to generate double-strand cDNA for sequencing. The
differences in copy number of rRNA operons between bacteria is an issue even worse for ecological analysis at level of RNA
respect  to DNA, being the bacteria  with low copy number, less represented than those  with high copy number. However,
bioinformatics methods have been developed to correct the copy number and make more accurate inferences about microbial
diversity and abundance based on 16S sequence data (Kembel et al. 2012).
1.6.2.2. "OMICS" APPROACHES TO STUDY THE FUNCTIONS OF THE GUT MICROBIOTA
The SSU rRNA-based approaches are useful  for describing the composition of  microbial communities, but the results are
limited only to describe the microbial diversity, since the potential functions of the microbes present cannot be extracted from
these  kinds  of  data.  A  recent  computational  approach  called  PICRUSt  (phylogenetic  investigation  of  communities  by
reconstruction of unobserved states) is able to predict the functional composition of a sample using a marker gene as the 16S
rRNA and a database of  reference genomes  (Langille et al. 2013). However, the most realistic way to gain insights into the
functions and activities of microbes without cultivation is by applying metagenomics and other community-based approaches.
Metagenomics, which studies all  the genomes from an ecosystem, can be used to determine the phylogenetic, physical and
functional properties of microbial communities  (Handelsman 2004). The first golden standard was the use of metagenomic
libraries by cloning DNA from metagenomes in fosmids, cosmids or bacterial artificial chromosomes (Lepage et al. 2013). The
next generation sequencing technologies, mainly pyrosequencing, SOLiD or Illumina, have enabled to sequence the clones from
metagenomic libraries, but also the direct sequencing of the total DNA content from an ecosystem, deeply, rapidly and in a cost-
effective manner  (Niedringhaus et al. 2011). Screening of  gut metagenomic libraries has allowed to identified carbohydrate
active enzymes that are of interest in human nutrition, bile salt hydrolases, or bacterial genes involved in colorectal carcinoma
cell line proliferation (Gloux et al. 2007, Jones et al. 2008, Tasse et al. 2010).
Overall, metagenomic  studies  have  shed light  on the  effect  of  different  factors  as  host  health, age, or  diet  on the
functions of the gut microbial community (Arumugam et al. 2011, Gill et al. 2006, Kurokawa et al. 2007, Qin et al. 2010) . For
instance, the first human metagenomic study showed a significant enrichment of  the gut microbiome of  healthy adults in
metabolic pathways related to metabolism of glycans, amino acids and xenobiotics (Gill et al. 2006). A different metagenomic
study revealed an enrichment of carbohydrate transport and metabolism favouring milk intake on infants, while the adult gut
microbiome was enriched in energy harvest from diet (Kurokawa et al. 2007). 
The larger catalogue of microbial genes from the human gut was obtained by sequencing the total DNA from 33 faecal
samples  with Ilumina Genome Analyser  technology  (Qin et  al. 2010). The catalogue highlighted  functions  important  for
bacterial survival in the intestine and for the homeostasis of the gut ecosystem, as well as the existence of a functional core in
spite  of  the  high inter-individual  variability  of  the  microbial  composition. A latter  study  carried  out  by  Arumugam and
colleagues enabled to distinct "types" of gut compositon (named as enterotypes) that also differ in some metabolic capabilities
(Arumugam  et  al.  2011).  Metagenomic  sequencing  has  also  allowed  to  identify  signatures  that  differentiate  obesity,
inflammatory bowel disease and diabetes from healthy status (Greenblum et al. 2012, Karlsson et al. 2013, Qin et al. 2010). 
Although the importance of metagenomic contribution to the human microbiome characterization is out of doubt, it
has, however, some important limitations. For example, the methods for total DNA extraction and storage that are crucial for
the  representativeness  of  the  metagenomic  DNA respect  to  the  original  microbial  community  is  not  standardized  (Yu &
Morrison 2004). Other problem is the high proportion of data that cannot be functionally assigned due to a lack of reference in
databases  (Qin et al. 2010, Walker et al. 2014). In spite of that metagenomics is a powerful tool for exploring the genes of a
microbial ecosystem, it does not provide information about the actual activity or gene expression of the microorganisms that
46
are present. Other meta-"omics" approaches focus on messenger RNA (metatranscriptomics), proteins (metaproteomics) or
metabolites (meta-metabolomics) (Figure 1.11) and provide information about the activity of microbial ecosystems (Lepage et
al. 2013, Zoetendal et al. 2008).
Figure 1.11.  Integrated meta-omics.  Different  levels of  analyses  are  represented from phylogeny to  metabolomics (Adapted from
Lepage et al. 2013).
Frias-Lopez  et  al  were  pioneers  in  applying  metatranscriptomics  to  characterize  the  gene  expression  of  microbial
communities  of  ocean  surface  waters.  They  found that  the  most  expressed  genes  were  not  the  most  represented  on the
metagenome, suggesting the combination of these two approaches to better address the dynamics of ecosystems (Frias-Lopez et
al.  2008). Since  them, metatranscriptomics  has  been  applied  to  investigate  the  gut  microbiota  under  different  conditions
(Booijink et al. 2010, Maurice et al. 2013, McNulty et al. 2011, Turnbaugh et al. 2010). Our group carried out one of the first
metatranscriptomic studies of  the human gut microbiota analyzing the total gene expression of 10 healthy individuals. The
mRNA  characterization  revealed  a  uniform  functional  pattern,  being  carbohydrate  metabolism,  energy  production  and
synthesis of cellular components the main roles (Gosalbes et al. 2011, 2012). 
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Some limitations of metatranscriptomics are the purification of high-quality total RNA and the enrichment in mRNA
depleting the 16S rRNA and 23S rRNA, which are the most abundant types of RNA (Sorek & Cossart 2010, Stewart et al. 2010,
Walker  et  al.  2014).  Also,  the  short  half-life  of  mRNAs  makes  difficult  to  detect  short-term  responses  of  the  microbial
community to environmental changes (Simon & Daniel 2011). 
Other challenging approach to be combined with metagenomics is metaproteomics. As in the metatranscriptome, the
human faecal metaproteome presents a skewed distribution relative to the metagenome, with more proteins for translation,
energy production and carbohydrate metabolism (Verberkmoes et al. 2009). The combination of these two approaches allowed
comparing the gut microbial community between an obese and a lean adolescent. The two gut communities maintained largely
similar gene repertoires and functional profiles, but for example a higher abundance of proteins involved in B12 synthesis and
butyrate production were observed in the obese gut, whereas bacteria from lean gut seem to be more engaged in vitamin B6
synthesis (Ferrer et al. 2013). A different follow-up study showed that the adult fecal metaproteome is subject specific and stable
over time and also identified core functions as carbohydrate metabolism and transport (Kolmeder et al. 2012). An important
limitation of  this approach is the large gaps in databases that limit the functional annotation of  the proteins  (Walker et al.
2014).
Finally, meta-metabolomics is at present the most used of the meta-"omics" approaches to study the human microbiota
also combinable with metagenomics  (Turnbaugh et  al. 2008). It has been used to investigate several  digestive disorders as
colorectal cancer, inflammatory bowel disease, irritable bowel syndrome, or obesity, as well as to address the consequences of
antibiotic treatment on the metabolic status of the human gut microbiota (Ferrer 2013, Lepage et al. 2013). 
The  application  of  these  innovative  exploratory  approaches  and  especially  their  integration  could  reveal  new
information about the gut ecosystem, its functioning and dynamics as well as its relation with the human health. 
1.6.2.3. BIOINFORMATICS METHODS
The recently developed sequencing technologies as those commercialized by 454 Life Sciences/Roche Applied Sciences (454),
Illumina Incorporated (Solexa) or Applied Biosciences (SOLiD) has increased the depth of sequencing by orders of magnitude
compared to traditional Sanger sequencing (Mardis 2008, Robinson et al. 2010, Shendure & Ji 2008). 
The  studies  based  on these  techniques  have  generated huge amount  of  data  difficult  to  analyse, since  it  is  time-
consuming  and  usually required several gigabytes of  memory to store and multiple processors to deal with the sequences.
However, many programs, pipelines websites and databases have been developed or improved in the last years to store and
analyse the generated data. In big databases as the National Center for Biotechnology Information (NCBI) or the European
Bioinformatics Institute (EMBL-EBI), among others, the amount of information has significantly increased over these years. At
the same time, various specific databases have been created, especially for the analysis of the 16S rRNA data. For instance, the
Ribosomal Database Project (RDP), SILVA or greengenes are comprehensive rRNA gene databases used for the taxonomic
affiliation of the 16S rRNA gene sequences (Cole et al. 2009, DeSantis et al. 2006, Pruesse et al. 2007). Moreover, databases
containing  functional  information  such  as  the  Kyoto  Encyclopedia  of  Genes  and  Genomes  (KEGG)  or  TIGRFAMs  are
continuously improved and updated (Haft et al. 2003, Kanehisa & Goto 2000).
Many of  the programs and pipelines are able of  process the information (sequences) and to perform most of  the
ecological and statistical analysis from the raw data. Some of the most currently used in microbial ecology are the software
packages Mothur and Quantitative Insights Into Microbial Ecology (QIIME) that can process the 16S rRNA sequences (as
trimming, denoising, aligning, etc...)  and to  perform ecological  analysis  (estimators  of  richness, diversity, similarity, etc...)
(Caporaso et al. 2010, Robinson et al. 2010; Schloss et al. 2009). 
Regarding  the  functional  and  taxonomic  analysis  of  metagenomes  or  metatranscriptomes,  other  software  as
Metagenomics  Rapid  Annotation  using  Subsystem  Technology  (MG-RAST),  or  the  web  server  for  metagenomic  analysis
(WebMGA) have also been developed (Meyer et al. 2008, Wu et al. 2011). Additionally, to graphically represent data and results,
as well as to perform several types of ecological and statistical analysis, the use of The R Project for Statistical Computing (R)
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has been standardized in recent years (mainly for statistics) (R Development Core Team 2011). Several packages of this software
for statistical and ecological analysis (bioconductor, vegan, etc.), as well as for graphic data representation (lattice, ggplot2) are
continually released (Gentleman et al. 2004, Oksanen et al. 2011, Sarkar 2008, Wickham 2009).
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2. OBJECTIVES
The human gut microbiota represents a very complex ecosystem involved in essential functions for the host physiology. Since
the antibiotics are one of the strongest disturbing agents of its equilibrium, their uses exert a great impact on human health.
The study of microbial communities has changed dramatically since the development of culture-independent approaches, in
combination  with  high-throughput  sequencing  technologies.  The  emerging  of  "omics"  technologies  as  metagenomics,
metatranscriptomics, meta-metabolomics and metaproteomics have proven effective in characterizing the structure, activities,
functions and interactions of the human gut microbiome.
The general aim of this thesis was to gain insight into the effect of antibiotics on the human gut microbiota and its implications
in human health through the application of these ecological approaches. This has been achieved by three specific objectives:
The first  objective  was to  study in-depth the  evolution of  the  human faecal  microbiota  under  antibiotic  therapy
through the combination of multiple "omics" approaches, since each of them provides information about a different biological
level. The specific aim was to characterize the structure (diversity and microbial composition of the total and active fraction)
and activity (genes, mRNAs, proteins and metabolites) of the microbial ecosystem in response to stress induced by beta-lactam
antibiotics. This proof-of-concept study corresponds to the original  article: "Gut microbiota disturbance during antibiotic
therapy: a multi-omic approach" (Chapter 3.1).
The second objective was to study the effect of  different classes of  antibiotics in the human intestinal microbiota.
Specifically, we wanted to test if differences in spectrum, mode of action and antimicrobial effect are reflected in the respective
changes of the total and active microbiota and in the genetic potential of the gut ecosystem. We also wanted to characterize the
evolution of resistance genes (resistome) during therapy and its relation with the type of antibiotics. The main results of this
research are included in the original article "Differential effects of antibiotic therapy on the structure and function of human
gut microbiota" (Chapter 3.2).
The third goal consisted in to better understand the development of CDI and its relation with an antibiotic-associated
altered microbiota.  First, we wanted to evaluate the structural  and functional  changes  of  the intestinal  microbiota due to
infection by the pathogen. Moreover, we were interested in identifying microorganisms and metabolic functions associated with
infection and other bacteria and functions that might be involved in colonization resistance against  C. difficile. This work is
included in the original research article: "Structural and functional changes in the gut microbiota associated to  Clostridium
difficile infection" (Chapter 3.3).
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ABSTRACT
Objective Antibiotic (AB) usage strongly affects
microbial intestinal metabolism and thereby impacts
human health. Understanding this process and the
underlying mechanisms remains a major research goal.
Accordingly, we conducted the ﬁrst comparative omic
investigation of gut microbial communities in faecal
samples taken at multiple time points from an individual
subjected to β-lactam therapy.
Methods The total (16S rDNA) and active (16S rRNA)
microbiota, metagenome, metatranscriptome (mRNAs),
metametabolome (high-performance liquid
chromatography coupled to electrospray ionisation and
quadrupole time-of-ﬂight mass spectrometry) and
metaproteome (ultra high performing liquid
chromatography coupled to an Orbitrap MS² instrument
[UPLC-LTQ Orbitrap-MS/MS]) of a patient undergoing AB
therapy for 14 days were evaluated.
Results Apparently oscillatory population dynamics were
observed, with an early reduction in Gram-negative
organisms (day 6) and an overall collapse in diversity and
possible further colonisation by ‘presumptive’ naturally
resistant bacteria (day 11), followed by the re-growth of
Gram-positive species (day 14). During this process, the
maximum imbalance in the active microbial fraction
occurred later (day 14) than the greatest change in the
total microbial fraction, which reached a minimum
biodiversity and richness on day 11; additionally, major
metabolic changes occurred at day 6. Gut bacteria respond
to ABs early by activating systems to avoid the
antimicrobial effects of the drugs, while ‘presumptively’
attenuating their overall energetic metabolic status and the
capacity to transport and metabolise bile acid, cholesterol,
hormones and vitamins; host–microbial interactions
signiﬁcantly improved after treatment cessation.
Conclusions This proof-of-concept study provides an
extensive description of gut microbiota responses to follow-
up β-lactam therapy. The results demonstrate that ABs
targeting speciﬁc pathogenic infections and diseases may
alter gut microbial ecology and interactions with host
metabolism at a much higher level than previously
assumed.
INTRODUCTION
The human colon harbours a vast ensemble of
microbes that carry out vital processes for human
physiology and nutrition, and the microbes in this
complex ecosystem are deﬁned as the microbiota.
Accordingly, the human colon can be viewed as an
Open Access
Scan to access more
free content
Signiﬁcance of this study
What is already known on this subject?
▸ Changes in gut microbiota have been shown to
be associated with antibiotic (AB) usage.
▸ Broad-spectrum ABs result in a signiﬁcant
reduction in Bacteroidetes and a concurrent
increase in Firmicutes.
▸ The understanding of the dynamics and
mechanisms underlying functional changes in
the microbiome in response to AB treatments
remains limited.
What are the new ﬁndings?
▸ AB treatment provoked apparently oscillatory
population dynamics with major changes at the
level of gut microbiota metabolism and total
and active microbial fraction compositions at
days 6, 11 and 14, respectively, after the
initiation of the therapy.
▸ ABs have ecological implications related to the
energy metabolism of colonic bacteria, which
partially improved at day 6 to cope with an
intermittent nutrient supply and AB stress but
decreased at later stages and after treatment
cessation.
▸ Although no abundant bacteria can be very
active at a given moment in the presence of
ABs, minor community members play a
signiﬁcant active role in overall gut metabolism
and host interactions.
How might it impact on clinical practice in the
foreseeable future?
▸ The treatment of patients with ABs targeting
speciﬁc pathogenic infections and diseases
might inﬂuence the global metabolic status of
gut microbes in such a way that could affect
human biology. Integrative omics approaches
represent a promising strategy for preventing
metabolic diseases associated with AB uptake
during therapeutic and clinical interventions.
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anaerobic bioreactor in which trillions of microorganisms add a
vast catalogue of genes to the genetic resources of the host to
provide complementary metabolic pathways for energy harvest,
food digestion, detoxiﬁcation, the production of bioactive com-
pounds and the assimilation of otherwise inaccessible dietary
nutrients.1–5 Recent studies have shown that each individual har-
bours a unique and relatively stable gut microbiota, generally
dominated (over 90%) by the Bacteroidetes and Firmicutes, in
addition to minorities of Actinobacteria, Proteobacteria and
Verrucomicrobia, the majority of which have not yet been iso-
lated or characterised.6 However, this well engaged bacterial
machinery can be disrupted by external factors such as antibiotic
(AB) treatment.7–9 AB therapy has been successfully used for
many years to treat bacterial infections, but the emergence of
AB-resistant bacteria has caused enormous public health pro-
blems. Moreover, resistant species can persist in the human gut
for years.7 10–12
AB therapies affect not only the target microorganism but also
the host-associated microbial communities, particularly those in
the intestine. In recent years, the effects of distinct ABs on the
gut microbiota have been evaluated, primarily by 16S rRNA ana-
lysis.7 10 11 13–16 The patterns of microbial diversity and
gene-encoded functions are highly intricate,11 and contradictory
reports on the compositions of microbial communities have com-
plicated the identiﬁcation of functional and molecular hotspots
associated with AB therapy in humans. Recent experiments have
revealed that treatment with broad-spectrum ABs affects the
microbiota composition, resulting in a signiﬁcant reduction in
Bacteroidetes and a concurrent increase in Firmicutes.13
Moreover, different studies have reported bacterial resilience fol-
lowing AB treatment.11 14 15 17
The understanding of the dynamics and mechanisms under-
lying functional changes in the microbiome in response to AB
treatments remains limited, primarily because most research to
date has relied on indirect evidence from DNA-based
approaches that fail to provide information on actual gene
expression, protein synthesis and metabolite composition and
variation. Moreover, no integrated metatranscriptomic, meta-
proteomic or metametabolomic surveys on AB-treated human
microbiota have been performed. Speciﬁcally, in the gut ecosys-
tem, few studies have focused on metatranscriptomics.
Turnbaugh et al18 focused on gene expression analysis in faecal
samples from a monozygotic twin pair, whereas Booijnk et al19
and Gosalbes et al20 studied the faecal metatranscriptomes of
healthy volunteers using cDNA ampliﬁed fragment length poly-
morphism and pyrosequencing, respectively. Proteomic plat-
forms have also been used to separate and identify thousands of
proteins in faecal samples from healthy individuals,21–24 but
these analyses have not uncovered the effect of ABs on the sta-
bility or expression of core proteins or their functions. Finally,
metabolic changes in mouse—but not human—gut microbiota
following treatment with the broad-spectrum AB enroﬂoxacin
were recently evaluated using nuclear magnetic resonance based
metabolomics.25 However, this study yielded limited informa-
tion because the faecal samples were only analysed for changes
in eight metabolites, including increased levels of amino acids
and urea caused by the loss of microbial proteases and ureases,
and reduced levels of acetate, butyrate and propionate generated
by lactate-using bacteria.
In this study, we provide the ﬁrst report of AB-treatment
related changes in the faecal microbiota, including the total
microbiota, active microbiota, metagenome, metatranscriptome,
metametabolome and metaproteome. This multi-omics
approach yielded a global picture of the microbial community
structure and the metabolic status of the gut ecosystem, which is
paramount to understanding the total effect of a given AB and
to establishing correlations with host physiology. This study of
one patient constitutes a proof of concept for this approach.
MATERIALS AND METHODS
Fresh faecal samples were collected from a patient who had not
taken ABs within the previous 3 months. The patient
(a 68-year-old man) was admitted to the Department for
Internal Medicine at the University Hospital Kiel (Germany)
due to an infected cardiac pacemaker. A clinical examination
identiﬁed inﬂamed skin and subcutaneous tissue around the
pacemaker, and laboratory ﬁndings revealed an elevated
C-reactive protein level (CRP 19.7 mg/litre; normal value
<8 mg/litre) and a full blood count within normal ranges. The
patient did not present any intestinal disorders. The pacemaker
had been placed to treat the patient’s sick sinus syndrome, ﬁrst
diagnosed in 1994. His cardiovascular risk factors were arterial
hypertension and non-insulin-dependent diabetes mellitus. The
patient was regularly taking amlodipine, ramipril, hydrochlor-
othiazide and glimepiride on a daily basis and Marcumar
according to his international normalised ratio values. AB
therapy was initiated with a combined intravenous therapy of
ampicillin/sulbactam and cefazolin on the day of admission as a
single dose and continued with intravenous cefazolin alone for
the next 14 days. The patient’s CRP level returned to normal
within 1 week after the beginning of AB therapy. Faecal samples
were collected on the day of admission, prior to AB treatment
(day 0, FS-0), on days 3, 6, 11 and 14 of AB treatment (FS-3,
FS-6, FS-11 and FS-14, respectively) and 40 days after AB
therapy (FS-40). Fresh faeces were collected, frozen immediately
and stored at −80°C until further processing. Informed consent
was obtained from the patient, and the study was approved by
the Ethical Board of the Medical Faculty of the Christian-
Albrecht-University, Kiel, Germany. The patient provided
written informed consent. Full descriptions of the materials and
methods used for the following are available in the Materials
and Methods in the online supplement: nucleic acid and RNA
extraction; 16S rDNA and 16S rRNA sequencing; metagenome
sequencing; mRNA puriﬁcation, ampliﬁcation and sequencing;
metagenomic and metatranscriptomic analysis; protein extrac-
tion, separation and identiﬁcation and data processing; and
metabolite extraction, separation and identiﬁcation and data
processing. All sequences have been entered in the European
Bioinformatics Institute database, under accession number
ERP001506.
RESULTS
Total and active faecal microbiota
We used 16S rDNA and 16S rRNA analyses to characterise the
total bacteria (16S rDNA) and metabolically active bacteria (16S
rRNA), respectively, in each faecal sample.26–28 As shown in
ﬁgure 1, there were large ﬂuctuations in the relative abundances
of the various bacterial taxa in the total and active microbiota
throughout the follow-up study. In the ﬁrst days of treatment,
the majority of the total microbiota comprised species from the
phylum Firmicutes, with the exception of FS-11 (11 days after
AB treatment), which exhibited a remarkable shift towards
Bacteroidetes (Parabacteroides and Bacteroides genera) and a sig-
niﬁcant increase in Betaproteobacteria (ﬁgure 1 and ﬁgure 1 in
online supplement). The Lachnospiraceae and Ruminococcaceae
families constituted the most abundant taxa on days 3 and 6 of
AB treatment. Meanwhile, the Firmicutes represented the most
abundant active phylum in most samples. However, the shift
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towards the Bacteroidetes was even more distinct and occurred
later, at the 14th day (FS-14) of AB treatment, among the active
bacteria, with the Parabacteroides genus (74%) being the pre-
dominant taxa.
As shown in ﬁgure 1, there was a general tendency towards the
restoration of the original (day 0) untreated total and active bac-
terial composition at 40 days after cessation of the AB treatment.
However, certain taxa, such as Actinobacteria (Slackia and
Biﬁdobacterium genera), Betaproteobacteria (Gemmiger genus),
Streptococcaceae (Streptococcus genus), Lachnospiraceae
(Roseburia genus), Porphyromonadaceae (Barnesiella genus) and
Clostridiales (Eubacterium and Subdoligranulum genera) were
lost. The heat map and clustering analysis (see ﬁgure 1 in online
supplement) results support the restoration of the microbiota
because untreated samples clustered together regardless of
whether we considered the total bacterial composition or the
active bacterial composition. The results of a correspondence
analysis of the relative abundance of each taxon in the total and
active microbiota fractions are shown in ﬁgure 2 in the online
supplement. Approximately 55.90% of the total variation can be
bundled in two axes (CA1 and CA2), each of which contributed
a similar degree of variation. CA1, bundling 23.81% of the vari-
ation, indicates how divergent a given sample is from the average
abundance of taxa, whereas CA2, bundling 22.09% of the vari-
ation, clearly differentiates the composition of the total (DNA)
and active (RNA) microbiota. Moreover, the active microbiota
clearly behaved in a more homogeneous manner than the total
microbiota, and samples FS-40 and FS-11 exhibited the most
divergent microbiota among the samples analysed.
As shown using the Chao1 richness estimator (table 1), the
diversity of the total bacterial community decreased during AB
treatment and reached a minimum value after 11 days of AB treat-
ment (FS-11). At this time point, the microbiota also exhibited a
lower Shannon index value, indicating that there were fewer and
more heterogeneously distributed bacterial families in the FS-11
sample compared with the other samples (ﬁgures 1, and ﬁgures 1
and 2 in online supplement). Interestingly, the biodiversity even-
ness and richness of the active bacteria remained essentially
uniform until the 14th day of treatment (FS-14), at which time
there was a marked decrease in bacterial taxa and richness.
Table 1 Biodiversity measures of total and active microbiota
Genetic material Sample N Shannon Chao1 SD
DNA FS-0 41 3.5 46.9 5.4
FS-3 17 2.7 21.8 5.6
FS-6 21 2.8 23.0 3.8
FS-11 13 1.2 14.5 0.3
FS-14 21 3.2 21.5 1.4
FS-40 38 3.1 43.9 6.8
RNA FS-0 30 3.3 38.3 9.5
FS-3 31 3.6 38.4 7.6
FS-6 39 3,9 50.7 1.9
FS-11 32 3,3 45.1 12.0
FS-14 18 1.5 26.1 9.0
FS-40 35 3.7 47.8 13.3
The number of observed taxa (N), the biodiversity index value (Shannon) and the
richness estimator (Chao1) are shown, with the SD.
Figure 1 Total and active bacterial composition based on 16S rDNA and 16S rRNA analyses, respectively, in the follow-up study. Samples FS-0,
FS-3, FS-6, FS-11 and FS-14 correspond to the materials collected on days 0, 3, 6, 11 and 14 of antibiotic (AB) treatment, respectively. The FS-40
sample corresponds to the materials collected 40 days after cessation of the AB treatment.
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At the species level, the principal component analysis (PCA)
showed that the total bacterial community (16S rDNA) proﬁles
of samples FS-0 and FS-40 differed from those of the other
samples (see ﬁgure 3 in online supplement). Together, the two
axes projected 69% of the total variance in the data. Fourteen
operational taxonomic units (OTUs) responsible for the differ-
ences between the samples were identiﬁed by the lengths of their
vectors in the PLS-DA (see ﬁgure 4 in online supplement). Before
and after AB treatment, OTUs with homology to
Faecalibacterium prausnitzii and Blautia wexlerae, belonging to
the phylum of Firmicutes, were highly abundant. However,
Enterococcus durans, an abundant OTU in FS-3, FS-6 and FS-11,
was absent in the FS-0 and FS-40 samples. Furthermore, we
observed an increase in OTUs with homology to different species
of Bacteroides and Parabacteroides such as B fragilis, P merdae, B
dorei, P distasonis, B uniformis and B ovatus in the FS-11 and
FS-14 samples. Thus, during AB therapy, the relative abundance
of Bacteroidetes increased, whereas OTUs with homology to
Firmicutes regained their dominance after cessation of the AB.
Abundance and diversity of gene transcripts by
metatranscriptome analysis
To identify the major regulated pathways and processes under
AB pressure, we evaluated the microbiota-regulated genes
(mRNAs) (see table 1 in online supplement).29 30 Figure 2A
shows the correspondence analysis for the expressed genes in
each sample, independent of the gene functions. The two axes,
CA1 and CA2, bundle 39.91% and 33.12% of the total
observed variation, respectively, which represents a substantial
percentage (73.03%) of the total variation. The mRNA tran-
script contents of samples FS-6 and FS-40 were clearly distinct
(ﬁgure 2B). Moreover, at the expression level, a drastic shift
occurred on the 6th day of AB therapy, and the initial proﬁle
was recovered on the 14th day.
Using a self-organising map package,31 the gene expression
proﬁles were analysed and yielded six groups (ﬁgure 5 in online
supplement). The genes included in clusters 0 and 1 exhibited
increased expression only on the 3rd day following AB treatment
and returned to basal levels at later stages of the treatment. These
genes were functionally categorised to have roles in protein trans-
port and binding (potassium uptake protein, TonB-dependent
receptor, nitrile hydratase propeptide microcin bacteriocin
system ATP-binding cassette transporter, peptidase/ATP-binding
protein), toxin production and resistance (resistance-nodulation-
cell division superfamily and hydrophobe/amphiphile efﬂux-1
transporters), detoxiﬁcation (heavy metal efﬂux and CzcA per-
meases), mobile and extrachromosomal elements (phage lambda
tail tape measure protein) and protein fate determination (TolC
type I secretion outer membrane protein). Genes belonging to
clusters 2, 3 and 4 (DNA metabolism/DNA replication, recom-
bination and repair, protein fate/protein and peptide secretion
and trafﬁcking and protein synthesis/tRNA and rRNA base modi-
ﬁcation) presented a more uniform proﬁle before, during and
after AB treatment. The genes in cluster 5 remained constant but
exhibited a relatively higher expression level on the 14th day fol-
lowing the beginning of AB treatment, returning to the basal
level after the discontinuation of AB treatment; these genes func-
tioned in molecule renewal and transport (proteins, peptides,
amino acids, polysaccharides, purines, purine ribonucleotides,
pyrimidines and glycopeptides (bio)synthesis, secretion, trafﬁck-
ing, transport, binding and/or degradation) and DNA metabol-
ism/DNA replication, recombination, and repair and cellular
processes related to sporulation and germination.
As illustrated in ﬁgure 3, the taxonomic assignment of
expressed genes showed that the compositions of the FS-6 and
Figure 2 (A) Correspondence analysis of the expressed genes in each sample. (B) Clustering of the samples based on the type and abundance of
expressed genes, applying the Bray–Curtis distance.
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FS-40 samples were clearly different. The FS-6 sample contained
primarily Streptococcaceae (27%), Clostridiaceae (13%) and
Bacteroidaceae (13%). In the FS-40 sample, Burkholderiaceae
(46%) (phylum Proteobacteria) were the most abundant, despite
the low abundance of 16S rRNA from these organisms (ﬁgure 1).
However, in the other samples (FS-0, FS-3, FS-11 and FS-14),
the Bacteroidaceae family was the major taxon responsible for
the observed gene expression. This family contains genera, such
as Parabacteroides and Bacteroides, that are resistant to ampicillin
and cephalosporins, as previously reported.32 These results
account for the three clusters shown in ﬁgure 2B.
We statistically evaluated the changes in gene expression fol-
lowing treatment according to various functional categories by
applying a regression analysis in the ShotgunFunctionalizeR
package.33 The categories that demonstrated signiﬁcant changes
in expression during treatment are shown in ﬁgure 6 in the
online supplement. Samples FS-6 and FS-40 exhibited major
differences, whereas the rest of the samples were more closely
related. This observation was further supported by the corres-
pondence analyses (see ﬁgure 7 in online supplement), in which
the ﬁrst two axes, CA1 (56.72%) and CA2 (34.13%), accounted
for 90.85% of the total variation.
Abundance and diversity of metabolites by
metametabolome analysis
The metabolite contents (type and abundance) of samples FS-6
and FS-40 were clearly different (ﬁgure 4), consistent with
the correspondence analysis of the observed gene expression
(ﬁgure 2). Of the 382 different features identiﬁed (29 being
common), the FS-40 sample revealed the greatest number (280)
of associated mass features, followed by the FS-6 sample, with
234 features (see ﬁgures 8 and 9 in online supplement); FS-14
(185), FS-11 (121) and FS-0 (139) showed fewer features.
According to the probability of match with the isotopic pattern
shown in table 2 in the online supplement, 49 distinct common
features were tentatively identiﬁed. Based on their abundance
level, ﬁve groups of molecules were established (see ﬁgure 12 in
online supplement). Most long-chain fatty acids and peptides
exhibited increased abundance on the 6th day (sample FS-6) as
well as after the discontinuation of AB treatment (FS-40);
they included two masses corresponding to putative
sphingolipid-related compounds, such as C17 sphinganine and
dihydroceramide C2, six unsaturated fatty acyls, two fatty acid
amides, a lysophosphatidic acid and a tri-peptide formed by Asp/
Ile/Phe, Asp/Leu/Phe or Phe/Glu/Val. Most of the putative gly-
cerol(lyso)phospholipids (including ﬁve putative glyceropho-
spholipids and fatty acid carnitines) exhibited increased
abundance on the 11th and 14th days, but signiﬁcantly decreased
(from 4 to 20 000 fold) after the discontinuation of AB treat-
ment. Finally, nine putative human-associated derivatives of chol-
esterol, the cholesterol-precursor vitamin D, bile acids,
prostaglandins and sterol lipids appeared only after AB treatment
(FS-40), with production levels of up to six orders of magnitude
higher than that of samples before and during AB therapy.
Abundance and diversity of proteins by metaproteomic
analysis
A total of 3011 proteins (1359 common) were unambiguously
quantiﬁed (see table 3 and ﬁgure 10 in online supplement).
Considering a threshold of at least 1.5 and −1.5 log2 ratios of
abundance levels, we observed that AB treatment reduced the
number of highly abundant proteins compared with the control
Figure 3 Taxonomic assignments of mRNAs for each sample according to the lowest common ancestor algorithm.
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sample (FS-0) over time but promoted the number of low-
abundance proteins (ﬁgure 5), with the FS-40 sample containing
the lowest number of high-abundance proteins and the highest
number of low-abundance proteins. Samples FS-11 and FS-40
exhibited clearly different protein expression proﬁles based on
the correspondence (ﬁgure 6A) and clustering (ﬁgure 6B) ana-
lysis of differentially expressed proteins (ﬁgure 6A), which was
corroborated by the corresponding functional analysis (see
ﬁgure 11 in online supplement). These results suggest the restor-
ation of the microbiota because untreated samples (FS-0 and
FS-40) clustered together, indicating that the initial proﬁle was
recovered at the end of the treatment despite the drastic shift
that occurred on the 11th day (see table 1 in online supple-
ment), consistent with the analysis of the total and active bacter-
ial compositions (ﬁgure 1).
According to the lower and over-representation of functional
gene categories (clusters of orthologous groups; COGs), we
found a rather stable distribution between the samples, with sig-
niﬁcantly different contributions from only 29 out of 494 COGs.
As shown in ﬁgure 7, we observed speciﬁc differences that clearly
indicated drastic shifts on day 6 of AB therapy (FS-6) and after
treatment cessation (FS-40) of proteins assigned to 23 distinct
COGs within the functional categories of glycolysis, pyruvate
and glutamate metabolism, iron uptake and translation
Figure 4 Partial least-squares
discriminant analysis score plots and
clustering analysis of metabolite
proﬁles after different comparisons.
(A) The whole dataset (8600 features)
with the prediction for quality control
(QC) samples, seven components,
R2=0.989, Q2=0.670; the robustness of
the analytical procedure was
demonstrated by the tight clustering of
the QC samples. (B) Discriminant
variables identiﬁed by comparing
samples in a pairwise fashion (382
discriminant features from 988 of the
4349 initial variables that were present
in all three replicates of samples from
any group), four components,
R2=0.978, Q2=0.928. (C) Statistically
signiﬁcant variables identiﬁed in the
METLIN database (49 features), four
components, R2=0.968, Q2=0.915.
(D) The effect of antibiotics on the
human gut microbiota, as determined
by a two-way hierarchical clustering
analysis of the metabolite proﬁles.
Hierarchical clustering was performed
with a matrix of the total masses that
passed the ﬁltering and statistical
treatments for each sample. Less
abundant masses in a given
community are shown in blue, whereas
more abundant masses are shown in
red. Note: sample FS-3 was discarded
from the analysis due to the presence
of faecal material in the cell extracts.
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(ﬁgure 7A–C); a transient increase in expression at day 6 was fol-
lowed by depletion during and after the follow-up period.
AB-treated samples were also characterised by a striking deple-
tion of the translation elongation factors required for protein
synthesis, such as GTPases, which facilitate the release of nascent
polypeptide chains; this depletion was accentuated after treat-
ment cessation (ﬁgure 7B). By contrast, samples taken during AB
treatment were characterised by an enrichment of antimicrobial
peptide transporters and multidrug efﬂux pumps that peaked on
the 3rd day of AB treatment (ﬁgure 7D) and were absent in
untreated samples (FS-0 and FS-40). Additional key proteins,
such as aerobic CobN cobaltochelatases (COG1429) essential for
the biosynthesis of vitamin B12, were also found to be depleted
(see table 3 in the online supplement) in samples FS-3, FS-11 and
FS-14 compared with untreated samples.
DISCUSSION
The effects of ABs and the mechanisms underlying the connec-
tion between AB treatment and microbial gut metabolism
require clariﬁcation, which can only be achieved through an
integrated approach that goes well beyond the 16S DNA ana-
lysis that has been the cornerstone of previous research in this
area. Thus, the aims of this study were as follows: to provide a
proof of concept for an integrated workﬂow to assess the nature
of such changes in the intestines of patients undergoing AB
treatment at the structural and functional levels; and to evaluate
whether there is a relationship between these types of changes.
For instance, changes in the total composition at a given time
point may also be associated with changes in the AB-resistant
bacteria, although not necessarily at the same moment or during
the same interval. Two major active factors that modulate
changes in the microbiota should be considered. First, it is
important to understand how AB treatment determines the
emergence of bacterial species that are resistant to β-lactams
(such as ampicillin and cephalosporins) and how the microbiota
recovers once ABs have been removed. Second, the speed at
which such changes are observed according to the different
levels under consideration should be carefully evaluated.
In our study, we demonstrated that the greatest change in the
active microbial fraction occurred later (day 14) than that in the
total microbial fraction, which reached a minimum biodiversity
and richness on the 11th day of AB treatment (ﬁgure 1).
Further, oscillatory population dynamics were observed (at both
the DNA and RNA levels). An early reduction in Gram-negative
bacteria at day 6 and an overall collapse in diversity was fol-
lowed by possible colonisation of the upper gut by naturally
resistant Bacteroidetes by day 11, a consequent increase in the
colonisation of the lower gut with dominance at 11–14 days
and eventual re-growth of the Gram-positive bacteria at day 14.
Various studies based on 16S rDNA analysis revealed important
variability in the recovery of the baseline bacterial composition
after AB therapy depending on the individual and the AB used
(type and dose).11 14 15 The large ﬂuctuations in the relative
abundances of the various bacterial taxa for the total and active
microbiota throughout the follow-up study were most likely
associated with an additive effect of ampicillin/sulbactam and
Figure 6 (A) Correspondence analysis of the expressed proteins in each sample. (B) Clustering of the samples based on the type and abundance
of expressed proteins, with Pearson’s correlation applied to calculate the distances. The two axes, CA1 and CA2, in (A) bundle 33% and 28% of the
total observed variation, respectively.
Figure 5 Number of quantiﬁed proteins showing either high (black
bars) or low (white bars) abundance levels relative to the proteins
identiﬁed in sample FS-0. Only proteins with values ≥1.5 or ≤-1.5 log2
ratios were considered.
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the ﬁrst-generation cephalosporin cefazolin as well as the wide-
spread development of β-lactamases (for details, see the
Discussion in the online supplement).13
The apparent oscillations in the population dynamics were shown
to further inﬂuence the biodiversity and richness of metabolites and
active proteins; these changes, some of which may play essential
roles in protection against ABs (for details, see the Discussion in the
online supplement), may also have important ecological implica-
tions. In our study, we observed a drastic shift 6 days after the onset
of AB treatment, at which time the predominantly active taxa were
mainly members of the Streptococcaceae, Clostridiaceae and
Bacteroidaceae, and at 40 days after the end of AB treatment, when
the most abundant active bacteria were members of the
Burkholderiaceae (Proteobacteria phylum). Thus, these bacteria
may have contributed to the distinct functional proﬁles and meta-
bolic statuses of colonic bacteria during the follow-up therapy.
A notable ﬁnding in this study was that protein expression
appeared to decrease as a consequence of AB treatment; further-
more, the production of proteins needed for glycolysis, pyruvate
decarboxylation, the tricarboxylic acid cycle, glutamate metabol-
ism, iron uptake, GTP hydrolysis and translation termination
were enhanced at the initial stages of AB treatment (day 6),
most likely to cope with an intermittent nutrient supply and the
stress caused by the ABs, but decreased at later stages and after
treatment cessation. Together, these results suggest for ﬁrst time
that AB treatment may ‘presumptively’ negatively affect the
Figure 7 Graphical representation of the high-abundance and low-abundance proteins in different pathways, according to the clusters of
orthologous group (COG) number assigned to each protein. (A) Rubrerythrin/ferritin COGs: COG1592 (rubrerythrin) and COG1528 (ferritin-like
protein). (B) Translation factor and translation enzyme COGs: COG0193 (peptidyl-tRNA hydrolase), COG0264 (translation elongation factor Ts),
COG0050, COG0532 (GTPases—translation elongation factors), COG0216 (protein chain release factor A), COG0480 (translation elongation factors
(GTPases)) and COG0231 (translation elongation factor P/translation initiation factor 5A). (C) Glycolysis, pyruvate, glutamate and other related COGs:
COG0126 (3-phosphoglycerate kinase), COG0205 (6-phosphofructokinase), COG0148 (enolase), COG0076 (glutamate decarboxylase and related
proteolipid protein-dependent proteins), COG1830 (DhnA-type fructose-1,6-bisphosphate aldolase and related enzymes), COG0334 (glutamate
dehydrogenase/leucine dehydrogenase), COG1053 (succinate dehydrogenase/fumarate reductase, ﬂavoprotein subunit), COG0588 (phosphoglycerate
mutase 1), COG0479 (succinate dehydrogenase/fumarate reductase, Fe-S protein subunit), COG0191 (fructose/tagatose bisphosphate aldolase),
COG0149 (triosephosphate isomerase), COG0166 (glucose-6-phosphate isomerase), COG0057 (glyceraldehyde-3-phosphate dehydrogenase/
erythrose-4-phosphate dehydrogenase) and COG0469 (pyruvate kinase). (D) Antimicrobial transporters, multidrug efﬂux pumps and other
transporter COGs: COG0841 (cation/multidrug efﬂux pump), COG2825 (outer membrane protein), COG3292 (predicted periplasmic ligand-binding
sensor domain), COG3264 (small-conductance mechanosensitive channel), COG1538 (outer membrane protein) and COG1629 (outer membrane
receptor proteins). Only proteins with values ≥1.5 or ≤-1.5 log2 ratios were considered.
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overall metabolic status of the colonic space (for an example,
see the Discussion in the online supplement), although further
studies may be required to further conﬁrm this hypothesis.
Additionally, the expression levels of all the genes belonging to
the ‘mobile and extrachromosomal element functions’ category
were decreased during treatment, and all of them were asso-
ciated with clustered regulatory interspaced short palindromic
repeats (CRISPRs). These genes encode a system that functions
as a type of bacterial adaptive ‘immune’ response.34 Speciﬁcally,
the genes that belong to the CRISPR/Cas system are involved in
protecting cells from invasion by foreign DNA (viruses and plas-
mids) through an RNA-interference-like process.35 Thus, the
decreases in the expression of these genes may render the bac-
teria more susceptible to the acquisition of foreign DNA. This
could provide an advantage in an AB-containing environment
because it increases the likelihood of obtaining resistance genes
by horizontal gene transfer.
Of major metabolic signiﬁcance was the observation that the
production of metabolites that are known to be produced by the
host and further metabolised by colonic bacteria, such as deriva-
tives of bile acids, cholesterol and hormones, was altered during
the AB treatment and was signiﬁcantly improved after treatment
cessation. In essence, this ﬁnding suggests that AB treatment
altered the continual interplay between the liver/pancreas and
bacterial enzymes operating in the colonic space and that AB
therapy may have a positive long-term effect in human biology.
This result is consistent with the ﬁnding that the biological pro-
duction of host-beneﬁcial molecules such as vitamin B12 and the
uptake of key metals such as Co2+ by colonic bacteria were
affected by AB therapy because the expression of genes and pro-
teins associated with those functions was restored after treat-
ment cessation. This is particularly important because it has
been demonstrated that the microbiota from the distal guts of
different individuals exhibit partial functional redundancy in
Figure 8 The ‘presumptive’ model related to the follow-up effect of antibiotics (ABs) on the microbial and metabolic composition of the human
gut. The model is based on the combination of experimental multi-omics data. The biliary excretion of ABs triggers a cascade of metabolic events.
At the earlier stages of AB therapy, the bacteria respond by promoting systems to avoid the antimicrobial effects of the drugs (expressing
beta-lactamases, antimicrobial peptide transporters and multidrug efﬂux pumps and producing glycero(lyso)phospholipids—G(L)PL) and to cope with
an intermittent nutrient supply while decreasing polysaccharides and lipopolysaccharide (LPS) production. Genes involved in cell envelope
biosynthesis and the degradation of peptidoglycan-like components are increasingly expressed until the end of AB treatment but with a time delay
compared with other drug-detoxifying mechanisms. Finally, the bacterial metabolism of the bile acid, hormones and cholesterol synthesised in the
liver and pancreas is attenuated by AB therapy, thus possibly affecting entero-hepatic recirculation and systemic lipid metabolism, that is, the
emulsiﬁcation, absorption and transport of dietary fats; however, after treatment cessation, the metabolism of these factors improved signiﬁcantly.
Similarly, the pool of vitamins that are directly synthesised by gut bacteria was signiﬁcantly improved after treatment cessation. The nutrient supply
mechanisms, such as glycolysis, pyruvate decarboxylation, tricarboxylic acid (TCA) cycle, glutamate metabolism, and iron uptake, that are induced at
earlier stages (day 6) become attenuated during the late stages of the therapy and become signiﬁcantly attenuated after treatment cessation,
suggesting that the entero-hepatic recirculation system may contain a lower amount of iron, sugars, branched amino acids, short organic acids and
pyruvate produced or transported by colonic bacteria. At the active bacterial structure level, an apparently oscillatory population dynamic was
further observed, with the initially predominant active Bacteroidaceae becoming replaced by Burkholderiaceae after treatment cessation. The broken
line indicates the overall trend in each of the gut bacteria components during the follow-up treatment.
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addition to clear differences in community structure in the
absence of ABs.36 By contrast, although further experimental
evidence is required, our results suggest that the presence of
ABs per se may have additional ‘presumptive’ collapse effects in
key metabolic pathways independent of the community struc-
ture and that functional replacement events may be affected
under AB stress.
Although, the investigation reported here was for a single
patient and should generally be considered qualitative, it consti-
tutes a proof of concept for an integrated, multi-omics approach
towards unravelling the dynamics and mechanisms underlying
the response of intestinal microbiota to AB treatment. A ‘pre-
sumptive’ model related to the follow-up effects of ABs on bac-
terial and metabolic composition is summarised in ﬁgure 8.
These data may help to identify speciﬁc strains of gut microbiota
with potential beneﬁts in human health or to design speciﬁc
therapies to decrease intestinal inﬂammation or normalise dys-
functions of the gut mucosa; for example, minor bacterial taxa
such as Proteobacteria have been shown to play a signiﬁcant,
active role in overall gut metabolism and host interaction
despite their low number. Further studies investigating different
ABs and (un)related individuals are required to better ascertain
the link between bacterial producers and the presence of par-
ticular proteins and molecules, and the metabolic consequences
of AB treatment; this may serve as a promising focus for thera-
peutic interventions or the treatment of pathogenic infections
and diseases.
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SUPPLEMENTAL MATERIALS AND METHODS
DNA AND RNA EXTRACTION
For nucleic acid extraction, samples were resuspended in phosphate-buffered saline solution (PBS). The samples were then
centrifuged at 2000 rpm at 4ºC for 2 minutes to remove faecal debris. The supernatant was then centrifuged at 13000 rpm for 5
min to pellet the cells. Total DNA was extracted from pelleted cells using the QIAamp® DNA Stool kit (Qiagen), according to
the manufacturer's instructions. In the analysis of the species-level microbiota composition, the total DNA was purified from
faecal samples as previously described 37. 
Total RNA was extracted from pelleted cells using the RiboPure-Bacteria kit (Ambion)
and then treated with DNAse I. To verify the removal of total DNA, a polymerase chain reaction (PCR) for each RNA sample
was performed with universal 16S primers. The DNA and RNA extractions were verified by standard agarose gel electrophoresis
and quantified with a Nanodrop-1000 spectrophotometer (Thermo Scientific). Total DNA was used for 16S rDNA biodiversity
and  metagenome  determinations,  whereas  total  RNA  was  used  for  16S  rRNA  biodiversity  and  metatranscriptome
determinations.
AMPLIFICATION OF THE 16S rDNA GENE AND METAGENOME DETERMINATION
For  each  sample,  a  region  of  the  16S  rDNA  (ssu  gene)  was  amplified  by  PCR  using  theuniversal  primers  E8F  (5'-
AGAGTTTGATCMTGGCTCAG 3') and 530R (5'-CCGCGGCKGCTGGCAC 3'). For species-level analysis we used the primers
27F (5'-AGAGTTTGATCCTGGCTCAG 3') and 338R (5'-TGCTGCCTCCCGTAGGAGT 3'). The amplified region comprises
the hypervariable regions and V1, V2 and V3 for the first pair ofprimers and V1, V2 for the second. In both cases we applied the
sample-specific Multiplex Identifier (MID) for pyrosequencing. PCR was performed under the following conditions:
95ºC for 2 minutes, followed by 25 cycles of 95ºC for 30 s, 52ºC for 1 minute and 72ºC for 1 minute, and a final extension step
at 72ºC for 10 minutes. Amplification was verified by electrophoresis in an agarose gel (1.4%). PCR products were purified
using QIAquick gel extraction Kit (QIAGEN) or the NucleoFast® 96 PCR Clean-Up kit (Macherey-Nagel) and quantified with a
Nanodrop-1000 spectrophotometer (Thermo Scientific) and with the QuantiT PicoGreen dsDNA Assay Kit (Invitrogen). The
pooled PCR products were directly pyrosequenced.
The metagenome was directly obtained by sequencing the total DNA using a Roche 454 GS FLX sequencer. Assembly
was performed using Roche's Newbler assembler v. 2.5.3 with default parameters. We sequenced the metagenomes for each time
sample, obtaining 17.37 Mb for FS-0; 245.33 Mb for FS-3; 22.74 Mb for FS-6; 12.07 Mb for FS-11; 23.22 Mb
for FS-14; and 53.57 Mb for FS-40.
16S rRNA SEQUENCING AND mRNA EXTRACTION AND AMPLIFICATION
Total RNA was directly retrotranscribed to obtain the 16S rRNA (as a measure of active bacteria) as well as the rest of the RNA,
particularly the mRNA. Prior to mRNA amplification, to remove the maximum amount of rRNA, rRNAs were first depleted
with the MICROBExpress kit (Ambion), which captures and removes the rRNA (16S rRNA, 23S rRNA) by hybridization.  38
Second,  we  used  the  mRNA-ONLY  Prokaryotic  mRNA  isolation  kit  (Epicentre),  which  uses  a  terminator  5'-phosphate-
dependent exonuclease that specifically digests rRNAs due to the presence of 5' monophosphate groups. Finally, mRNA was
linearly amplified using the MessageAmp II-Bacteria kit (Ambion), which adds poly(A) tails to the
mRNAs.
To retrotranscribe the total RNA and the amplified mRNA into single-stranded cDNA, we used the High-Capacity
cDNA Reverse Transcription kit (Ambion). To synthesize doublestranded cDNA (ds-cDNA), we used standard procedures. The
products were quantified with a Nanodrop-1000 spectrophotometer (Thermo Scientific) prior to sequencing.
All sequencing was performed by Life Sequencing (Valencia, Spain) with a Roche GS FLX sequencer and titanium
chemistry.
BIODIVERSITY ANALYSIS
The 16S rRNA reads  were  retrieved from the  total  cDNA by comparing  the  total  reads  against  the  Small  Subunit  rRNA
Reference Database (SSUrdb)39 with BLASTN40 and an e-value of 10-16. For 16S DNA reads, we removed the sequences with low-
quality  scores (<20) and a short  length (<200 bp). Sequences were checked for chimeras using MOTHUR software. 41 For
species-level analysis sequences were clustered into Operational Taxonomic Units (OTUs) by 3% distance level based on the
average neighbour algorithm.
The taxonomic information for the 16S rDNA and the 16S rRNA sequences was obtained by comparison against the Ribosomal
Database  Project-II (RDP).28 We considered only annotations with a  bootstrap cutoff  value above 0.8 and terminated the
assignation  at  the  lowest  phylogenetic  category  identified  at  or  above  this  support  level.  For  species  identification,  the
taxonomical assignment was performed also with RDP and a bootstrap threshold of 60%. An additional web-based matching
against type strain sequences was conducted with RDP Seqmatch (http://rdp.cme.msu.edu/seqmatch/seqmatch_intro.jsp). OTU
abundances  were  Hellinger  transformed42 and a Principal  Component  Analysis  (PCA) based on the  covariance  matrix  of
transformed OTU abundances was performed. To assess the number of interpretable axes within the PCA, a Kaiser-Guttman
and broken-stick-model were computed (data not shown). Additionally, OTUs responsible for differences between the samples
were identified in a scree plot based on their vector length in the PCA.
Two biodiversity parameters were calculated: Shannon and Chao1. The Shannon index is a measure of the degree of
homogeneity of the microbiota,43 and Chao1 is a richness estimator that also permits the assessment of the number of bacterial
taxa  in  the  samples.44,45 To  avoid  a  sequencing  effort  bias,  both  indices  were  calculated  after  subsampling  with  the
multiple_rarefactions.py script of QIIME.46
Microbial communities were compared using heatmaps of taxa abundance and composition. Correspondence analyses
and clustering by means of the Bray-Curtis distance were obtained by applying the statistical package R.47
METATRANSCRIPTOME ANALYSIS BY MAPPING THE METAGENOME
We sequenced metatranscriptomes for each time sample, obtaining 7.33 Mb for FS-0; 5.85 Mb for FS-3; 7.27 Mb for FS-6; 5.68
Mb for FS-11; 4.37 Mb for FS-14; and 2.58 Mb for FS-40. Our aim was to identify coding regions in the metagenomes and then
map the corresponding transcriptomes to determine the relative expression of the genes. To identify the coding regions, two
different strategies were used. First, our dataset was compared against the sequences belonging to the bacterial superkingdom in
the NCBI-nr protein database using BLASTX40 and an e-value of 10-3. Second, we used Glimmer48 to identify coding regions
present in our samples but not in the NCBI-nr protein database. For coding regions identified using BLASTX, we performed
taxonomic assignment by applying the Lowest Common Ancestor (LCA) algorithm.49
To obtain a relative measure of gene expression for each sample, we followed the methodology described by Turnbaugh
et al.18 Briefly, this methodology consists of adjusting the number of transcripts mapping to each coding region by dividing it by
its associated copy number. To assign the copy number of each gene, we applied the BLASTX40 coding regions
against themselves with an e-value of 10-3.
To functionally annotate the identified coding regions, we used HMMER against the database of prokaryotic models
TIGRFAM with default parameters.30 We used an integrative algorithm based on homology that enabled us to obtain a matrix
containing the relative expression of the same coding regions in the different samples. To apply the copy numbercorrection to
the  functional  and taxonomical  annotation, each taxon or function must  have  an associated integer frequency to  recover
abundance matrices for each individual sample. To achieve this goal, we transformed the measure of  relative expression to
integer values by applying univariate standardization within each sample followed by logarithmic scaling. We performed a
clustering analysis to classify the genes identified for each sample according to their expression profile with the SOM package
(Self-Organizing Map).31 This analysis applied a univariate scaling to the expression gene matrix to obtain all expression gene
profiles with the same mean of 0 and standard deviation of 1. The scaled expression profiles were clustered by creating a Self-
Organizing-Map. Using the information associated with each gene, we performed multivariate analyses, such as correspondence
analysis  or  clustering.  For  this  purpose,  we  used  the  package  Vegan 50 in  R.47 We  used  different  tools  of  the
ShotgunFunctionalizeR33 library of R52 to perform the statistical comparisons. Specifically, we performed regression analyses at
different functional levels for general roles and gene families based on a Poisson model to identify the functional levels that
change significantly during treatment.
All of the analyses were integrated within a script written in the shell language of Linux that calls other scripts written
mainly in R47 and Perl (http://www.perl.org/).
PROTEIN EXTRACTION, SEPARATION AND IDENTIFICATION AND DATA PROCESSING
Protein extraction was performed by incubating 1.2 ml BugBuster Protein Extraction Reagent (Novagen) for 30 min at room
temperature with the bacterial pellet obtained as described above. Faecal bacteria were further disrupted by mechanical lysis
followed by sonication for 2.5 min on ice. The extract was then centrifuged for 10 min at 12000 rpm to separate cell debris and
intact cells. The supernatant was carefully aspirated (to avoid disturbing the pellet) and transferred to a new tube, and protein
concentrations were determined with the Bradford assay.51 For 1-DE analysis, two 75- g protein samples (technical replicatesμ
denoted by a or b) were precipitated with five-fold volumes of ice-cold acetone and separated on a 12% acrylamide separating
gel with the Laemmli buffer system.52 After electrophoresis, protein bands were stained by colloidal Coomassie Brilliant Blue G-
250 (Roth, Kassel, Germany). Entire protein lanes were individually cut into six bands prior to performing in-gel tryptic
digestion.53 Tryptic peptides of each band were desalted with a C18 ZipTip prior to MS analysis.
Peptides were analyzed by UPLC-LTQ Orbitrap-MS/MS, as described in Bastida et al.54 The peptides were eluted over 77
min with a gradient of 2 to 60% solvent (acetonitrile, 0.1% formic acid). Continuous scanning of the eluted peptide ions was
performed at 300-1,600 m/z, automatically switching to MS/MS CID mode on ions exceeding an intensity of 2000. Raw data
were searched using MaxQuantTM (version 1.2.18).55 Each sample was measured with two technical replicates. The raw data
obtained from peptide samples originating from the same lane on the 1-DE gel were searched together, and technical replicates
were analyzed separately. The database that was searched against contained the metagenomic data obtained from samples FS-0
to FS-40. The settings for MaxQuant were the following: the peptide modifications included methionine oxidation as variable
and cysteine carbamidomethylation as fixed; first search ppm of 20; main search ppm of 6; maximum number of modifications
per peptide: 5; max. missed cleavages: 2; and a maximum charge for the peptide of 5. The parameters for identification included
a minimum peptide length of 5 amino acids and a false discovery rate for peptides and proteins and a level of modification sites
of 1%. A minimum of 2 unique peptides was required for protein identification. Apart from unmodified peptides, only peptides
with oxidized methionine and carbamidomethylized cysteine were used for quantification. Only unique or razor peptides were
chosen  for  use  in  quantification. Miscellaneous  settings  included  “re-quantified”,  “keep  low scoring  versions  of  identified
peptides”, “match between runs” (time window of 2 min), “label-free quantification” and “second peptides”.
To analyze the data, the intensity attributed to each identified protein was divided by the number of peptides assigned
to the protein. Normalization was then performed by dividing these corrected intensity values by the median of all corrected
intensities from the same sample. The ratio of the normalized intensities was calculated for each protein by dividing the mean
of the normalized intensities from samples FS-3, FS-6, FS-11, FS-14 and FS-40, respectively, by the mean of the normalized
intensities from sample FS-0. Ratio values were then calculated by taking the logarithms of the ratios to the base of 2. For up
regulation of protein expression in the gut environment, a threshold of at least 1.5 for the ratio value was set, and for down
regulation, a maximum value of -1.5 was set.
METABOLITE EXTRACTION, SEPARATION AND IDENTIFICATION AND DATA PROCESSING
Metabolite extraction was performed by adding 1.2 ml of cold (-80ºC) HPLC-grade methanol (MeOH) to the bacterial pellet
obtained as described above. Samples were then vortex-mixed and stored at -80ºC for 60 min. Then, the samples were again
vortex-mixed and sonicated for 30 seconds on liquid nitrogen and stored at -80ºC for 60 min. This protocol was repeated 5
times. The final pellet was removed by centrifugation at 16000 rpm for 10 min at 4ºC, and the supernatant was stored in a 20-
ml penicillin vial at -80ºC. The methanolic extract was centrifuged at 13000 rpm and 4ºC for 20 min to precipitate any solid
impurity. The supernatant was removed and transferred to analytical vials. Quality control (QC) samples
were prepared by pooling equal volumes of the supernatant from each of the 18 samples (6 samples x 3 replicates each). QC
samples were analyzed throughout the run to provide a measurement of the system’s stability and performance.
The HPLC-ESI-QTOF-MS system consisted of a degasser, two binary pumps and an autosampler (1200 series, Agilent).
Ten l of the sample was injected onto a reversed-phase column (Discovery HS C18 150x2.1 mm, 3 m; Supelco) with a guardμ μ
column (Discovery HS C18 20x2.1 mm, 3 m; Supelco), both of which were maintained at 40ºC. The system was operated inμ
positive ionization mode at a flow rate 0.6 ml/min. Solvent A was composed of water with 0.1% formic acid, and solvent B was
composed of  acetonitrile  with 0.1% formic acid. The gradient was from 25% B to 95% B in 35 min, returning to initial
conditions in 1 min, and re-equilibration was performed at 25% B for 9 min. Data were collected in positive ESI mode in
separate runs on a QTOF (Agilent 6520) operated in full scan mode from 50 to 1000 m/z. The capillary voltage was 3000 V with
a scan rate of 0.77 scan per second. The gas temperature was 330ºC, the drying gas flow was 10.5 l/min, and the nebulizer was
52 psi. The MS-TOF parameters were the following: fragmentor at 175 V, skimmer at 65 V and octupole radio frequency voltage
(OCT  RF  Vpp)  of  750  V.  During  the  analysis,  two  reference  masses  were  used:  121.0509  (C5H4N4)  and  922.0098
(C18H18O6N3P3F24). These masses were continuously infused into the system to permit constant mass correction. Samples
were analyzed in one randomized run, during which time they were kept in the LC autosampler at 4ºC.
Background noise and unrelated ions were removed from the resulting data file using the Molecular Feature Extraction
(MFE)  tool  in  the  Mass  Hunter  Qualitative  Analysis  software  (B.04.00,  Agilent).  Primary  data  treatment  (filtering  and
alignment) was performed with MassProfiler Professional software (B.02.01, Agilent). The multivariate analyses were performed
using SIMCAP+ software (12.0.1.0, Umetrics) to generate a PLS-DA model with all the variables, and QCs were predicted into
this model (figure 4A). Data from samples P 3.1, P-3.3, P-3.4, P-3.5 and P-3.6 were then aligned and filtered by selecting
features present in a minimum of 100 % of 1 of 5 groups. These data were then represented in a hierarchical condition tree
(HCA) (figure 4D). Finally, t-tests were performed to compare samples FS-0/FS-6, FS-6/FS-11, FS-11/FS-14 and FS-14/FS-40
(p 0.01) (figure 4B). The accurate masses of features representing statistically significant differences were searched against the≤
METLIN database and represented in a PLS-DA model built using SIMCAP+ software (figure 4C).
SUPPLEMENTAL DISCUSSION
APPARENT OSCILLATORY DYNAMICS OF POPULATIONS
A remarkable increase in the abundance of  Lachnospiraceae (28.25%),  Roseburia (18.29%) and Clostridiales (11.43%) was
found at day 3 of treatment. Regarding this, some members of Bacteroidaceae family, as Bacteroides, that had an abundance of
16.37% showed a relative high gene expression (90%), noting that no abundant bacteria can be very active at a given moment in
the gut. This result supports what was found in the active bacteria analysis where Bacteroidaceae family was very abundant
among the active microbiota. At day 6 an increase in Ruminococcaceae family (34.81%) was detected, showing that the first
days of treatment were characterized by a dominance of the phylum Firmicutes. In fact, Streptococcaceae, Clostridiaceae, and
Eubacteriaceae, previously described as resistant to penicillin and other -lactamsβ 56,57, presented a relative gene expression of
22.87%, 11.27% and 11.06%, respectively  at  day  6  of  treatment. At  day  11 a  significant shift  to  Bacteroidetes  was found,
specifically in the genus Parabacteroides (73.23%) that reached the highest abundance of all samples. The Bacteroidaceae family
showed also a high level of  gene expression (63.05%) and  Parabacteroides genus, Porphyromonadaceae family, with a gene
expression of 19.82%. Also, it was found a considerable increase in the abundance of Betaproteobacteria (19.82%). At day 14
there  was  homogeneity  in  abundances  and  in  recovery  of  some  taxa,  being  the  most  abundant  Bacteroides (19.15%),
Betaproteobacteria (15.75%), Lachnospiraceae (14.56%), Ruminococcaceae (12.01%), Roseburia (11.43%) and Parabacteroides
(11.24%). The expression of genes was almost dominated by Bacteroidaceae family (89.6%). By temporal temperature gradient
gel electrophoresis, De La Cohetière et al.13 identified similar dominant taxa during a 5-day -lactam (amoxicillin) treatment.β
After  treatment,  the  microbiota  was  mainly  constituted  by  Faecalibacterium (30.5%),  Ruminococcaceae  (29.24%)  and
Bacteroides (9.4%), being the abundance of Firmicutes phylum higher than before treatment. Interestingly, the taxon more
active at gene level was Burkholderiaceae (circa 46%), a member of Proteobacteria phylum, highlighting the importance of
groups that are present in low abundance that can have an essential role in some process or that are growing at that time.
The  large  fluctuations  in  the  relative  abundance  of  the  various  bacterial  taxa  for  the  total  and  active  microbiota
throughout the follow-up study may be most likely due to an additive effect of Ampicillin/Sulbactam and the first-generation
cephalosporin  Cefazolin.  Both,  Ampicillin  and  Cefazolin  act  on  Gram-positives  and  Gram-negatives  by  cell  wall  lysis.
Widespread development of beta-lactamases among Gram-negatives, e.g. due to PBP modification, results in a better antibiotic
effect  of  Cefazolin  against  Gram-positives.  Having  said  that,  it  should  be  also  taken  into  consideration  that
Ampicillin/Sulbactam  and  Cefazolin  act  on  the  microbiota  mainly  because  their  biliar  excretion,  and  accordingly  their
concentrations in the upper intestine (where Firmicutes  are  more abundant) should be  higher than in  the  colonic space.
Ampicillin/Sulbactam may increase the effect of Cefazolin on natural beta-lactamase producer populations of the gut (as many
Bacteroidetes), and then, most of the time, the attribution of the observed effects may be only attributed to Cefazolin as a single
drug. At the same time, Cefazolin may be probably degraded and extensively bound to proteins in the colonic space, reducing
the effect on susceptible Gram-negatives at large. It is likely possible that once beta-lactamase producing organisms are selected
by  Cefazolin,  the  local  amount  of  beta-lactamase  could  eliminate  all  locally  available  Cefazolin,  thus  allowing  residual
susceptible populations (including Gram-positives  as  Streptococci, but also  other  groups)  to re-grow, even under therapy.
Under this scenario the apparent oscillatory dynamics of  populations (both in DNA and RNA) observed might be due to
compartmental changes, with early reduction in Gram-negatives, and overall collapse in diversity, possible colonization of the
upper gut by naturally-resistant Bacteroidetes, and consequent increased colonization of the lower gut with dominance at 11 th
-14th days, and then re-growth of  Grampositives. Having said that, since -lactams interfere with the synthesis of  cell-wallβ
peptidoglycans  to  prevent  bacterial  growth, the  possibility  that  active  fraction  of  the  microbiota  is  represented  by  those
microorganisms that were ‘presumptively’ resistant to the administered antibiotics cannot be ruled out; therefore, additional
time of treatment would have been required to disrupt the composition of this group. Recently, Nakano et al. 32  demonstrated
that intestinal Bacteroides and Parabacteroides genera carry resistance genes for several antibiotics, including -lactams. Thus,β
OTUs belonging to Bacteroides fragilis, Bacteroides dorei, Parabacteroides distasonis and Bacteroides ovatus recovered in FS-11
and FS-14, when the effect of Ampicillin/Sulbactam stopped and only Cefazolin interacted on Gram-positive bacteria of the
microbiota. The observed shift in the composition at the 11th  day is compatible with the detection at day 6 of bacteria such as
Clostridium, Ruminococcus and  Burkholderia, which are ‘presumptively’ resistant to the applied antibiotics. Other potential
facultative pathogenic bacteria, which may be possibly selected due to AB treatment, such as those belonging to the genera
Klebsiella, Escherichia and Salmonella, were not found at any time of the treatment.
The identification of 3 beta-lactamases, likely attributed to single or several species of  Bacteroides such as  B. fragilis,
which were significantly expressed (up to 27-fold) in FS-3, FS-6 and FS-14 metaproteomes as compared to FS-11 and FS-40
(table 3 in online supplement) may agree with the oscillatory dynamics of populations. Additionally, functional assignments
and  analysis  of  the  predicted  genes  further  evidenced  the  presence  of  381  betalactamases  in  the  consensus  metagenome
sequences; among them we found 231 being expressed in the faecal microbiota (mRNAs) at different levels before, during and
after AB treatment. As shown in figure 13 in online supplement, an apparent oscillatory dynamics of the number of expressed
proteins was also observed with early abundance of beta-lactamases being expressed (day 3), then a decrease with a minimum at
day  11  and  then  re-expression  at  day  14.  Only, 9  beta-lactamases  were  found  to  be  expressed  after  treatment  cessation.
Although, beta-lactamases produced by different bacterial species may have quite a distinct substrate specificity and further
studies may be required to ascertain their implication in AB resistance, the decrease of abundance of these expressed genes may
be directly related to the decrease of abundance and variety of species during the follow-up treatment, namely at day 11 (table 1
and figure 1). The over-abundance of beta-lactamase sequences in the metagenome after treatment cessation (167 or 0.116% of
open reading frames), but their low expression level may indicate these genes not being required in the absence of AB and that
their overabundance might be a side-effect of the treatment. Binning analysis further evidenced that in the FS-0, FS-3, FS-11
and F-14 there are mainly Bacteroidaceae expressed beta-lactamases, whereas in FS-40 Burkholderiaceae are most abundant, in
agreement with the contribution of these groups to the active community.
METAPROTEOMIC AND METAMETABOLOMIC CHANGES
Results suggest a “presumptive” lower capacity following AB therapy to feed the tricarboxylic acid cycle with intermediates to
meet the demand for carbon skeletons for the synthesis of  organic acids and amino acids. In addition, results highlight a
‘presumptive’  decrease  in  the  use  of  glutamate  because  the  expression  of  glutamate  dehydrogenase  (COG0334)  and
decarboxylase (COG0076) was reduced following AB treatment (figure 5). If the flux through glutamate to -ketoglutarate andα
glutamate  to  gamma-aminobutyric  acid  decreases,  it  seems  logical  to  presume  that  the  flux  through  the  entire  pathway
decreases as a consequence of AB treatment. The production of branched-chain fatty acids in the membrane is linked to the
turnover of -ketoglutarate to glutamate by glutamate dehydrogenase (COG0334), and we would expect them to be altered inα
concert.
A  notable  additional  finding  in  this  study  was  that  it  appears  that  additional  AB  treatment  time  is  required  to  activate
membrane permeability systems (day 14) as compared to detoxifying drug transport systems (day 3 and 6),58,59,60 and that
antibiotic differentially affected cell wall components of gut bacteria with (lipo)polysaccharides being altered at earlier stages of
the therapy while maintaining or improving the glycero(lyso)phospholipids, murein sacculus and peptidoglycan biosynthesis
during the follow-up treatment. This is in agreement with the observed early activation in Gram-positive bacterial families,
such as Streptococcaceae and Clostridiaceae, and the reduction in Gram-negatives.
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SUPPLEMENTAL TABLES
Supplemental Table 1 Summary of the metagenomic and metatranscriptomic data for each
sample collection time.
FS-0 FS-3 FS-6 FS-11 FS-16 FS-40
Metatranscriptome (reads) 76374 60253 72691 66093 51349 5751
Metagenome (reads) 44653 519776 53893 29156 54901 126639
mRNA (reads) 40517 37107 50952 40785 28787 4635
TIGRFAM(reads) 29014 26120 13115 27461 19240 1968
NOTE: Supplemental tables 2 and 3 are included in the file Supplemental_tables_2_3.pdf in the CD due to their size.
SUPPLEMENTAL FIGURES
Supplemental figure 1 Heat map and hierarchical cluster based on the relative abundance of each bacterial taxon and
the composition  of  the total  (16SrDNA)  and active  (16SrRNA)  microbiota.  Colors  depict  the percentage  ranges of
sequences assigned to the main taxa (abundance >1% in at least one sample).
Supplemental figure 2 Correspondence analysis of total (DNA) and active (RNA) microbiota based on the relative abundance of each taxon per sample.
  Supplemental figure 3 PCA of the Hellinger transformed OTU abundances for the samples FS-0 to FS-40.
  Supplemental figure 4 Distribution of prominent OTUs and their abundance identified by OTU vector length n the PCA.
Supplemental figure 5 Clusters of genes based on their expression profile during antibiotic treatment. “n” corresponds
to the number of genes included in each cluster.
Supplemental figure 6 Relative abundance of functional categories exhibiting a statistically significant change due to AB treatment. These categories
were obtained from a regression analysis based on a Poisson model, considering the sampling time during the antibiotic course.
Supplemental figure 7 Correspondence analysis based on the relative proportion of functional categories showing a statistically significant change
due to AB treatment.
Supplemental figure 8 Distribution of common and distinct mass features identified in the gut communities of the human gut microbiota during and
after AB treatment. Clustering was performed with a matrix of the 382 accurate masses representing significant differences from each sample. The
number of mass features identified in the corresponding sample(s) is shown at the bottom. The black color indicates the presence of mass features in
a given sample, whereas the white color represents the absence of such features. As shown, only 29 of 382 features were identified in all of the gut
samples examined in this study, and 8, 9, 6, 14 and 80 were uniquely obtained in the FS-0, FS-6, FS-11, FS-14 and FS-40 samples, respectively
Supplemental figure 9 Number of mass features that passed the filtering and statistical  treatments and were found in
microbial cells from faecal samples in this study.
Supplemental figure 10 Distribution of the common and distinct proteins found in the gut communities of the human gut microbiota during AB
treatment. Clustering was performed with a matrix of the total protein that has passed the filtering treatment for each sample. The number of
proteins identified in the corresponding sample(s) is shown at the bottom. The black color indicates the presence of proteins in a given sample,
whereas the white color represents the absence of such proteins. Note: a total of 3,011 proteins (FS-0: 2,802; FS-3: 2,429; FS-6: 2,696; FS-11: 2,044; FS-
14; 2,716; and FS-40: 2,289) were unambiguously quantified using GeLC-MS/MS approaches. Only 11 (FS-0), 2 (FS-3), 4 (FS-6), 11 (FS-11), 2 (FS-14)
and 16 (FS-40) were community-specific, whereas 1,359 (or 45%) conformed the common set. As shown, 1359 proteins were found to be expressed in
all of the gut samples examined in this study.
Supplemental  figure  11 Correspondence  analysis  based  on  the  relative  proportion  of  functional  categories  exhibiting  a  statistically  significant
metaproteome change due to AB treatment. (A) CA for the COG categories where CA1 explains the 33% of the variance and CA2 the 28%. (B) Clustering
of the samples based on type and abundance of expressed proteins, applying the Pearson's correlation to calculate the distances.
Supplemental figure 12 Metabolomic-based model of the response of the human gut to antibiotic treatment. Schematic representation of distinct
mass feature profiles based on the abundance level in bacterial cells from the faecal samples investigated in this study. Features were grouped
based on the metabolite class, and the average corrected intensity values were calculated. Group 1: fatty acids (18), sphingolipids (1), glycerolipids (2),
glycerophospholipids – LPA (1),  sterol lipids – alkaloid  (1);  Group 2:  fatty acid  aldehyde/alcohol (1),  sphingolipid (1),  glycero(lyso)phospholipids –
LysoPE/PA/PC/PE, fatty acid carnitine (2), fatty acid ethanolamide (1); Group 3: fatty acid ethanolamide (1), sterol lipid – D3/bile acid/cholesterol
(4), prostaglandin derivative (2), unsaturated fatty acid (1); Group 4: sphingolipid (1), sterol lipid – D3/bile acid/cholesterol (1); Group 5: sterol lipid –
corticoid (1). The number of metabolites per class is indicated in brackets.
Supplemental figure 13 Number of genes having close sequence similarity to genes that encode beta-lactamases found in metagenomes of microbial
cells  from faecal  samples in  this  study that  were  found to  be  expressed  (mRNAs).  Functional  assignment  of  predicted  genes encoding beta-
lactamases was performed via BLASTP analysis against the NCBI-nr database for similar sequences. All hits with an E-value of less than e- 05 and
sequence homology ≥ 50% were considered and manually analyzed. As a result, out of 401,555 sequences (FS-0: 83,622; FS-3: 63,159; FS-6: 58,853; FS-
11: 19,267; FS-14: 33,288; FS-40: 143,366), 381 distinct beta-lactamase proteins (FS-0: 55 or 0.065% total open reading frames; FS-3: 69 or 0.109%; FS-6:
52 or 0.088%; FS-11: 11 or 0.057%; FS-14: 27 or 0.081%;  FS-40: 167 or 0.116%) were identified.  Among them 231 distinct genes were found to be
expressed in the faecal microbiota (mRNAs) at different levels before, during and after AB treatment. The total number and relative percentage
(referred  to  the  total  number  of  expressed  beta-lactamases:  231)  of  expressed  genes coding  betalactamases is  shown on  the  left  and  right,
respectively.
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Abstract
The human intestinal microbiota performs many essential functions for the host. Antimicrobial agents, such as antibiotics
(AB), are also known to disturb microbial community equilibrium, thereby having an impact on human physiology. While an
increasing number of studies investigate the effects of AB usage on changes in human gut microbiota biodiversity, its
functional effects are still poorly understood. We performed a follow-up study to explore the effect of ABs with different
modes of action on human gut microbiota composition and function. Four individuals were treated with different
antibiotics and samples were taken before, during and after the AB course for all of them. Changes in the total and in the
active (growing) microbiota as well as the functional changes were addressed by 16S rRNA gene and metagenomic 454-
based pyrosequencing approaches. We have found that the class of antibiotic, particularly its antimicrobial effect and
mode of action, played an important role in modulating the gut microbiota composition and function. Furthermore, analysis
of the resistome suggested that oscillatory dynamics are not only due to antibiotic-target resistance, but also to fluctuations
in the surviving bacterial community. Our results indicated that the effect of AB on the human gut microbiota relates to the
interaction of several factors, principally the properties of the antimicrobial agent, and the structure, functions and
resistance genes of the microbial community.
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Introduction
Throughout evolution mammals have established symbioses
with microbial communities, which are located in different organs
and tissues of the body such as skin, mucosa, or the gastrointestinal
tract. The gut microbiota in humans is a particularly complex
ecosystem with few dominant phyla (Firmicutes, Bacteroidetes,
Proteobacteria and Actinobacteria) but show greater microbial
diversity at lower taxonomic levels and a high functional
redundancy [1,2]. The gut microbiota seems to be host-specific
and rather stable under non- or small perturbations [3] and is
involved in a large number of host beneficial functions such as
food processing, growth regulation of the intestinal epithelium,
development of the immune system, or protection against
pathogens [2,4,5]. Because of the essential role of the microbiota
in host life, imbalances in the gut microbial community may have
an important impact on human health. This is apparent in some
intestinal pathologies such as inflammatory bowel diseases or
antibiotic-associated diarrhea [6].
Systematic antibiotic (AB) therapy represents a major public
health problem because gut microbiota may be transformed into a
reservoir of antibiotic resistance genes, promoting the appearance
of harmful resistant strains [7,8,9,10]. It also suppresses some
protective members of the resident microbiota promoting over-
growth of opportunistic pathogens such as Clostridium difficile [11].
Moreover, AB therapy disturbs the gut microbiota and, concom-
itantly, affects human physiology, for instance carbohydrate
metabolism or immunity [7,12].
Antibiotic features such as class, spectrum or pharmacological
properties affect the gut microbiota in different ways [13]. In
addition, host-associated factors such as diet, life history, genetic or
health status, properties of the gut microbial ecosystem itself like
resistance and resilience, or even the interplay between the
microbiota and its host also have an effect on microbiota
composition and function. All these factors can mask changes
caused exclusively by antibiotics, representing a real challenge
when it comes to understand microbiota responses. Most recent
studies into the impact of antibiotics on the microbiota have
focused on the emergence of resistant strains, but few have
described their influence on the microbial community itself
[14,15,16,17,18]. These latter surveys, using 16S rRNA gene
sequencing, have shown that short and long-term AB courses
affect diversity and biomass of the intestinal microbiota, with
microbial composition resilience remaining deficient for long time
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after AB-treatment [15,16,17,18]. By contrast, the functional
impact of AB on the microbial ecosystem has been addressed less
frequently [19].
The use of the meta-‘‘omics’’ approaches (metagenomics,
metatranscriptomics, metaproteomics) has provided deeper in-
sights into microbial communities in different ecosystems
[2,20,21,22,23]. A recent integrated analysis has provided a better
understanding of the nature of the complex processes underlying
the whole human gut microbiota and its responses during beta-
lactamic-therapy [12].
In the present work we studied the effect of different antibiotics
on the human gut microbiota by a follow-up study comparing
microbial communities before, during and after AB therapy in four
individuals. We analyzed the changes in composition of the total
(16S rRNA gene) and active (16S rRNA transcripts) microbiota
throughout treatment. Furthermore, the functional analysis of the
total gene content of the community showed, for the first time,
how the mode of action and the antimicrobial effect of AB affected
the functional potential of the community. Finally, we described
the dynamics of resistance genes (i.e. the resistome) throughout the
study, paying particular attention to those that become resident
after AB-therapy.
Materials and Methods
Ethics statement
The study was approved by the Ethics Committee of the
Medical Faculty of the Christian-Albrechts University Kiel,
Germany. Informed written consent was obtained from all patients
involved in the study.
Sample collection and AB treatment regimen
Fecal samples were collected from four patients (herein referred
to as patient A, B, C and D) at the Department of Internal
Medicine of the University Hospital Schleswig-Holstein, Campus
Kiel, Germany (UK-SH). Patient A was treated with moxifloxacin
(400 mg/day) for 13 days. Moxifloxacin is a fourth-generation
synthetic fluoroquinolone antibacterial agent with a bactericidal
effect inhibiting cell replication. AB treatment for patient B
consisted of a combined therapy with penicillin G and clindamycin
on the day of admission, and subsequently with clindamycin alone
(36300 mg/day) for seven days. This semi-synthetic derivative
belongs to the lincosamide class exerting a bacteriostatic effect due
to the inhibition of protein synthesis. For patient C, AB therapy
was initiated with cefazolin (362 g/day) for seven days and
continued with ampicillin/sulbactam (26750 mg) for seven more
days. Patient D received an amoxicillin (361000 mg/day)
treatment. The antibiotics used for these two latter two patients
belong to the beta-lactam class and have a bactericidal effect
inhibiting cell envelope synthesis. Main features of patients and
therapy are shown in Table 1.
Fecal samples from patients (named A, B, C and D) were
collected on the day of admission, before the antibiotic treatment
(day 0), during and after AB therapy. In two cases (A and B), the
last sample was taken 3 days after therapy, in the other two cases
(B and D) the last sample was provided 7 and 28 days after
treatment, respectively (Table1). Patients did not present any
intestinal disorder. Samples were collected in sterile tubes and
stored at 280uC until further processing.
DNA extraction
Tubes containing fecal samples with sterile PBS (containing, per
liter, 8 g of NaCl, 0.2 g of KCl, 1.44 g of Na2HPO4, and 0.24 g
of KH2PO4 [pH 7.2]) were centrifuged at 1250 g and 4uC for 2
min to remove fecal waste. DNA was extracted from bacterial
pellets using QIAampH DNA Stool Kit (Quiagen) following the
manufacturer’s instructions. The product was concentrated by
precipitation using 0.1 V of NaCl 3 M and 2 V of ethanol 100%
and diluted in 75 ml of nuclease-free water. A standard agarose gel
electrophoresis was run to check the integrity of DNA. The total
DNA obtained was quantified with Nanodrop-1000 Spectropho-
tometer (Thermo Scientific) and with the QuantiT PicoGreen
dsDNA Assay Kit (Invitrogen).
Amplification of the 16S rRNA gene
For each sample a region of the 16S rRNA gene was amplified
by polymerase chain reaction (PCR). The primers used were the
universal E8F (5’-AGAGTTTGATCMTGGCTCAG-3’) with
adaptor A and 530R (5’-CCGCGGCKGCTGGCAC-3’) with
adaptor B using the sample-specific Multiplex Identifier (MID) for
pyrosequencing. The amplified region comprises hyper-variable
regions V1, V2 and V3. For each sample a 50 ml PCR mix was
prepared containing 5 ml of Buffer Taq (10X) with 20 mM
MgCl2, 2 ml of dNTPs (10 mM), 1 ml of each primer (10 mM),
0.4 ml of Taq Fast start polymerase (5 u/ ml), 39.6 ml of nuclease-
free water and 1 ml of DNA template. PCR was run under the
following conditions: 95u for 2 min followed by 25 cycles of 95u for
30 s, 52u for 1 min and 72u for 1 min and a final extension step at
72u for 10 min. The amplification process was checked by
electrophoresis in agarose gel (1.4%). PCR products were purified
using NucleoFastH 96 PCR Clean-Up Kit (Macherey-Nagel) and
quantified with Nanodrop-1000 Spectrophotometer (Thermo
Scientific) and with the QuantiT PicoGreen dsDNA Assay Kit
(Invitrogen). The pooled PCR products were directly pyrose-
quenced.
Total RNA extraction and double-strand cDNA synthesis
Total RNA was extracted from fecal samples using RiboPur-
eTM-Bacteria Kit (Ambion). DNase treatment was applied to
remove traces of genomic DNA from the eluted RNA using the
same kit. The integrity of RNA was checked by electrophoresis
in agarose gel (0.8%). The efficiency of the DNase treatment
was checked by amplifying each RNA sample by PCR. To
retro-transcribe total RNA into single-stranded cDNA the High-
Capacity cDNA Reverse Transcription Kit (Ambion) was used.
To synthesize double-stranded cDNA, 7.5 ml of Escherichia coli
ligase buffer (10X), 2 ml of dNTPs (10 mM), 0.2 ml of E. coli
RNAse H (5 u/ml), 3 ml of E. coli DNA pol I (10 u/ml), 0.5 ml of
E. coli ligase (10 u/ml) and 41.8 ml of nuclease-free water were
added to each single-stranded cDNA sample. The mixture was
placed in a Thermocycler at 15uC for 2 hours. Then, 2.5 ml of
T4 DNA polymerase (3 u/ml) were added and kept at 15uC for
30 min. The metatranscriptome obtained thus was purified by
precipitation and quantified using Nanodrop-1000 Spectropho-
tometer (Thermo Scientific) and the QuantiT PicoGreen
dsDNA Assay Kit (Invitrogen). A standard agarose gel electro-
phoresis was run to check the integrity of double-stranded
cDNA.
Pyrosequencing
For each sample, the total DNA (metagenome), double-stranded
cDNA and amplicons of the 16S rRNA gene were sequenced with
a Roche GS FLX sequencer and Titanium chemistry in the
company Life Sequencing (Valencia, Spain) and in the Center for
Public Health Research (CSISP-FISABIO) (Valencia, Spain). We
obtained an average of 58,928, 41,838 and 4,872 reads per
sample, respectively.
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Taxonomic assignment of 16S rRNA amplicons
We have used the Ribosomal Database Project (RDP)
pyrosequencing pipeline [24] to trim off the MID and primers
and to obtain the taxonomic classification. Sequences with a phred
quality score less than 20 (Q20) and short length (,250pb) were
discarded. We considered only annotations that were obtained
with a bootstrap value greater than 0.8, leaving the assignation at
the last-well identified level and consecutive levels as unclassified
(uc).
Taxonomic assignment of 16S rRNA transcripts
Due to the procedure followed to obtain the metatranscriptome,
the vast majority of transcripts belonged to ribosomal genes (16S
and 23S). The 16S rRNA reads were obtained from the total
cDNA by comparing the total reads against the Small Subunit
rRNA Reference Database (SSUrdb) [25] with BLASTN [26] and
an e-value of 10-16. All sequences with detected homology were
considered as 16S rRNAs and used to evaluate the phylogenetic
diversity of the active bacteria. The taxonomic classification was
performed in the same way as the amplicons.
Analysis of total and active microbiota
To study the phylogenetic structure of the bacterial community
we applied two approaches that involved the 16S rRNA gene. The
widely used analysis of 16S rRNA gene amplicons shows the
composition of the total microbiota (16S rRNA gene). However,
since the growing (active) bacteria contain more ribosomal RNA
than latent or starved cells, studying the 16S ribosomal RNA
transcripts enabled the active members of the microbiota to be
identified (16S rRNA transcripts) [12,22]. We calculated sample
diversity of the throughout the treatment for total and active
bacteria by applying three parameters: two richness estimators,
Chao1 [27] and the abundance-based coverage (ACE) [28], and
the Shannon index [29]. These estimators are implemented in
package Vegan [30] under R software (http://cran.r-project.org)
[31]. The biodiversity index and richness estimators were
calculated after sub-sampling with the multiple_rarefactions.py
script of QIIME to avoid the bias of the sequencing effort [32]. We
used heat maps based on taxonomic composition to study the
similarity between samples due to the relative abundance of each
taxon using the Vegan library in the R software (http://cran.r-
project.org) [30,31]. Canonical correspondence analysis (CCA)
was performed to determine the relation between the sample
composition and the class and mode of AB-treatment. To
statistically assess the effect of such factors on the bacterial
composition a multivariate ANOVA based on dissimilarity tests
(Adonis) was applied, as implemented in the package Vegan, R
software (http://cran.r-project.org) [30,31].
Metagenomics: functional analysis
To eliminate reads that were artifact replicates of pyrosequenc-
ing, we used the 454 Replicate Filter Program [33] with the
following parameters: sequence identity cutoff = 1; length
difference requirement = 0; number of beginning base pairs to
check = 10. Unique reads were compared against the human
genome using BLASTN [26] with an e-value of 10210 in order to
remove human sequences. To identify the sequences encoding the
ribosomal gene 16S rRNA we compared the dataset against the
Small Subunit rRNA Reference Database (SSUrdb) described in
Urich et al. [25] using BLASTN [26] with an e-value of 10216.
Sequences that did not give homology were used to identify the
reads corresponding to the ribosomal gene 23S rRNA by
BLASTN [26] against the Large Subunit rRNA Reference
Database (LSUrdb) described in Urich et al. [25] with an e-value
of 1024. Reads that matched with the LSUrdb were discarded.
The remaining reads were compared to the NCBI-nr protein
Table 1. Main features of the follow-up study.
Patient Antibiotic Mode of action/ Antimicrobial effect Pathology Sampling date Samples
A Moxifloxacin Cell replication inhibitor/ Bactericidal Bronchitis, pneumonia day0-before AB A_before
day3-during AB A3_D
day6-during AB A6_D
day10-during AB A10_D
day13-during AB A13_D
3 days after AB A_after
B Clindamycin Protein synthesis inhibitor/ Bacteriostatic Erysipelas day0-before AB B_before
day2-during AB B2_D
day5-during AB B5_D
day6-during AB B6_D
28 days after AB B_after
C Cefazolin/ Ampicillin/ Sulbactam Cell envelop synthesis inhibitor/ Bactericidal Infection pacemaker day0-before AB C_before
day3-during AB C3_D
day6-during AB C6_D
day10-during AB C10_D
3 days after AB C_after
D Amoxicillin Cell envelop synthesis inhibitor/ Bactericidal Chronic sinusitis maxillans day0-before AB D_before
day3-during AB D3_D
7 days after AB D_after
AB, antibiotic; D, during the treatment.
doi:10.1371/journal.pone.0080201.t001
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database using BLASTX [26] to identify the protein-coding genes.
Taxonomic assignment was based on the output of BLASTX
applying the lowest common ancestor (LCA) algorithm. Fasta files
were used to identify the Open Reading Frames (ORFs) by
applying the facility of Fraggenscan from the web server of
metagenomic analysis (WebMGA) [34]. To annotate the functions
of the predicted ORFs, we applied HMMER 3.0 program [35]
against TIGRFAM database [36] using default parameters. To
identify the genes involved in resistance to antibiotics, we
compared the identified ORFs against the Antibiotic Resistance
Genes Database by BLASTp [37] with an e-value of 10210. We
used the ShotgunFunctionalizeR package [38] in the R software
http://www.R-project.org/ [31] for functional comparison of
metagenomes. Specifically, we applied the testGeneCategories.-
dircomp function to compare the distribution of functional
categories between groups of samples. The test is based on a
Poisson model and compares each gene family of a higher
functional category to decide if the category is statistically
significant among two groups of samples [38].
Data accession number
All sequences have been entered in the European Bioinfor-
matics Institute database, under accession number ERP002192.
Results
Dynamics of total and active microbiota composition
throughout therapy
We analyzed total (16S rRNA gene) and active (16S rRNA
transcripts) microbiota from the four patients (A, B, C and D)
throughout AB treatment. The antibiotics administered to patients
A, C and D had a bactericidal antimicrobial effect, whereas in
patient B the effect was bacteriostatic. Regarding the mode of
action, the antibiotic used in patient A was a cell replication
inhibitor, in patient B it was an inhibitor of protein synthesis,
whereas patients C and D were treated with a cell envelop
synthesis inhibitor (Table 1). Each patient not only presented their
own microbiota profile for both total (Figure 1A) and active
(Figure 1B) microbiota before treatment, but also there was
apparently a rather large variation in bacterial taxa abundance
during and after treatment, which we describe succinctly. In
patient A, both total and active microbiota showed a high presence
of the families Lachnospiraceae (Coprococcus and Roseburia genera)
and Ruminococcaceae (Faecalibacterium, Blautia and Subdoligranulum
genera) during AB treatment with fluoroquinolone (Figure 1).
However, some genera such as Faecalibacterium and Subdoligranulum
were negatively affected by the AB, while others such as Blautia,
Coprococcus, Coprobacillus and Collinsella appeared to be resistant in
the first stage of treatment. We also found that the bactericidal
effect of AB had a negative impact on Bacteroides genus
(Bacteroidetes phylum) in the first days of treatment, but the
trend changed on day 13 with a great increase in its abundance.
Treatment with clindamycin of patient B resulted in a high
presence of Enterobacteriaceae (Escherichia, Salmonella genera), as
shown in Figure 1B. We also observed an increase in the Bacteroides
genus after the 5th day of treatment in active microbiota. For
patient C, Oscillibacteriaceae and Ruminococcaceae families
(Firmicutes phylum) as well as Rikenellaceae and Bacteroidaceae
(Bacteroidetes phylum) constituted the most abundant taxa in the
total microbiota (Figure 1A). The first important change occurred
on day 6 with an increase in Parabacteroides (Bacteroidetes phylum),
which remained abundant after treatment. However, in the active
microbiota we observed a shift towards the Bacteroidetes phylum
(Alistipes and Bacteroides genera) at the two last time points. On the
10th day of treatment, an increase in facultative anaerobic
families, Enterobacteriaceae (Proteobacteria) and Enterococcaceae
(Firmicutes) was found. Finally, in patient D, the initial microbiota
composition consisted mainly of Enteriobacteriaceae (Escherichia
genus) and Ruminococcaceae (Faecalibacterium genus). However,
both genera were greatly affected by the antibiotic as there was an
increase in resistant bacterial taxa of the Bacteroides genus
(Bacteroidetes).
After the AB course, patients A, C and D who received a
bactericidal antimicrobial agent clustered together in both cases,
total (Figure 2A) and active (Figure 2B) microbiota, apart from the
patient treated with a bacteriostatic antibiotic (patient B) (Figure 1
and 2). Moreover, we observed that the two patients treated with
cell envelope synthesis inhibitors (C and D) grouped together in
the case of the active microbiota (Figure 2B).
For all patients, the diversity parameters (Shannon index,
Chao1 and ACE estimators) of both total and growing microbiota,
showed notable fluctuations with a decrease in the number of
bacterial taxa and evenness on the first days of treatment (Figure
S1). At the end of the AB course, these three biodiversity
parameters increased but they did not reach the initial values
observed before AB therapy (Figure S1).
Effect of the class of antibiotic
To evaluate the pattern of variation shown by bacterial taxa or
gene abundances and its relationship with two variables (the
antimicrobial effect -bactericidal and bacteriostatic- and the mode
of action of the antibiotic -protein synthesis inhibitor, cell
replication inhibitor and cell envelope synthesis inhibitor-) we
applied a CCA at the different levels: 16S rRNA gene, 16S rRNA
transcripts, genes and the taxonomy of the identified coding
regions (gene taxonomy). The results showed that these two factors
(antimicrobial effect and mode of action) accounted for variability
in a particular direction and with different strength (Figure 3).
Figure 3A shows that the first axis explained 19% of variability,
splitting the total microbiota (16S rRNA gene) of the patients that
were medicated with bactericidal AB (patients A, C and D) from
the one treated with a bacteriostatic AB (patient B). The second
axis explained 12% of variability, placing the two groups of
samples treated with cell replication inhibitor (patient A) and
protein synthesis inhibitor (patient B) antibiotics on one side of the
graph; these ABs inhibit both essential and related cellular
processes, such as DNA replication and protein synthesis. By
contrast, the samples from patient C, treated with a cell envelope
synthesis inhibitor AB affecting synthesis of the bacterial cell wall,
fell on the other side of the graph. Both variables (antimicrobial
effect and mode of action) introduced significant variance in the
microbiota composition (Adonis test: p = 0.02, p = 0.04,
respectively).
Regarding active microbiota (Figure 3B), the first and second
axes explained 12% and 6% of the total variability, respectively.
With respect to the first axis, the samples from patient B (protein
synthesis inhibitor antibiotic) situated on the right side of the
graph. The latter AB, as occurred for the total microbiota,
introduced higher variance. The second axis separated the samples
taken from patients C and D, treated with cell envelope synthesis
inhibitor AB from the rest. Despite both factors, the antimicrobial
effect and mode of action were not significant (Adonis test: p =
0.18, p = 0.069), the second explained more variability (Adonis
test, p = 0.069).
The CCA applied at gene level (Figure 3C) showed a
distribution similar to that found for the total microbiota (Figure
3A), with the first and the second axes explaining 25% and 6% of
the total variance, respectively. The samples are separated chiefly
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by antimicrobial effect and then by mode of action. However, in
this case the strength of the different vectors is weaker, probably
due to the great functional homogeneity of the gut microbial
community (Adonis test: antimicrobial effect p = 0.27, mode of
action p = 0.41).
Finally, we performed a CCA using the taxonomy of the
identified coding regions (Figure 3D). The two axes explained 19%
and 7% of the total variation of the data. As can be seen, the
different classes of antibiotics affected the taxonomy of the
identified coding regions in a similar way to the results reported
for total microbiota (Figure 3A) and gene analysis (Figure 3C)
(Adonis test: antimicrobial effect p = 0.044, mode of action p =
0.049).
Functional analysis of the metagenomes
The functional annotation of the ORFs was derived using the
TIGRFAM database, providing a hierarchical order: main roles,
the highest functional level (described in Figure S2), sub-roles,
more specific metabolic functions for each one of the main roles
and genes [36]. Regarding the main roles, the profiles were fairly
homogeneous for all patients and time points. The most abundant
categories before, during and after treatment were ‘‘Protein
synthesis’’, ‘‘Energy metabolism’’, ‘‘Cellular processes’’ and
‘‘Transport and Binding Proteins’’ with average values of relative
abundance of 13.5%, 13.2%, 9.6% and 9.5%, respectively, which
highlights the importance of these functions performed by the gut
microbiota (Figure S2). However, when considering the sub-roles,
Figure 1. Microbiota composition of patients A, B, C, and D. (A) total microbiota (16S rRNA gene) (B) active microbiota (16S rRNA transcripts).
The mode of action for each AB used is indicated.
doi:10.1371/journal.pone.0080201.g001
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we detected significant changes in the corresponding profiles for
each patient before, during and after treatment. For all patients we
detected a total of 53 sub-roles that differed significantly in gene
content (Table 2). Only two sub-role functional categories changed
significantly in all patients: ‘‘Menaquinone and ubiquinone’’
(within the main function ‘‘Biosynthesis of cofactors, prosthetic
groups, and carriers’’) and ‘‘Carbohydrates, organic alcohols, and
acids’’ (within the main function of ‘‘Transport and binding
proteins’’). Genes participating in the biosynthesis of menaquinone
and ubiquinone were under-represented during the treatment for
all patients, except in the case of patient B. Regarding the sub-role
of ‘‘Carbohydrates, organic alcohols, and acids’’ the gene
functions were overrepresented during the treatment in patients
A, B and C and under-represented in patient D. Most of the genes
belonging to this functional group were related to the phospho-
transferase system (PTS), which is essential for translocating
carbohydrates in bacteria [39]. Within this family, we have found
genes involved in the transport of various sugars such as mannose,
fructose, sorbose, glucitol or glucose. It is noteworthy that the
related sub-role ‘‘PTS’’ (within the main role ‘‘Signal transduc-
tion’’), associated to genes participating in regulation, was also
over-represented during the treatment in patients A and C and
under-represented in patient D.
The changes in the sub-roles ‘‘Biosynthesis and degradation of
surface polysaccharides and lipopolysaccharides’’ and ‘‘Other’’
(from the ‘‘Cell envelope main role’’) were significant in patients A,
B and D. In general, we detected a lower presence during
treatment of genes involved in the synthesis of lipopolysaccharides
(LPS). The sub-role ‘‘Pathogenesis’’ (within the main category
‘‘Cellular processes’’) and ‘‘Degradation’’ (within the ‘‘Fatty acid
and phospholipid metabolism’’ main category) decreased signifi-
cantly during treatment for patients A and D and increased in
patient B. The fatty acid and phospholipid metabolism genes were
involved in fatty acid beta-oxidation. On the contrary, the sub-role
‘‘Sporulation and germination’’ (within ‘‘Cellular processes’’) was
more abundant during treatment in patients A and D, with most of
the genes being involved in different stages of endospore
formation. Finally, we found that the sub-role ‘‘TCA cycle’’
(within the main category ‘‘Energy metabolism’’) and ‘‘Amino
acids, peptides and amines’’ (within ‘‘Transport and binding
proteins) underwent an increase in the number of genes encoding
different enzymes of the citric acid cycle during antibiotic
treatment for patient A and B and a decrease for D. Regarding
the transport of amino acids, peptides and amines, we found the
presence of genes encoding ABC transporters for amino acids and
urea.
Analysis of the resistome
We performed a search of the resistome by identifying AB
resistance genes in the 19 metagenomes analyzed by comparing
the predicted ORFs against the Antibiotic Resistance Genes
Database [37]. We identified the resistance genes that represented
0.2%, 0.8%, 0.22%, and 0.5% of the total determinants found for
patients A, B, C and D respectively. We found that while patients
A, B, and C showed an increase in resistance genes after
treatment, patient D presented the lowest relative abundance of
these determinants, decreasing from 0.81% to 0.14% (Figure 4A).
Figure 4B shows the profiles of resistance genes that varied during
the treatment for patient A, B and C, administered with antibiotics
belonging to different classes: fluoroquinolone, lincosamide and
beta-lactams, respectively (Table 1). Overall, we observed that the
resistance induced by each antimicrobial was associated with other
resistance determinants. Also, we found that its profiles matched
fairly well with the oscillatory dynamics of the surviving bacterial
community. Patient A showed an increase in the relative
abundance of the total resistance genes at the end of the
treatment, raising values from 0.18% before treatment to 0.28%
after the AB course. Fluoroquinolone resistance, multidrug
Figure 2. Heat map and clustering based on taxon composition and abundance. (A) total microbiota, (B) active microbiota. Colors in the
figure depict the percentage range of sequences assigned to main taxa (abundance .1% in at least one sample).
doi:10.1371/journal.pone.0080201.g002
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resistance efflux pump, appeared on day 10, when the microbiota
composition was dominated by the Firmicutes phylum, with high
abundance of members of the genus Enterococcus, described as
resistant to this type of antimicrobial [40]. This patient presented
high relative abundance of tetq gene, which confers tetracycline
resistance before and after the treatment, being Bacteroides genus
one of the most abundant taxa. Bacitracin profile showed a
maximum on day 6, with baca gene being associated to Streptococcus
and Clostridiales taxa (Figure 1 and 2). Patient B showed a strong
increase in the relative abundance of resistance genes during
treatment, increasing from 0.29% up to 0.89%. In fact all the
genes increased in abundance after AB treatment except those
involved in bacitracin resistance. The most remarkable increase
was found in a group of genes coding for multidrug resistance
efflux pump, which confer resistance against clindamycin and
related antimicrobials (aminoglycoside, glycylcycline, beta-lactam,
macrolide, and acriflavine). Patient C also showed an increase in
the total relative abundance of resistance genes at the last time
point and after treatment, from 0.16% to 0.36%. The genes that
code for multidrug resistance efflux pumps are the most abundant
on the 10th day of treatment. However, beta-lactamase genes
increased throughout the AB course and reached the maximum at
Figure 3. Canonical Correspondence Analysis (CCA) of the patients A, B, C and D in the follow-up study. (A) total microbiota, (B) active
microbiota, (C) genes and (D) gene taxonomy. The antimicrobial effect is represented as a vector with two levels (bactericidal and bacteriostatic). The
mode of AB action is represented as a vector with three levels (cell envelop synthesis inhibitor, cell replication inhibitor and protein synthesis
inhibitor).
doi:10.1371/journal.pone.0080201.g003
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Table 2. Functional profiles.
Patient
Main Role Sub-Role A B C D
Amino acid biosynthesis Glutamate family q 2.06E-004 NS NS NS
Histidine family q 0.02 NS NS NS
Serine family q 4.36E-004 NS NS q 0.01
Biosynthesis of cofactors* Biotin NS q 0.02 NS Q 2.33E-004
Glutathione and analogs NS q 2.95E-003 NS Q 0.04
Menaquinone and ubiquinone Q 0.02 q 2.19E-005 Q 0.04 Q 4.68E-003
Molybdopterin NS NS NS Q 4.35E-003
Pantothenate and coenzyme A q 0.01 NS NS NS
Other q 1.33E-004 NS NS NS
Cell envelope Biosynthesis and degradation of surface** Q 0.05 q 3.01E-005 NS Q 0.02
Other q 0.01 Q 0.01 NS q 0.02
Surface structures NS NS NS q0.04
Cellular processes Biosynthesis of natural products NS NS NS Q0.05
Cell division NS Q 0.01 NS q 3.07E-004
Chemotaxis and motility NS NS NS q0.01
Detoxification NS NS NS Q 0.04
DNA transformation Q 2.32E-003 NS Q 0.01 NS
Pathogenesis Q 9.43E-004 q 1.47E-005 NS Q 2.22E-009
Sporulation and germination q 0.03 Q 7.07E-017 NS q 2.65E-017
Toxin production and resistance NS Q 2.85E-004 NS NS
Central intermediary metabolism Amino sugars NS NS NS q 0.03
Nitrogen metabolism NS q 0.02 NS NS
DNA metabolism Chromosome-associated proteins NS NS Q 0.01 NS
Restriction/modification q 0.02 NS NS NS
Energy metabolism Aerobic Q 0.01 NS NS Q 0.01
Amino acids and amines NS q 9.26E-007 NS Q 2.22E-009
Anaerobic NS NS NS Q 4.80E-005
Biosynthesis and degradation of polysaccharides Q1.58E-003 NS NS NS
Chemoautotrophy NS Q0.01 NS NS
Electron transport NS q 0.01 NS NS
Entner-Doudoroff NS q 2.85E-004 NS Q 0.01
Fermentation NS NS NS q0.01
Pentose phosphate pathway NS q 0.01 NS Q 0.03
Sugars NS q 2.47E-005 NS Q 0.04
TCA cycle q 0.05 q 0.02 NS Q 4.59E-003
Fatty acid and phospholipid metabolism Degradation Q 0.05 q 0.04 NS Q 0.03
Protein fate Protein and peptide secretion and trafficking NS NS NS Q 0.02
Protein folding and stabilization NS Q 0.01 NS NS
Protein synthesis Other Q 0.03 Q 4.57E-005 NS NS
Ribosomal proteins: synthesis and modification NS Q 2.85E-004 NS q 4.80E-005
tRNA and rRNA base modification NS NS q 2.04E-003 NS
Regulatory functions Other NS NS q 0.01 NS
Signal transduction PTS q 1.40E-005 NS q 3.59E-009 Q 7.09E-009
Two-component systems NS NS NS Q1.52E-003
Transcription DNA-dependent RNA polymerase NS Q 4.49E-003 NS q 0.03
Transport and binding proteins Amino acids, peptides and amines q 4.36E-004 q 2.85E-004 NS Q 4.32E-005
Anions Q 4.36E-004 NS NS NS
Carbohydrates, organic alcohols, and acids q 4.36E-004 q 3.62E-006 q 1.46E-004 Q 3.76E-033
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the end of treatment. Patient C also presented a high abundance of
tetracycline resistance genes before treatment (teto, tetq and tetw)
associated to different taxa (Blautia, Bacteroides, Clostridium, and
Ruminococcus), which have been described as resistant to this
antibiotic [41,42,43] but underwent a dramatic decrease on day
10 associated with a major presence of the Proteobacteria phylum.
Discussion
Dynamics of the gut microbiota structure over the AB
course
The human gut microbiota consists of a highly complex
community whose members establish close relationships with the
host. ABs have strong direct and indirect effects on the human gut
microbiota and consequently on the functions they perform,
affecting the ecosystem maintenance and therefore host physiology
[7,13]. The microorganisms that carry certain genetic determi-
nants have an advantage under AB pressure, allowing them to
survive and grow. It is well known that the human gut microbiota
presents a high inter-individual variability and that its composition
depends on factors such as genetics, age, diet, health status and
AB-therapy, among others.
In our study, each patient presented their own initial microbiota
and thus there was an individual response to AB treatment with
fluctuations in the bacterial diversity and composition for both
total and active gut microbiota. These results highlight the
importance of the initial microbial structure in shaping the
changes in microbiota during the AB course. The individual
character of the response and incomplete recovery of initial
microbiota after AB treatment has previously been described by
Dethlefsen and coworkers [18] in a follow-up study of three
patients that received two courses of ciprofloxacin. However, we
also observed that the selection of resistant microorganisms led to a
similar microbiota composition after analogous antibiotic treat-
ment. Thus, AB seems to have a major impact on the structure of
the final bacterial community.
The gut microbiota has been described as an ecosystem that is
relatively resistant to perturbations [16]. However we observed
that a particular assembly of microorganisms can confer greater
resistance to a disturbance than others in terms of presence and
abundance of taxa, which could be related with the specific effect
of the AB. In patient A, there was a decrease in Faecalibacterium and
Bacteroides genera during the AB course, with AB-resistant strains
appearing at the end of treatment. However, on the first days of
treatment, other butyrate-producing taxa (Roseburia and Lachnospir-
aceae incertae sedis) and H2-consuming bacteria (Blautia, Collinsella
and Bifidobacterium) were present as active microbiota, obtaining
energy sources for the colonocytes of the host. A similar behavioral
pattern of these members of the intestinal microbiota has also been
reported by the above mentioned group of Dethlefsen et al.
[15,18] when they used ciprofloxacin, as in our patient A, an AB
belonging to the cell replication inhibitor group. In the case of
patient B, since clindamycin affected anaerobic bacteria, there
were marked decreases in Bacteroides and Blautia genera in the
active microbiota just after AB administration (Figure 2B).
However, three days later, high abundances of Bacteroides were
detected in the active bacterial community, suggesting these
bacteria acquired resistance. The presence of clindamycin-
resistant Bacteroides in gut microbiota has also been described in
other studies [9,44]. Moreover, we observed that the decrease in
anaerobic bacteria is compensated for by an important increase in
members of the family Enterobacteriaceae. Patients C and D were
treated with ABs which have a similar mode of action as both are
of the b-lactam class. As stated, the initial microbiota composition
was very different between both subjects, showing a differential
response to ABs. However, the active microbiota changed
throughout AB treatment with both patients acquiring a similar
composition by the end of it (Figure 2B). Patient C received a
combination of two ABs, Cefazolin and Ampicillin/Sulbactam,
which cover a broad spectrum of microorganisms and showed a
significant increase in Parabacteroides and Bacteroides genera.
Interestingly, resistance genes against ampicillin and cephalosporin
in these two taxa have been described previously [43]. On day 10
of treatment, an increase in the Enterobacteriaceae family
occurred and some of its genera, such as Escherichia or Klebsiella
are considered as opportunistic pathogens [45], suggesting that AB
use creates opportunistic infections by these harmful microorgan-
isms. Patient D was treated with amoxicillin, described as active
against some Proteobacteria such as Escherichia or Klebsiella. During
treatment, these genera were almost eliminated, whereas Bacteroi-
des, Blautia and Faecalibaterium taxa proved less susceptible to
treatment, as occurred in patient C. It is worth pointing out that
this bacterial profile, with Bacteroides, Blautia and Faecalibaterium
after the AB stress, has been found in the case of bactericidal
agents but not when a bacteriostatic antimicrobial was used.
Furthermore, a previous study [12] found a similar pattern of
active bacteria after beta-lactam treatment.
Antimicrobial effect and mode of action of ABs on the
gut microbiota
It has been stated that external variables such as ABs shift the
microbial composition [46]. In our study, the class of AB
Table 2. Cont.
Patient
Main Role Sub-Role A B C D
Cations and iron carrying compounds q 3.03E-003 NS NS Q 0.04
Nucleosides, purines and pyrimidines NS q 2.61E-003 NS Q 1.52E-003
Other NS q 1.33E-003 NS Q 5.56E-004
Porins NS q 0.01 NS NS
Unknown function Enzymes of unknown specificity Q 0.04 NS NS Q4.97E-005
Main roles and sub-roles that change significantly during treatment and their associated p-values (p-value , 0.05). The upward arrow indicates those categories that
were more abundant during treatment and the downward arrow those that were less abundant. NS, not significant.
*Biosynthesis of cofactors, prosthetic groups, and carriers.
**Biosynthesis and degradation of surface polysaccharides and lipopolysaccharides.
doi:10.1371/journal.pone.0080201.t002
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significantly shaped the microbiota on the basis of the antimicro-
bial effect (bactericidal or bacteriostatic) and the mode of action.
In addition, we have found that specific mechanisms of action
affect some organisms more than others, leading the bacterial
community towards an alternative temporary equilibrium state.
Clindamycin (protein synthesis inhibitor) introduced higher
variance in microbiota composition than the other agents, giving
way to a different bacterial community structure. This was
probably due to the bacteriostatic nature of clindamycin when
compared to the bactericidal effect of the other AB treatments.
Interestingly, in the case of the active microbiota representing the
surviving community, the bacterial composition was affected by
the mode of action rather than the antimicrobial effect clearly
distinguishing the three modes of action (Figure 3B). At a
functional level, the microbial community profile was driven by
the antimicrobial effect rather than by the mode of action.
However, the strength of the AB class, considered as an external
factor exerted at gene level was less intense, resulting in major
uniformity.
AB impact on bacterial metabolic functions
High homogeneity was observed in the main roles for all the
patients. This uniformity at a functional level has been also shown
in both DNA and RNA-based surveys [22,47,48,49,50] since the
microbiota is characterized by high functional redundancy. When
we considered sub-roles, 51% with significant variation corre-
sponded to inter-individual variability, representing the specific-
subject response to AB course. The over-representation of genes
involved in sugar transport in most of the patients suggested that
this functional category could play an important role under stress
conditions, as is the case of AB treatment. The phosphotransferase
system (PTS), in addition to its main role in sugar transport, which
is an essential function in itself, is involved in different regulatory
processes such as stress response in bacteria and, hence, it could
confer some extra advantages in presence of ABs [51]. Then, an
efficient system of importing sugars could facilitate the energetic
metabolism and, therefore, it could counteract the negative effect
of ABs on the bacterial growth. Pe´rez-Cobas and coworkers [12]
showed an increase in proteins belonging to the glycolysis pathway
and pyruvate metabolism, as well as higher expression of genes
related to energy metabolism/sugars category during beta-lactam
treatment.
As we mentioned previously, the bacteriostatic effect drives
the bacterial community to a characteristic composition, which
is also reflected at a functional level. In patient B, most of the
functional categories over-represented during treatment could
be related with the increase in Enterobacteriaceae members. In
this regard, we found an increase in the number of genes
involved in lipopolysaccharide synthesis, which is the main
component of the outer membrane for most Gram-negative
bacteria. This barrier plays an important role in nutrient
uptake and also confers resistance against ABs [52]. Likewise,
the genes of secretion systems typical of Gram negative
bacteria pathogenesis showed an increase only in patient B.
However, patients A, C, and D, who received bactericidal
treatment, presented a high abundance of Gram positive
Ruminococcaceae and Lachnospiraceae families, and an over-
representation of genes involved in endospore formation, a
resistance mechanism typical of Gram positive bacteria.
Another category that presented differences between bacteri-
cidal and bacteriostatic ABs was catabolism of fatty acids and
phospholipids, to produce acetyl-CoA through the beta-
oxidation process. As clindamycin inhibits mainly the anaer-
obic bacteria, the genes belonging to this sub-role were more
abundant in patient B whose bacterial composition proved rich
in Enterobacteriaceae family members.
Changes in the resistome
It has previously been pointed out that the AB usage is the
most influential agent in the spread and stabilization of
resistance genes in the gut environment [13]. One of the
multidrug resistant genes that increased in patients A and B
was a multidrug resistance efflux pump, which confers
resistance against aminoglycoside, glycylcycline, beta-lactam,
macrolide and acriflavine antibiotics. Since these ABs have
different properties such as spectrum or mode of action, the
transmission of these genes to a pathogen could hinder clinical
treatment in the event of infection. These resistance genes have
been described in some Proteobacteria genera such as
Escherichia or Klebsiella, thereby supporting the increase in the
abundance of these genera during treatment, principally in
patient B. Patients A, B and C reached higher values of gene
resistance abundances after AB treatment, with patient B, who
was treated with clindamycin, attaining maximum values. It
has been reported that besides the strong effect on the
microbial composition, clindamycin also promotes increased
AB resistance, which can persist in the microbial population for
a long time [53]. In contrast, patient D showed a decrease in
the relative abundance of resistance genes in the bacterial
community. In fact, we found different dynamics in patient D
as compared to the other three patients. This sample presented
an initial composition with prevalence of the Enterobacteria-
ceae family, which has been described as a considerable source
of resistance genes [54] and hence, the data indicated that
these taxa were strongly affected by the ABs. Thus, the final
resistome in the human gut after AB therapy would be
determined by the resistance genes carried by the surviving
bacteria and by the class of AB administered.
Conclusions
In this study, using high-throughput methodology, we have
provided new insights into the complex antibiotic resistance
scenario, related to the different modes of action of antibiotics and
the consequences for the gut microbiota composition and function
during antibiotic therapy. We have shown that specific properties
of ABs such as antimicrobial effects or mode of action, are
powerful forces for the selection of intestinal microbiota, and are
partially responsible for the shifts in bacterial composition during
AB therapy. The resulting structure of the microbial community
showed its specific metabolic capabilities giving a different
functional profile. Additionally, we have shown that the AB also
modified the resistome composition, increasing the abundance of
resistance genes in the gut environment, which is also important in
shaping the post-treatment composition of the microbiota.
However, further research into a larger group of subjects would
be necessary to establish a quantitative evaluation of changes in
gut microbiota.
Figure 4. Resistance gene profiles. (A) The dashed lines represent the relative abundance of the total number of resistance genes for patients A,
B, C, and D. (B) Relative abundance of the resistance genes throughout AB treatment for patients A, B, and C. The symbol "*" highlights the resistance
gene profiles which coincide with the antibiotic administered to patients C, A and B, respectively.
doi:10.1371/journal.pone.0080201.g004
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Antibiotic therapy is a causative agent of severe disturbances in microbial communities.
In healthy individuals, the gut microbiota prevents infection by harmful microorganisms
through direct inhibition (releasing antimicrobial compounds), competition, or stimulation
of the host’s immune defenses. However, widespread antibiotic use has resulted in
short- and long-term shifts in the gut microbiota structure, leading to a loss in colonization
resistance in some cases. Consequently, some patients develop Clostridium difficile
infection (CDI) after taking an antibiotic (AB) and, at present, this opportunistic pathogen
is one of the main causes of antibiotic-associated diarrhea in hospitalized patients. Here,
we analyze the composition and functional differences in the gut microbiota of C. difficile
infected (CDI) vs. non-infected patients, both patient groups having been treated with AB
therapy. To do so we used 16S rRNA gene and metagenomic 454-based pyrosequencing
approaches. Samples were taken before, during and after AB treatment and were checked
for the presence of the pathogen. We performed different analyses and comparisons
between infected (CD+) vs. non-infected (CD−) samples, allowing proposing putative
candidate taxa and functions that might protect against C. difficile colonization. Most
of these potentially protective taxa belonged to the Firmicutes phylum, mainly to the
order Clostridiales, while some candidate protective functions were related to aromatic
amino acid biosynthesis and stress response mechanisms. We also found that CDI
patients showed, in general, lower diversity and richness than non-infected, as well as
an overrepresentation of members of the families Bacteroidaceae, Enterococcaceae,
Lactobacillaceae and Clostridium clusters XI and XIVa. Regarding metabolic functions,
we detected higher abundance of genes involved in the transport and binding of
carbohydrates, ions, and others compounds as a response to an antibiotic environment.
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INTRODUCTION
The human intestinal microbiota is involved in many host func-
tions, such as food processing, regulating intestinal epithelium
growth, immune system development, synthesis of essential vita-
mins, or protection against pathogens (Hooper et al., 2002;
Guarner and Malagelada, 2003; Hattori and Taylor, 2009; Leser
and Mølbak, 2009; Montalto et al., 2009). Because of its role in
human health, imbalances in the gut microbiota have been associ-
ated to pathologies such as inflammatory bowel disease, diabetes,
obesity, or Crohn’s disease (Kang et al., 2010; Sekirov et al., 2010;
Morgan et al., 2012; Shanahan, 2013). Antibiotic (AB) therapy has
been crucial to treat bacterial infections for over half a century,
but it strongly disturbs the gut commensal bacteria and, con-
sequently, the beneficial functions they perform (Jernberg et al.,
2010; Willing et al., 2011; Pérez-Cobas et al., 2013a). In fact, AB
usage has been associated to short and long-term changes in the
intestinal microbiota, reducing colonization resistance to oppor-
tunistic pathogens such as Clostridium difficile (Vollaard and
Clasener, 1994; Bartlett, 2002; Jernberg et al., 2010; Reeves et al.,
2011; Britton and Young, 2012). C. difficile is an anaerobic, spore-
forming, Gram-positive toxin-producing bacterium, which is the
most common cause of nosocomial diarrhea, and broad spectrum
ABs constitute one of the primary risk factors for infection by
this pathogen (Hookman and Barkin, 2009; Cohen et al., 2010).
Under normal conditions, the human gut microbiota is able to
prevent pathogen invasion through general mechanisms such as
direct inhibition (by releasing inhibitory compounds, bacteri-
ocins), nutrient depletion (consuming growth-limiting nutrients)
or stimulating host immune defenses (reviewed in Stecher and
Hardt, 2011). The exact mechanism by which the microbiota pro-
tects against C. difficile infection (CDI), preventing its growth
and virulence, is still unknown. In this regard, direct antagonism
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was found in vitro since C. difficile is a target of bacteriocin pro-
duced by an intestinal strain of Bacillus thuringensis (Britton and
Young, 2012). Since the gut microbiota participates actively in
the fermentation of diet carbohydrates, amino acid and lipid
metabolism and protein digestion, Theriot et al. used a metabolic
model of CDI in mice and found that ABs affect all these func-
tions, leading to a disturbed microbiota functional state that
favors C. difficile germination and growth (Theriot et al., 2014).
Moreover, gut microorganisms participate in bile acid transfor-
mation, which otherwise stimulate C. difficile spore germination
and growth (Britton and Young, 2012). Thus, the loss of key
taxa which play these roles can trigger a structural and func-
tional imbalance, allowing colonization by this opportunistic
pathogen.
In recent years, high-throughput molecular techniques, such
as 16S rRNA gene sequence analyses (taxonomic composition
of microbial communities), metagenomics (genetic potential
of microbial communities) and other meta-“omics” (metatran-
scriptomics, metaproteomics, metabolomics) have extended our
knowledge of intestinal microbiota diversity and functions (Gill
et al., 2006; Kurokawa et al., 2007; Zoetendal et al., 2008; Tap et al.,
2009; Gosalbes et al., 2011; Pérez-Cobas et al., 2013a,b). Some of
these approaches have recently been used to address the effects of
ABs in the gut ecosystem (Dethlefsen et al., 2008; Antonopoulos
et al., 2009; Dethlefsen and Relman, 2010; Jakobsson et al., 2010;
Antunes et al., 2011; Pérez-Cobas et al., 2013b) showing that
ABs considerably alter the gut microbial ecology and the host-
microbiota interactions (Pérez-Cobas et al., 2013a). The response
of the microbiota to ABs is related to properties of the agent,
such as the antimicrobial effect, mode of action, dosage and dura-
tion of treatment, or route of administration (Jernberg et al.,
2010; Pérez-Cobas et al., 2013b). In addition, biological factors of
the host-microbial ecosystem itself such as taxonomic and func-
tional composition, resistance gene reservoir, or host immune
homeostasis also contribute to the microbial community shifts
associated to AB therapy (Jernberg et al., 2010; Willing et al.,
2011; Relman, 2012). To date, few studies have aimed to ascer-
tain whether specific changes in the microbiota composition due
to AB therapy lead to CDI. Past surveys have shown that diver-
sity of the intestinal microbiota is significantly reduced in patients
prior and/or during CDI, as well as important structural changes
associated to infection (Antharam et al., 2013; Vincent et al.,
2013).
The main goal of the present follow-up study is to gain
insights into the development of CDI and its relation to an
altered human gut microbiota. We have used 16S rRNA gene and
metagenomic approaches to characterize the structure and func-
tions of the intestinal microbiota before, during and after broad
spectrum AB therapy in patients who developed CDI. In two pre-
vious studies we explored the effect of broad spectrum ABs on
human gut microbiota composition and function in patients that
did not develop CDI at any time (Pérez-Cobas et al., 2013a,b).
Comparative analyses of these two groups of patients identified
bacterial taxa and metabolic functions associated to an infection
status, as well as specific taxa and functions that could pro-
tect against the C. difficile, and thus contribute to colonization
resistance of the human gut microbiota.
MATERIALS AND METHODS
SAMPLE COLLECTION
Three patients under AB therapy at the Department of Internal
Medicine of the University Hospital Schleswig-Holstein, Kiel,
Germany were recruited for the study due to the fact that they
were positive for C. difficile at some time points of the treat-
ment. The patients were older than 65 years, no antibiotic ther-
apy was administered to them in the previous 6 months to
their hospital admission. The diagnosis at the entrance to the
hospital were ischaemic colitis, sigmoid diverticulitis and infec-
tion of unknown origin for patients referred as F, G, and H,
respectively. The patients stayed in the hospital during the AB
therapy. Written, informed consent was obtained from all the
subjects.
Fecal samples were collected, before, during and after AB treat-
ment, from the three patients in sterile tubes and stored at−80◦C
until processing all sample together. Fecal samples were screened
by multiplex PCR for C. difficile toxin genes, tcdA and tcdB, and
triose phosphate isomerase gene (tpi), considering C. difficile pos-
itive those samples that resulted positive for the three examined
genes (referred as CD+, whereas CD− is used for the rest of
samples). Patients F and H were found positive after 16 and
35 days after AB treatment, respectively, whereas patient G was
found positive on entering hospital (Table 1). The three patients
presented diarrhea during AB theraphy.
In two previous studies we evaluated the effect of broad-
spectrum antibiotics on five patients (A, B, C, D, E) through
similar approaches of those presented in this work (16S rRNA
gene and metagenomics) as part of the same research sur-
vey (Pérez-Cobas et al., 2013a,b) that was approved by the
Ethical Committee of the University Hospital Schleswig-Holstein.
None of these patients developed CDI (they were negative for
the multiplex PCR for C. difficile tcdA, tcdB, and tpi genes),
or presented diarrhea. The main features and therapy of all
patients (A, B, C, D, E, F, G and H) are shown in Table 1.
Only the time-points used in this study are shown for the
patients A, B, C, D, and E (all CD− samples) of the previous
studies.
DNA EXTRACTION AND SEQUENCING PROCESS
The fecal samples were resuspended in sterile PBS [contain-
ing, per liter, 8 g of NaCl, 0.2 g of KCl, 1.44 g of Na2HPO4,
and 0.24 g of KH2PO4 (pH 7.2)] and centrifuged at 1250 g
and 4◦C for 2min to remove fecal debris. The supernatants
were centrifuged at maximum speed at 4◦C for 5min to pel-
let the cells. DNA was extracted with the QIAamp® DNA Stool
Kit (Quiagen) following the manufacturer’s instructions. Total
DNA integrity was checked by running a standard agarose gel
electrophoresis and the concentration was quantified with the
QuantiT PicoGreen dsDNA Assay Kit (Invitrogen). For each sam-
ple, except of F_after from which there was no enough amount of
DNA, the total DNA (metagenome) was directly pyrosequenced
with a Roche GS FLX sequencer and Titanium chemistry in
the Center for Public Health Research (FISABIO-Salud Pública)
(Valencia, Spain). Thus, a total of 12 metagenomes were analyzed.
We obtained a mean of 78,976 reads per sample with an average
length of 374 bp.
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Table 1 | Description of the patients involved in the study.
Patient Antibiotic Sampling date Samples code Study CD (+/−)
A Moxifloxacin Day0—before AB A_before Pérez-Cobas et al., 2013b −
Day3—during AB A3_D −
Day6—during AB A6_D −
Day10—during AB A10_D −
Day13—during AB A13_D −
B Clindamycin Day0—before AB B_before Pérez-Cobas et al., 2013b −
Day2—during AB B2_D −
Day5—during AB B5_D −
Day6—during AB B6_D −
C Cefazolin/Ampicillin/Sulbactam Day0—before AB C_before Pérez-Cobas et al., 2013b −
Day3—during AB C3_D −
Day6—during AB C6_D −
Day10—during AB C10_D −
D Amoxicillin Day0—before AB D_before Pérez-Cobas et al., 2013b −
Day3—during AB D3_D −
E Ampicillin/Sulbactam/Cefazolin Day0—before AB E_before Pérez-Cobas et al., 2013a −
Day3—during AB E3_D −
Day6—during AB E6_D −
Day11—during AB E11_D −
Day14—during AB E14_D −
F Amoxicillin/Ciprofloxacin/Clarithromycin Day0—before AB F_before Present study −
Day16—during AB F16_D +
3 days after AB F_after +
G Ciprofloxacin Day0—before AB G_before Present study +
Day4—during AB G4_D +
4 days after AB G_after +
H Vancomycin/Ampicillin/Sulbactam Day0—before AB H_before Present study −
Day7—during AB H7_D −
Day14—during AB H14_D −
Day20—during AB H20_D −
Day35—during AB H35_D +
Day38—during AB H38_D +
26 days after AB H_after −
CD (+/−), positive and negative detection for C. difficile. AB, antibiotic.
16S rRNA GENE AMPLIFICATION
A region of the 16S rRNA gene (V1, V2, and V3) was amplified by
polymerase chain reaction (PCR) for each sample. The primers
were the universal E8F (5′-AGAGTTTGATCMTGGCTCAG-3′)
with adaptor A and 530R (5′-CCGCGGCKGCTGGCAC-3′) with
adaptor B using the sample-specific Multiplex Identifier (MID)
for pyrosequencing according to 454 standard protocols. For
each sample a 50µl PCR mix was prepared, containing 5µl of
Buffer Taq (10X) with 20mM MgCl2, 2µl of dNTPs (10mM),
1µl of each primer (10mM), 0.4µl of Taq Fast start poly-
merase (5 u/µl), 39.6µl of nuclease-free water and 1µl of DNA
template. PCR conditions were: 95◦C for 2min followed by 25
cycles of 95◦C for 30 s, 52◦C for 1min and 72◦C for 1min
and a final extension step at 72◦C for 10min. The amplifica-
tion products were checked by electrophoresis in agarose gel
(1.4%). PCR products were purified using NucleoFast® 96 PCR
Clean-Up Kit (Macherey-Nagel) and quantified with the QuantiT
PicoGreen dsDNA Assay Kit (Invitrogen). The pooled PCR prod-
ucts were directly pyrosequenced in the same way as the total
DNA (described above). We obtained an average of 5394 reads
per sample.
ANALYSIS OF THE 16S rRNA GENE READS
We used the Ribosomal Database Project (RDP) pipeline (Cole
et al., 2009) to trim off the MID and primers and also to fil-
ter sequences by quality. Sequences with a phred quality score
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below 20 (Q20) and short length (<250 bp) were discarded. The
denoising of the sequences was performed with the usearch pro-
gram in the QIIME pipeline (Caporaso et al., 2010). Then, the
pyrosequencing chimeras were discarded using the uchime filter-
ing also in the QIIME pipeline. After, OTUs were calculated at
97% of sequence similarity by clustering with the usearch pro-
gram in the QIIME pipeline. The taxonomic assignment of the
amplicons was based on the database of RDP. We included only
annotations obtained with a confidence level (bootstrap cut-off)
greater than 0.8, leaving the assignment at the last-well identified
level and the consecutive levels as unclassified (uc).
BIODIVERSITY AND ECOLOGICAL ANALYSIS
To analyze the microbial community structure at OTU level
(97%) we calculated two diversity parameters: number of OTUs
and Shannon index (Shannon, 1948) and two richness estima-
tors: Chao1 (Chao, 1984) and abundance-based coverage (ACE)
(Chao et al., 2000). These estimators are implemented in Vegan
package (Oksanen et al., 2011) under R software (http://cran.
r-project.org) (R Development Core Team, 2011). To statistically
compare the mean ranks of the biodiversity measures between
groups, we used the Wilcoxon signed-rank test implemented in
the R software.
We also performed a clustering based on OTU composition
to study the similarity between samples using the pvclust library
(Suzuki and Shimodaira, 2006) in the R software. This analy-
sis assesses the uncertainty in hierarchical clusters using boot-
strap resampling techniques.We used the approximately unbiased
(AU) p-value with 10,000 bootstraps to estimate the probability
of each cluster. This AU p-value indicates how strong the cluster
is supported by data.
FUNCTIONAL CLASSIFICATION OF METAGENOMES
We used the 454 Replicate Filter Program (Gómez-Alvarez et al.,
2009) to eliminate artifact replicate reads of pyrosequencing fol-
lowing the parameters: sequence identity cutoff= 1; length differ-
ence requirement= 0; number of beginning base pairs to check=
10. Reads were compared against the human genome database
using BLASTN (Altschul et al., 1990) with an e-value of 10−10
to eliminate possible contamination with human sequences. To
identify the sequences encoding the ribosomal 16S rRNA and 23S
rRNA genes we compared the dataset against the Small Subunit
rRNA Reference Database (SSUrdb) and the Large Subunit rRNA
Reference Database (LSUrdb) described in Urich et al. (2008)
using BLASTN with an e-value of 10−16 and 10−4 respec-
tively. After removing the ribosomal genes, the remaining reads
were compared to the NCBI-nr protein database using BLASTX
(Altschul et al., 1990) to identify the protein-coding genes, and
then we performed an Open Reading Frames (ORFs) search with
the Fraggenscan program from the metagenomic analysis web
server (WebMGA) (Wu et al., 2011). The predicted ORFs were
functionally annotated by HMMER 3.0 (Durbin et al., 1998)
against the TIGRFAM database (Haft et al., 2003) using default
parameters.
STATISTICAL ANALYSIS
Canonical correspondence (CCA) and detrended correspondence
(DCA) analyses were performed to explore the relationship
between different groups of samples and with C. difficile infec-
tion as a variable that could explain the variability pattern.
To statistically assess the effect of that variable in explaining
the bacterial composition differences, a multivariate ANOVA
based on dissimilarity tests (Adonis) was applied, implemented
in the Vegan package under the R software. These approaches
were applied to two different levels: the taxonomy based on
the 16S rRNA gene, and the biological functions based on the
TIGRFAMs annotations. We used the ShotgunFunctionalizeR
package (Kristiansson et al., 2009) in the R software to sta-
tistically compare samples at diversity and functional levels.
The differences in composition between samples were addressed
comparing groups of multiple samples with the function “test-
GeneFamilies.dircomp.” On the other hand, we applied the
“testGeneCategories.dircomp” function to compare the distri-
bution of functional categories between groups of samples. It
compares each gene family from a higher functional category
to decide whether the global category is statistically significant
among two groups of samples. All tests were based on Poisson
models.
SEARCHING FOR PUTATIVE CANDIDATE TAXA AND METABOLIC
FUNCTIONS TO PROTECT AGAINST CDI
We also used the “testGeneCategories.dircomp” test to identify
taxa and metabolic functions that could play a protective role
against C. difficile colonization. Specifically, we performed three
comparisons between groups of samples to identify taxa and
functions that were significantly over-represented in CD− com-
pared to CD+ samples. The taxa and functions resulting from
the different comparisons were intersected to define the candidate
protective group. For this purpose, we performed the following
comparisons:
Comparison 1.Since patients F and H were negative to
the pathogen before treatment but positive during therapy,
we compared the CD− samples before AB (F_before and
H_before) against the CD positive samples (CD+) during AB
(F_16D, H35_D and H38_D) (Table 1). We aimed to iden-
tify taxa and functions that significantly decreased (p-value
< 0.1) due to treatment, presumably allowing C. difficile
overgrowth.
Comparison 2. Since patients A, B, C, D and E did not develop
CDI, we performed a comparison of the samples before AB treat-
ment against their samples during treatment (Table 1). We aimed
to identify taxa and functions that significantly increased (p-value
< 0.1) due to therapy or that changed less drastically than those in
Comparison 1, since their presence could play a role in preventing
C. difficile infection.
Comparison 3. Since patient H was negative for the pathogen
26 days after AB, we carried out a comparison of the CD+
samples of patient H (H35_D and H38_D) against the CD−
sample taken after AB (H_after) (Table 1). We aimed to identify
taxa and functions whose significant increase (p-value < 0.05)
could be incompatible with pathogen overgrowth as this was not
detected.
Finally, we intersected all these results to obtain a group of
candidate taxa and functions that could participate in C. difficile
colonization resistance.
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CO-OCCURRENCE BAYESIAN NETWORKS OF CANDIDATES (TAXA AND
METABOLIC FUNCTIONS) IN CD− SAMPLES
To find positive correlations between candidate protective taxa
or functions found in the previous analyses and other taxa and
functions obtained for samples from patients A, B, C, D and E
during AB treatment (all CD− samples), we performed Bayesian
networks based on their relative abundance. The Bayesian net-
works were inferred using the bnlearn package (Scutari, 2010)
in the R software. The optimal network inference was con-
strained so that only those interactions exhibiting a Spearman
correlation p-value below 0.01 were included in the network.
Correlations and p-values were computed using the Spearman
method implemented in R software.
DATA ACCESSION NUMBER
All sequences have been entered in the European Bioinformatics
Institute database, under accession numbers: ERP002192
(patients A, B, C, and D), ERP001506 (patient E) and PRJEB5771
(patients F, G, and H).
RESULTS
MICROBIAL DIVERSITY AND BACTERIAL COMPOSITION IN PATIENTS
DEVELOPING CDI
Analysis of the gut microbiota of the three CDI patients (F, G,
and H) showed large variations in bacterial composition during
therapy (Figure 1).
Before AB treatment, the bacterial composition of patient
F was dominated by the Akkermansia genus (30.6%) belong-
ing to the family Verrucomicrobiaceae. Other bacterial fam-
ilies were also abundant such as Ruminococcaceae (20.8%),
Oscillibacteriaceae (Oscillibacter, 11.7%) and Bacteroidaceae
(Bacteroides, 14.8%). When C. difficile was detected, at day 16 of
AB treatment, all these taxa were almost absent in the commu-
nity except Bacteroides, which had increased to 41.9%, becoming
a predominant genus of the gut ecosystem. The Clostridium clus-
ter XlVa increased dramatically (from 0.7% before AB course
to 46.8% at day 16), being the most abundant group at this
time point. After treatment, the abundance of the main taxa
of the microbial community changed again, the predominant
being Enterococcaceae (Enterococcus, 48.3%), Streptococcaceae
(Streptococcus, 43.2%), Staphylococcaceae (Staphylococcus, 4.1%)
and Clostridium cluster XI (3.5%).
Patient G was found positive to C. difficile detection before,
during, and after AB treatment, showing the most simi-
lar bacterial composition at the three time points, though
there are some remarkable differences. The initial composi-
tion (G_before) consisted mostly of Bacteroidaceae (Bacteroides,
36.7%) and Ruminococcaceae (Faecalibacterium, 29.6%). During
AB (G4_D), although Bacteroides decreased in abundance to 25%,
it remained the most abundant genus, while Faecalibacterium
(5.9%) decreased radically. However, Enterococcus increased dur-
ing AB (from 1.3 to 14.9%). After therapy (G_after), Clostridium
cluster XI became the predominant group (62.4%) whereas
Streptococcus genus decreased progressively at each time point (3,
2.2, and 0.2%, respectively).
Patient H had a very unusual gut microbiota before AB treat-
ment, being dominated (85.7%) by Enterobacteriaceae family,
mainly Escherichia genus, but its abundance decreased dramati-
cally reaching the lowest values at days 35 and 38 of the broad-
spectrum AB treatment (4.2 and 2.8%, respectively), when C.
difficile was detected. During days 7 and 14 of AB treatment
the genus Bacteroides showed the higher abundance values (20.4
and 34.8%); however this taxon decreased on day 20, becoming
undetectable by days 35 and 38. Streptococcus genus increased
slightly in the two CD+ samples (1.5 and 4.5%, respectively).
The most striking shift occurred in the Lactobacillaceae family
(Lactobacillus genus), whose frequency increased from less than
1% at the beginning of treatment to 83.3 and 70% on days 35
and 38 of the AB course, and was reduced to 15.5% after AB. We
performed a statistical comparison to evaluate the differences in
bacterial composition between the samples immediately prior to
C. difficile detection (H14_D, H20_D) and in the CD+ samples
(H35_D, H38_D). (Table S2). The main significantly overrepre-
sented taxa were Lactobacillus, Streptococcus, Proteus, Sutterella
and the uc_Lactobacillaceae, while the Clostridium cluster XlVa,
Enterococcus, Bacteroides, Escherichia, Klebsiella, and Roseburia
were the least abundant taxonomic groups.
The three individuals exhibited great fluctuations in the
number of observed OTUs, as well as in the diversity parameters
analyzed (Table S1). The diversity (based on Shannon, Chao
1 and ACE estimators) of patient F was reduced in the CD+
samples, being minimal after the therapy. The microbial diversity
of patient G also reached the lowest values after treatment. The
decreased diversity after the course in these two patients could
be due to both, the AB and CDI effects. However, the patient H,
which was recovered of the infection after the therapy, presented
the lowest diversity parameters before the AB that could be due to
the massive presence of members of the Enterobacteriaceae
family detected in this sample and also during CDI
(Figure 1).
Finally, we performed a cluster analysis to find similari-
ties in microbiota composition between samples at OTU level
(97%) (Figure 2). The three samples corresponding to patient G
(G_before, G4_D and G_after) were clustered with F_after, being
all CD+ samples. This cluster was closer to the others two sam-
ples of patient F (F_before and F16_D). Patient H samples formed
two clear groups. One of the clusters included the prior infection
samples (before AB and 7, 14 and 20 days during AB) whereas the
CD+ samples (days 35 and 38), which are the most similar sam-
ples, grouped in a second cluster with the sample after treatment
(H_after). The clustering shows that both the individual and the
C. difficile presence contributed to explain the similarity pattern
of the samples.
DIFFERENCES IN MICROBIAL STRUCTURE BETWEEN
C. DIFFICILE -INFECTED AND NON-INFECTED PATIENTS
In previous studies we analyzed changes in bacterial composition
in AB-treated patients that did not develop C. difficile infection
(A, B, C, D and E), and thus all samples were CD−. To search for
differences in microbiota composition possibly related to infec-
tion, we compared the 15 time points during the AB therapy of
these CD− patients with samples from patients that were positive
for C. difficile detection (CD+) (F16_D, F_after, G_before, G4_D,
G_after, H35_D and H38_D) (Table 1).
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FIGURE 1 | Fecal microbiota composition in CDI patients (F, G, and H). The composition of each sample is based on the RDP taxonomic assignment of the
16S rDNA sequences. The phylum and the genus level are shown for the most abundant bacterial groups (>5%).
FIGURE 2 | Cluster analysis based on OTUs (97%) of CDI patients (F, G,
and H). The approximate unbiased (AU) p-values are shown.
First, we compared the Shannon index distributions between
CD+ and CD− samples (Figure S1). We found a lower diversity
for CD+, with an average of 3.1 ± 1.0 compared to CD− sam-
ples with 3.9 ± 0.8, respectively. The richness estimator, Chao1,
showed great variations for both groups; even so, the means were
also lower in the CD+ populations with values of 210 ± 132 vs.
287 ± 157 in CD− individuals. The Wilcoxon signed-rank test
was performed to compare the diversity measures between both
groups, and was not significant for the Shannon index (p = 0.14)
and the Chao1 estimator (p = 0.33). The gut microbiota of CD+
samples seems to be more heterogeneous and less rich than the
CD− samples corresponding to patients that did not develop
CDI, but a larger number of samples would be required to
support this observation.
Second, we performed a detrended correspondence analysis
(DCA) to explore the variations in bacterial composition between
the same CD+ and CD− samples tested above (Figure 3A).
The two axes explained 26. 7% of the total variance, and there
was large variability in the microbiota of both groups. Despite
this variability, two clusters can be distinguished with minimal
overlapping. We applied the Adonis test to evaluate whether
developing C. difficile infection is a factor that influences the
microbiota structure. The factor proved to be significant with a
p-value of 0.005.Thus, although the CD+ samples do not form a
well-defined cluster, they share some features in their microbiota
composition that differ from CD− samples.
Finally, we performed a statistical test to find those taxa
that explained the differences in composition between CD−
and CD+ groups. In CD+ samples there was significant
over-representation of the genera Lactobacillus, Bacteroides,
Enterococcus, Faecalibacterium, the family Lachnospiraceae incer-
tae sedis, and the Clostridium clusters XIVa and XI, the lat-
ter included C. difficile. However, commensal members of the
intestinal community, such as Roseburia, Coprococcus, Blautia, or
Subdoligranulum genera and the families Erysipelotrichaceae and
Ruminococcaceae were underrepresented (Table 2).
CANDIDATE TAXA INVOLVED IN C. DIFFICILE COLONIZATION
RESISTANCE
In order to obtain a subset of candidate bacteria that could
be involved in C. difficile colonization resistance, we per-
formed statistical comparisons between different groups of
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FIGURE 3 | Correspondence analyses. (A) Detrended correspondence
analysis (DCA) based on taxa abundance and composition of CD+ samples of
patients (F, G, and H) (red square) and CD− samples of patients (A, B, C, D,
and E), during treatment (blue square). Gray triangle indicates taxa
distribution. (B) Correspondence analysis (CA) based on the functional profile
(TIGRFAMs) of the same samples. Gray triangle indicates functions.
Table 2 | Differential taxa abundance between CD− (during time
points of A–E patients) and CD+ (F16_D, F_after, G_before, G4_D,
G_after, H35_D and H38_D) samples.
Taxa Abundance in CD+ samples P-value
Clostridium cluster XlVa Increase 0
Clostridium cluster XI Increase 0
Lactobacillus Increase 0
Bacteroides Increase 0
Lachnospiracea incertae sedis Increase 5.65E-137
Faecalibacterium Increase 2.30E-121
Enterococcus Increase 7.06E-120
uc_Lachnospiraceae Decrease 0
Blautia Decrease 0
uc_Ruminococcaceae Decrease 0
uc_Enterobacteriaceae Decrease 0
Roseburia Decrease 0
Parabacteroides Decrease 0
Subdoligranulum Decrease 0
Oscillibacter Decrease 0
Coprococcus Decrease 2.01E-84
Alistipes Decrease 1.78E-46
uc_Erysipelotrichaceae Decrease 8.51E-54
Butyricicoccus Decrease 1.18E-48
Lactococcus Decrease 1.62E-46
Streptococcus Decrease 0.01
samples (see Materials and Methods for the three specific
comparisons). The three comparative analyses gave a num-
ber of statistically significant taxa (Table 3), and intersec-
tion of the results of the three analysis indicated which
taxa may participate in colonization resistance to C. diffi-
cile. We found that the major number of taxa belonged to
the order Clostridiales (Firmicutes), specifically to the fam-
ilies Ruminococcaceae (Ruminococcus, Subdoligranulum, and
Gemmiger), Oscillibacteraceae (Oscillibacter) and Eubacteriaceae
(Anaerovorax). We also found unclassified Ruminococcaceae
and Erysipelotrichaceae belonging to the Clostridiales and
Erysipelotrichales orders, respectively, as well as other Clostridia
and Clostridiales members. Finally, the genus Escherichia from
the family Enterobacteriaceae, Proteobacteria phylum, was also
detected.
Once the candidate protective taxa had been detected, we
performed a Bayesian network (see Materials and Methods)
to find other related members of the bacterial community
and hence also putatively involved in pathogen coloniza-
tion resistance (Figure 4). Gemmiger, Subdoligranulum and uc_
Erysipelotrichaceae did not show any significant correlation and
thus they are not represented in the figure. It is worth noting that
most taxa showing a positive and significant correlation with the
candidates were phylogenetically related to them, mainly belong-
ing to the Clostridiales order, such as Roseburia and Coprococcus
(Lachnospiraceae family) and Anaerotroncus (Ruminococcaceae
family).
FUNCTIONAL CHANGES IN PATIENTS DEVELOPING CDI
In the present work, we performed the functional annotation of
the 12 metagenomes sequenced (metagenome of sample F_after
could not be analyzed, seeMaterials andMethods) by comparison
against the TIGRFAM database, obtaining the following hierar-
chical classification: main roles (the highest functional level), sub
roles (more specific metabolic functions for each one of the main
roles) and genes (metabolic functions) for all the reads. Figure
S2 shows great homogeneity in the main role distribution of dif-
ferent samples for all three patients (F, G, and H). On average,
the most abundant main role categories were: energy metabolism
(12.3% ± 2.1), protein synthesis (12% ± 2), transport and bind-
ing proteins (8.6± 2.5%) and cell processes (8.6± 1.3%). Similar
main role distribution was described for patients A, B, C, and
D in our previous study (Pérez-Cobas et al., 2013b), which is
expected due to the importance of these household functions for
the survival and growth of gut bacteria.
www.frontiersin.org July 2014 | Volume 5 | Article 335 | 7
Pérez-Cobas et al. Gut microbiota and Clostridium difficile
Table 3 | Significant taxa and associated p-value resulting from the
three comparative analyses to find protective candidate taxa.
Taxa Comparison Comparison Comparison
1(a) 2(b) 3(c)
Akkermansia 0 1.66E-4 NS
Anaerotruncus 4.62E-6 NS NS
Anaerovorax 1.12E-70 1.43E-3 3.41E-3
Clostridium cluster IV 6.11E-14 NS 1.27E-32
Clostridium cluster XlVb 0.02 NS NS
Clostridium cluster XVIII 2.16E-18 6.44E-73 NS
Enterococcus 2.63E-7 2.62E-258 NS
Erysipelotrichaceae
incertae sedis
1.46E-6 1.23E-6 NS
Escherichia 0 6.48E-22 6.01E-12
Faecalibacterium 6.71E-5 NS NS
Gemmiger 0.07 0.05 3.41E-3
Holdemania 0.07 1.52E-11 NS
Oscillibacter 0 1.33E-15 8.23E-42
Pseudoflavonifractor 5.42E-16 NS NS
Pyramidobacter 0.04 NS NS
Ruminococcus 4.85E-228 1.19E-6 5.25E-10
Subdoligranulum 1.03E-19 2.76E-8 3.41E-3
uc_Clostridia 1.62E-3 4.27E-5 3.46E-5
uc_Clostridiales 2.35E-11 0.06 1.57E-18
Clostridiales incertae
sedis XIII
1.62E-3 0.04 NS
uc_Enterobacteriaceae 3.18E-6 1.73E-17 NS
uc_Erysipelotrichaceae 0.02 0.07 3.46E-5
uc_Ruminococcaceae 0 7.85E-117 4.44E-129
Anaeroglobus NS NS 1.47E-33
Bacteroides NS NS 5.85E-11
Dialister NS NS 5.25E-10
Selenomonas NS NS 4.73E-9
uc_Betaproteobacteria NS NS 0.04
uc_Lachnospiraceae NS NS 1.50E-9
In bold are the candidate taxa that were significant in the three comparisons.
(a) (F_before and H_before) vs. (F_16D, H35_D, and H38_D).
(b) A, B, C, D, and E samples before vs. during AB treatment.
(c) (H35_D and H38_D) vs. (H_after).
In patient F, there were 51 significantly different sub
roles between samples corresponding to before and during
AB treatment (F_before vs. F16_D) (Table S3). The most
significant over-represented categories in AB treated samples
were: DNA metabolism/chromosome-associated proteins; cellu-
lar processes/DNA transformation; cell envelope/biosynthesis and
degradation of surface polysaccharides and lipopolysaccharides;
and energy metabolism/ pentose phosphate pathway. The under-
represented categories were: protein synthesis/tRNA aminoacyla-
tion; transport and binding proteins/amino acids; peptides and
amines; and cell envelope/surface structures.
Three different comparisons were made for patient H: (i)
before vs. during treatment but before C. difficile detection
(H_ before vs. H7_D, H14_D and H20_D); (ii) before vs. CD+
samples (H_before vs. H35_D and H38_D) and (iii) CD− prior
FIGURE 4 | Bayesian network of microbial composition in CD−
samples of patients (A–E), during treatment, and the candidate
protective taxa. The significant positive correlations (p-value < 0.01)
between the candidate protective taxa and other members of the bacterial
community are shown. The correlation coefficients are indicated. Gray and
white nodes represent candidate and correlated taxa, respectively.
Candidate taxa with no-correlations are not included.
to CDI vs. CD+ samples (H14_D and H20_D vs. H35_D and
H38_D). In total, we found 37 significant sub roles increased
or decreased in CD− samples. (i) Those that increased dur-
ing AB but before CDI were mainly involved in “cell pro-
cesses/DNA transformation” and “protein synthesis/translation
factors,” whereas we observed a significant decrease in “amino
acid biosynthesis/folic acid”; “mobile and extrachromosomal ele-
ments function/plasmid functions”; “signal transduction/PTS”
and “transport and binding proteins/carbohydrates, organic alco-
hol and acids.” (ii). A similar functional profile was found
when we compared before vs. CD+ samples. (iii) Finally, when
we specifically compared the two samples previous to infec-
tion with the two CD+ samples we found 54 significant sub-
roles. The most significant over-represented in the CD+ samples
were: “signal transduction/PTS”; “transport and binding pro-
teins/carbohydrates, organic alcohols, and acids”; “transport and
binding proteins/amino acids, peptides and amines” and “cell
envelope/biosynthesis and degradation of mureinsacculus and
peptidoglycan” (Table S3).
Patient G proved to be infected by the pathogen through-
out the study. Thus, we compared the sub roles distribu-
tion, before vs. during treatment, to find those functions that
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could be AB-related. The comparison showed that only two
categories changed during AB: “amino acid biosynthesis/serine
family” decreased (p = 0) while “cell envelope/other” increased
(p = 0.04).
DIFFERENCES IN THE FUNCTIONAL PROFILE BETWEEN
C. DIFFICILE -INFECTED AND NON-INFECTED PATIENTS
To compare the whole functional composition of CD+ sample
of patients F, G, and H with CD− samples during treatment of
patients A, B, C, D, and E, we applied a correspondence anal-
ysis based on TIGRFAM functions abundance, with both axes
explaining a total of 49.3% of sample variance. The analysis did
not show a clear differential functional pattern between the CD+
and CD− groups given the CD+ samples seem to be a subset of
the CD− group (Figure 3B). We also used the Adonis test to eval-
uate the significance of ABs in structuring the functional profile
of the microbial community in a different way for the two groups
(CD+ and CD−). The factor was not significant at the hierar-
chical level sub roles and metabolic functions, the p-values being
0.63 and 0.73, respectively. To find specific sub roles that could be
associated to CD+ samples, we compared the functional profile
of the same previously tested samples (Table 4), finding signifi-
cant enrichment in “transport and binding proteins,” mainly for
“carbohydrates, organic alcohols and acids,” and “signal transduc-
tion” by the phosphotransferase system (PTS). However, “mobile
and extrachromosomal element functions” and “aromatic amino
acid family biosynthesis” were significantly underrepresented.
CANDIDATE FUNCTIONS INVOLVED IN C. DIFFICILE COLONIZATION
RESISTANCE
Just as in the 16S rRNA gene survey, we performed three com-
parative analyses to find (in the intersection) those metabolic
functions that may play a role in colonization resistance. Table 5
shows the roles, sub roles, and functions that may be protec-
tive. Those with a clearly assigned role are involved in “aromatic
amino acid biosynthesis (chorismate mutase),” “endospore for-
mation (stage IV sporulation protein B and anti-sigma F factor),”
“metabolism of amino groups (agmatine diminase),” and “stress
response mechanisms (rrf2 family protein, redox-active disul-
fide protein 2 and glutamate decarboxylase).” Doubled CXXCH
domain belongs to a protein of unknown function but it is
postulated to be part of c-type cytochromes that participate
in electron transfer. UDP-N-acetylglucosamine 4,6-dehydratase
participates in the biosynthesis of pseudaminic acid. No sub-roles
were assigned to indolepyruvate ferredoxin oxidoreductase and
RNA polymerase sigma-70 factor.
We also performed a Bayesian network to find significant and
positive associations between the candidate protective functions
and other functions that may be important in pathogen infec-
tion resistance. Figure 5 shows the functional network according
to hierarchical categories. In a general overview, most of the can-
didate functions were connected with several different sub roles,
and correlations between candidates were also found. The most
frequently connected function was the doubled CXXCH domain
(26 correlations), and chorismate mutase (25 correlations).
Additionally, these two candidate functions shared some connec-
tions whose nodes are involved in different roles, the majority
Table 4 | Comparisons of sub-roles distribution between CD− (during
time points of A–E patients) and CD+ (F16_D, F_after, G_before,
G4_D, G_after, H35_D and H38_D) samples.
Main role Sub-role P-value
Amino acid biosynthesis Aromatic amino acid family ↓1.5E-29
Biosynthesis of
cofactors, prosthetic
groups, and carriers
Pantothenate and coenzyme A ↓8.2E-7
Riboflavin, FMN, and FAD ↑1.2E-2
Cellular processes DNA transformation ↓1.0E-3
Sporulation and germination ↓1.2E-2
Toxin production and
resistance
↓4.9E-3
Central intermediary
metabolism
Amino sugars ↑2.0E-6
One-carbon metabolism ↑2.3E-2
Other ↑3.9E-6
Phosphorus compounds ↓6.0E-4
Sulfur metabolism ↓8.6E-3
DNA metabolism Chromosome-associated
proteins
↑6.1E-8
Degradation of DNA ↓1.4E-2
DNA replication,
recombination, and repair
↑1.1E-2
Restriction/modification ↓1.0E-3
Energy metabolism Electron transport ↓1.7E-3
Fermentation ↑3.0E-4
Glycolysis/gluconeogenesis ↑1.6E-4
Pentose phosphate pathway ↑1.5E-2
Sugars ↑2.3E-2
Hypothetical proteins Conserved ↓9.4E-7
Mobile and
extrachromosomal
element functions
Other ↓3.4E-17
Protein synthesis Other ↑4.7E-2
tRNA and rRNA base
modification
↑8.2E-3
Purines, pyrimidines,
nucleosides, and
nucleotides
2′-Deoxyribonucleotide
metabolism
↓1.4E-2
Purine ribonucleotide
biosynthesis
↑3.6E-7
Salvage of nucleosides and
nucleotides
↑3.0E-4
Regulatory functions Protein interactions ↓3.6E-5
Signal transduction PTS ↑1.5E-20
Transcription Degradation of RNA ↑1.5E-3
DNA-dependent RNA
polymerase
↑1.5E-2
RNA processing ↑8.2E-3
(Continued)
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Table 4 | Continued
Main role Sub-role P-value
Transport and binding
proteins
Anions ↑9.5E-4
Carbohydrates, organic
alcohols, and acids
↑6.3E-18
Cations and iron carrying
compounds
↑1.2E-5
Unknown substrate ↑3.6E-5
Unknown function General ↑2.0E-6
Arrows indicate the sub-roles significantly over-represented (upward) and under-
represented (downward) in the CD+ samples.
Table 5 | Candidate functions involved in C. difficile colonization
resistance.
Main role Sub-role Function
Amino acid
biosynthesis
Aromatic amino acid
family
Chorismate mutase
Cellular processes Sporulation and
germination
Stage IV sporulation
protein B
Regulatory functions Protein interactions Anti-sigma F factor
Central intermediary
metabolism
Polyamine
biosynthesis
Agmatine deiminase
Unknown function General rrf2 family protein
Redox-active
disulfide protein 2
NA NA Glutamate
decarboxylase
Doubled CXXCH
domain
Indolepyruvate
ferredoxin
oxidoreductase
RNA polymerase
sigma-70 factor*
UDP-N-
acetylglucosamine
4,6-dehydratase
*RNA polymerase sigma-70 factor, Bacteroides expansion family 1.
being related to energy metabolism, protein synthesis and fate, as
well as amino acid biosynthesis. The UDP-N-acetylglucosamine
4,6-dehydratase showed 21 correlations, mainly with cell enve-
lope, protein fate and transport system roles. Also, this func-
tion was connected to another important candidate: glutamate
decarboxylase, with which it shares some correlations. The redox-
active disulfide protein 2 and glutamate decarboxylase presented
17 correlations each. The former, which is correlated to the
two candidates known as chorismate mutase and indolepyru-
vate ferredoxin oxidoreductase, showed associations with energy
metabolism and protein synthesis, while glutamate decarboxy-
lase is correlated to protein fate, regulatory and transport
functions.
DISCUSSION
In this study, we have analyzed changes in the bacterial
composition and functional profile of the gut microbiota of two
patients (F and H) that were positive for C. difficile (CD+ sam-
ples) after AB treatment and one patient (G) that despite not
having taken AB was already CD+ when entered to the hos-
pital. Patients F and H had an unusual microbiota at the start
of the study (before AB treatment), enriched in Akkermansia
genus (30.6%) and highly abundant in Escherichia genus (85.7%),
respectively. We also compared the gut microbiota of those three
patients with five individuals from two previous studies (Pérez-
Cobas et al., 2013a,b), who were also treated with AB but did
not develop CDI. All the patients fit the same inclusion crite-
ria. Despite the heterogeneity of the samples and only 15 time
points are overall compared, we consider that the results obtained
with the different analyses performed, provide new insights into
the effect of CDI on the structure and metabolic functions of the
human gut microbiota. Furthermore, we identified members of
the bacterial community and metabolic functions that are dif-
ferentially present in the CD− samples compared to the CD+
samples and thus could be involved in resistance to C. difficile
colonization.
The gut microbiota of the three CDI patients showed large
variations in bacterial composition and diversity throughout the
therapy, confirming that antibiotics disturb the ecological equi-
librium of microbial communities. Previous studies showed great
fluctuations and low diversity of the human gut microbiota under
the effects of a wide variety of ABs, although patients did not
develop CDI (Dethlefsen et al., 2008; Dethlefsen and Relman,
2010; Pérez-Cobas et al., 2013a,b). In addition to the influence of
AB on the microbiota structure, this survey found that CDI con-
tribute to decreasing bacterial diversity since the infected samples
showed, in general, lowest biodiversity index values and richness
estimators than non-infected samples. In this respect, a mouse
colitis model-based study has suggested that intestinal inflamma-
tion during colonization by some pathogens, includingC. difficile,
affect microbiota equilibrium (reviewed in Stecher and Hardt,
2011), contributing to reduced microbial diversity.
Similarly, significant alterations in the abundance of some taxa
(mainly from the Firmicutes phylum) and a decrease in microbial
diversity and species richness were found in individuals with CDI
(Antharam et al., 2013).
We have found that the microbiota of the infected samples
(CD+) share some common features, being depleted in commen-
sal genera such as Ruminococcus, Roseburia, Subdoligranulum,
Blautia orCoprococcus and enriched in Lactobacillus, Enterococcus,
Clostridium clusters XlVa and XI. The latter being the phyloge-
netic cluster which contains the C. difficile species (Collins et al.,
1994). Although the relative abundance of cluster XI was variable
between the infected samples, its presence is higher in CD+ than
in CD− samples, probably due to the high abundance of C. dif-
ficile. The higher abundance of Clostridium cluster XIVa could
be a consequence of the microbiota imbalance, since members
of this group have been characterized as opportunists (Lozupone
et al., 2012). This may also be the case of Enterococcus, which is
a common opportunistic pathogen that becomes dominant when
the normal gut microbiota is disturbed by ABs (Donskey, 2004;
Frontiers in Microbiology | Microbial Symbioses July 2014 | Volume 5 | Article 335 | 10
Pérez-Cobas et al. Gut microbiota and Clostridium difficile
FIGURE 5 | Bayesian network of microbiota potential functions in CD−
samples of patients (A–E), during treatment, and the protective
candidate taxa. The significant positive correlations (p-value < 0.01)
between the candidate protective functions and other functions of the gut
ecosystem are shown. Each node represents a specific function with the
corresponding subrole color. The candidate protective function nodes are
indicated by numbers: (1) Chorismate mutase; (2) Stage IV sporulation
protein B; (3) Anti-sigma F factor; (4) Agmatine deiminase; (5) rrf2 family
protein; (6) Redox-active disulfide protein 2; (7) Glutamate decarboxylase; (8)
Doubled CXXCH domain; (9) Indolepyruvate ferredoxin oxidoreductase; (10)
RNA polymerase sigma-70 factor, Bacteroides expansion family 1; (11)
UDP-N-acetylglucosamine 4,6-dehydratase.
Ubeda et al., 2010). Enterococcus was also over-represented in
samples of reduced biodiversity in other CDI studies (Antharam
et al., 2013; Vincent et al., 2013). The higher abundance of
Lactobacillus in the CD+ samples is also interesting. For example,
a murine model-based study found that Lactobacillaceae was
dominant in CDI samples (Rea et al., 2011) as did a study of
CDI in humans (Antharam et al., 2013). Although Lactobacillus
has been described as an intestinal probiotic genus, different
studies show that only specific strains (e.g., L. delbrueckii) can
inhibit C. difficile growth (Naaber et al., 2004; Banerjee et al.,
2009). Further research would be needed to clarify the role of
Lactobacillus strains in gut colonization by C. difficile.
The three comparisons performed enabled us to identify
taxa that were significantly over-represented in CD− sam-
ples, due to AB therapy, in individuals that either did not
develop CDI (comparison 2) or recover from CDI (comparison
3), but decreased in those CD+ samples (Comparison 1).
Thus, Anaerovorax, Escherichia, Gemmiger, Oscillibacter,
Ruminococcus, Subdoligranulum, uc_Clostridia, uc_Clostridiales,
uc_Erysipelotrichaceae, and uc_Ruminococcaceae were found
as candidates for protecting against C. difficile colonization.
Bayesian correlation networks are a powerful tool to search and
study ecological or metabolic associations in microbial commu-
nities (Durbán et al., 2012), and thus we used them to look for
other taxa associated to the above, which may be also indirectly
involved in resistance by ecologically interacting with the can-
didates. Most of the taxa in the network belonged to Clostridia:
Ruminococcus, Subdoligranulum, Oscillibacter, Anaerovorax,
Roseburia, Coprococcus, Anaerotroncus, Gemminger and other
unclassified members of Lachnospiraceae and Ruminococcaceae
families. It has been proposed that competition of normal gut
microbiota members with their related pathogens for limiting
resources or sites, called “niche exclusion,” could be a coloniza-
tion resistance mechanism (reviewed in Britton and Young,
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2012). Thus, this niche hypothesis could explain the role of these
related taxa belonging to Clostridiales in protecting against CDI.
In this regard, some studies in mice have shown that Clostridia
members, such as Lachnospiraceae, are C. difficile antagonists
and restore the microbiota when fed to infected mice (Itoh et al.,
1987; Reeves et al., 2011, 2012; Lawley et al., 2012). Another
study in hamsters showed that non-toxigenic C. difficile were
able to prevent the toxigenic pathogen (Sambol et al., 2002;
Merrigan et al., 2003), suggesting a more efficient utilization of
limiting nutrients (niche exclusion) as the protection mecha-
nism. In human studies, members of the Ruminococaceae and
Lachnospiraceae families were significantly depleted in CDI
patients (Antharam et al., 2013).
Some of the Clostridia members found to be associated to the
main protective candidate taxa, such as Roseburia or Coprococcus,
are active anaerobic short-chain fatty acids (SCFA) producers
(Barcenilla et al., 2000; Pryde et al., 2002). This could be other
mechanism through they are candidates to protect against CDI,
since SCFA are reported to inhibit C. difficile growth and also
to decrease the production of toxin in vitro (May et al., 1994).
Moreover, it has been postulated that the anaerobic fraction of
the microbiota is essential for gut ecosystem stability in healthy
individuals, because the butyrate and other SCFAs they produce
have anti-inflammatory effects and stimulate the immune system
and, thus, this imbalance increases the risk of C. difficile over-
growth (Bartlett, 2002; Roy et al., 2006; Jernberg et al., 2010).
However, a recent study in mice found that SCFA production was
no correlated with lower levels of C. difficile colonization (Reeves
et al., 2012). In addition, these authors found that the micro-
biota composition of CDI mice was partially restored when they
used only one isolate of the Lachnospiraceae family for inocula-
tion. Nevertheless, total restoration was obtained when total fecal
content was transferred from a wild-type mouse. These results
agree with our findings because we have found several putative
candidate protective taxa, indicating that more than one bac-
terial group is involved in pathogen protection. Hence, further
research should test in vivo the colonization resistance capacity of
the specific ensemble we have proposed.
In a previous study, we showed that the metabolic profiles of
AB-associated shifts in human gut microbiota were less dramatic
than those in bacterial composition, principally when considering
main roles. This is due to functional redundancy of the human
gut microbiota, and the fact it has a very general set of functions
(Pérez-Cobas et al., 2013b). We have also found great homogene-
ity in distribution of the main role in all the samples. However,
differences appear when considering more inclusive functional
levels (sub-roles and functions). In this study, patients showed
different functional responses (sub-roles) to ABs, in agreement
with our previous study where a great inter-individual variability
was found in AB-treated patients. Although no significant dif-
ferences between both groups of AB-treated patients (CDI and
non-infected) as a whole were detected, a specific functional
profile was found. Thus, the transport, metabolism, and regu-
lation of sugars such as mannose, fructose, lactose, glucitol, or
mannitol were over-represented functions in CDI samples, the
major sugar transport system being the phosphotransferase sys-
tem (PTS). In a previous work, we found that AB increases PTS
in metagenomes, since it seems to give advantage to bacteria
carrying them under stress conditions (Deutscher et al., 2006;
Pérez-Cobas et al., 2013b). The higher presence of these functions
in CD+ samples compared to CD− is noteworthy, even when
both were treated with ABs, because it could be related with the
infection, as shown in a metabolomic study in mice that devel-
oped CDI (Theriot et al., 2014). The same authors found an
increase in carbohydrates like mannose, fructose, lactose, gluci-
tol, or mannitol after AB treatment, and they postulated that these
increases favored C. difficile germination and growth. Related to
this finding, a transcriptomic study revealed that sugars released
by an altered microbiota are exploited by enteric pathogens such
as Salmonella enterica and C. difficile (Ng et al., 2013). Thus, C.
difficile and other opportunistic bacteria can efficiently catabolize
the excess of carbohydrates generated by the disruptedmicrobiota
and, in the absence of competitors, increase colonization rates.
Using the same three comparisons, we also found metabolic
functions that may play a role inC. difficile colonization resistance
(Table 5). Overall, there was a higher abundance of functions
related to aromatic amino acid biosynthesis, being chorismate
mutase the central node of the network, since it was strongly
connected to other important functions like energy metabolism
or protein fate. The chorismate mutase, which participates in
tyrosine, phenylalanine and tryptophan biosynthesis, could be
involved in colonization resistance through stimulation of the
immune system, since the tryptophan metabolite participates
in immune system equilibrium and inflammation regulation
(Zelante et al., 2013). Future research should be conducted to
discover the mechanism by which aromatic amino acid synthe-
sis could protect against colonization by C. difficile. Also, some
energy metabolism pathways seem important, such as TCA cycle,
electron transport, or fatty acid biosynthesis. A great number of
different transporter families, regulator genes, and genes involved
in responses to osmotic or acid stress were also highlighted in the
network, possibly playing a role in colonization resistance.
Another possible protective pathway was peptide catabolism
via tryptophan metabolism. Low abundance of protein digestion
markers was associated to susceptibility to CDI in the mouse
gut (Theriot et al., 2014). Regarding host immune response,
we found polyamine biosynthesis (putrescine or cadaverine) by
decarboxylation of amino acids to be another potential protec-
tive pathway. A previous study reported that these metabolites
interact with the gut microbiota, stimulating the immune sys-
tem and playing a role in intestinal maturation (Gómez-Gallego
et al., 2012). In this regard, Jung et al. (2003) found that glu-
tamate decarboxylase activity, related to polyamines, was also
a protective determinant, playing a role in protection against
acid stress. It is also relevant that this enzyme is connected
to other functions in the network, such as protein fate, tran-
scription regulation, or transport systems, thus reinforcing its
protective role. Moreover, other protective gene-products regu-
late metabolic pathways that are important for several cellular
physiology processes, like osmotic stress resistance and responses
to environmental changes (Wouters et al., 2010; Shepard et al.,
2011).
In summary, we found specific fecal microbiota in CDI
patients as it was enriched in Lactobacillus, Enterococcus,
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Clostridium clusters XIVa and XI but depleted in SCFA-
producing bacteria. The latter bacterial group could be involved
in C. difficile colonization resistance. A group of metabolic
processes related to the metabolism of proteins, amino acids
and responses to stress would seem to participate in avoiding
pathogen invasion in the human gut ecosystem. Further research
into these pathways should be undertaken to unravel the mech-
anism by which they participate in colonization resistance to C.
difficile. A larger cohort of patients with similar sampling would
be needed to deeper define the CDI microbiota at taxonomic and
functional level.
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 SUPPLEMENTARY TABLES 
Supplementary table 1 Biodiversity measures for C. difficile positive patients F, G and H based on OTUs (97%).
Sample CD(+/-) N Shannon Chao1 SE (Chao 1) ACE SE (ACE)
F_before CD- 211 2.83 255.2 16.99 255.54 7.99
F16_D CD+ 114 2.48 172.58 30.18 158.46 6.34
F_after CD+ 31 2.38 49 49.09 44.63 3.12
G_before CD+ 272 4.31 311.84 15.39 309.99 8.63
G4_D CD+ 357 4.77 433.78 22.06 428.53 10.11
G_after CD+ 158 2.45 236.55 26.97 263.6 9.98
H_before CD- 45 2.44 52.2 9.02 51.68 3.51
H7_D CD- 79 3.39 95.87 10.32 107.61 5.68
H14_D CD- 102 3.58 123 14.34 125 5.5
H20_D CD- 187 3.72 216.4 11.51 229.16 7.52
H35_D CD+ 53 2.25 87 36.98 72.82 4.45
H38_D CD+ 114 2.85 177.91 33.8 155.8 6.43
H_after CD- 112 4.09 140.96 13.41 147.94 6.32
N: Number of OTUs; SE (Standard Error); ACE: Abundance coverage estimator; NaN: not a number
Supplementary table 2 Differential taxa abundance between CD+ (H35_D, H38_D) and CD- samples (H14_D, H20_D) in patient H.
Bacterial taxa Abundance in CD+ samples P-value
Lactobacillus increase 0
Streptococcus increase 1.49E-47
uc_Lactobacillaceae increase 9.24E-10
Proteus increase 3.83E-4
Sutterella increase 3.74E-3
Bacteroides decrease 7.33E-103
Escherichia decrease 6.73E-165
Klebsiella decrease 1.18E-145
Enterococcus decrease 6.43E-10
Raoultella decrease 3.72E-3
Clostridium cluster XIVa decrease 1.31E-2
Supplementary Table 3. Comparisons of the sub-role abundance and p-value associated. Patient F: (B/D+)  before and during therapy (F_before vs
F16_D). Patient H: (B/D-) before vs during the treatment but prior C. difficile detection (H_before vs H7_D, H14_D and H_20_D); (B/D+) before vs
CD+ samples (H_before vs H35_D and H38_D); (D-/D+) during AB (H14_D and H20_D vs H35_D and H38_D). Arrows show sub-roles more (upward)
and less (downward) abundant. NS, not significant.
Patient F Patient H
Main Role Sub-Role B/D+ B/D- B/D+ D-/D+
Amino acid biosynthesis Aromatic amino acid family NS ↑0.02 NS ↓3E-04
Aspartate family NS ↑0.02 ↑2E-03 NS
Glutamate family ↓0.01 ↓0.02 NS ↑5E-05
Histidine family NS NS ↓2E-03 ↓2E-04
Pyruvate family NS ↓0.04 ↓2E-04 NS
Serine family NS NS NS ↓0.02
Biosynthesis of 
cofactors,
prosthetic groups, 
and carriers
Biotin ↑4E-03 NS ↓3E-03 ↓3E-05
Chlorophyll and bacteriochlorphyll ↓0.04 NS NS NS
Folic acid NS ↓9E-014 ↓2E-26 NS
Heme, porphyrin, and cobalamin NS NS NS NS
Menaquinone and ubiquinone ↓0.04 ↓0.04 NS ↑0.01
Molybdopterin NS NS NS ↑0.03
Other NS NS ↓4E-03 ↓5E-03
Pyridine nucleotides NS NS NS ↑0.03
Pyridoxine ↑4E-03 NS NS ↓0.01
Riboflavin, FMN, and FAD ↑0.02 NS NS NS
Cell envelope Murein sacculus and peptidoglycan* ↓2E-06 ↓0.03 ↑4E-03 ↑8E-012
Surface polysaccharides** ↑7E-019 NS NS NS
Other ↓0.04 NS NS NS
Surface structures ↓2E-011 ↓2E-07 ↓8E-12 NS
Cellular processes Adaptations to atypical conditions ↑2E-06 NS NS NS
Biosynthesis of natural products ↓4E-03 NS NS ↑0.02
Cell division ↓1E-04 NS NS NS
Chemotaxis and motility NS ↓0.02 ↓3E-02 NS
Detoxification ↑0.01 NS NS NS
DNA transformation ↑6E-019 ↑5E-08 NS ↓2E-07
Pathogenesis ↓0.01 ↓0.01 ↓7E-03 NS
Sporulation and germination ↓0.01 ↑0.01 NS ↓5E-03
Toxin production and resistance ↓0.02 ↑2E-04 NS ↓2E-06
Central intermediary metabolism Amino sugars NS ↓2E-06 ↓4E-05 NS
Nitrogen fixation NS ↑4E-03 NS ↓5E-03
Nitrogen metabolism NS NS ↓2E-03 NS
One-carbon metabolism NS NS ↑1E-02 NS
Other NS NS ↑2E-02 ↑5E-03
Phosphorus compounds ↓2E-04 NS ↑5E-02 ↑3E-03
Polyamine biosynthesis NS ↑0.01 NS ↓3E-04
Sulfur metabolism NS NS ↓4E-04 ↓5E-03
DNA metabolism Chromosome-associated proteins ↑9E-037 ↑2E-05 NS ↓2E-07
Degradation of DNA ↓3E-03 NS NS NS
DNA replication, recombination and repair ↓5E-03 NS ↑2E-03 ↑4E-05
Restriction/modification NS NS ↓1E-02 NS
Energy metabolism
Aerobic NS NS NS ↑0.01
Amino acids and amines ↑2E-05 NS NS ↓0.01
ATP-proton motive force interconversion ↑3E-03 NS ↑1E-02 ↑0.02
Biosynthesis/degradation of polysaccharides ↓2E-08 ↓0.01 NS ↑2E-06
Electron transport ↑0.03 NS ↓3E-05 ↓3E-010
Entner-Doudoroff NS ↓0.01 NS NS
Fermentation ↑1E-03 ↓0.02 ↑2E-02 ↑1E-07
Glycolysis/gluconeogenesis NS NS ↑2E-03 ↑0.05
Other NS NS NS ↓0.01
Pentose phosphate pathway ↑8E-011 ↓0.01 NS NS
Photosynthesis ↑0.01 ↑2E-04 NS ↓0.01
Pyruvate dehydrogenase ↓2E-05 NS NS NS
Sugars ↓0.01 ↓0.01 NS ↑0.01
TCA cycle NS NS ↓2E-03 ↓2E-03
Fatty acid+ Biosynthesis ↓0.02 NS NS NS
Degradation NS NS NS ↑0.05
Hypothetical proteins Conserved ↓0.04 NS NS NS
Domain ↓0.04 NS NS NS
Mobile and extrachromosomal element
functions
Other NS NS ↓3E-05 ↓2E-011
Plasmid functions NS ↓6E-010 ↓4E-25 ↓6E-04
Prophage functions NS ↑0.05 NS NS
Transposon functions NS NS ↑3E-02 NS
Protein fate Proteins, peptides, and glycopeptides*** NS NS ↑1E-03 ↑2E-03
Protein and peptide secretion and trafficking ↓2E-03 NS NS NS
Protein folding and stabilization ↓2E-04 NS ↑3E-02 ↑1E-05
Protein modification and repair ↓0.04 NS NS NS
Protein synthesis Other NS NS ↑8E-03 NS
Ribosomal proteins: synthesis/modification NS ↑3E-09 ↑4E-06 NS
Translation factors NS ↑4E-08 ↑1E-03 ↓0.03
tRNA aminoacylation ↓2E-014 NS ↑1E-03 ↑5E-07
tRNA and rRNA base modification NS ↑0.02 NS ↓9E-06
Purines, pyrimidines, nucleosides, and
nucleotides
2'-Deoxyribonucleotide metabolism NS NS ↑8E-03 NS
Purine ribonucleotide biosynthesis NS NS ↑4E-05 ↑3E-03
Pyrimidine ribonucleotide biosynthesis ↓0.02 NS ↑2E-03 NS
Salvage of nucleosides and nucleotides ↑0.02 NS NS ↑0.02
Regulatory functions DNA interactions NS ↓0.04 ↓2E-03 NS
Protein interactions NS NS ↓2E-03 NS
Other ↓3E-06 NS ↑3E-03 ↑0.01
Small molecule interactions ↑0.01 NS NS NS
Signal transduction PTS NS ↓1E-016 NS ↑5E-016
Two-component systems ↑0 ↑4E-05 NS ↓1E-05
Transcription DNA-dependent RNA polymerase NS ↑0.01 ↑2E-14 ↑3E-07
RNA processing ↑0.02 ↓0.05 NS NS
Transcription factors ↓0.04 NS NS NS
Transport and binding proteins Amino acids, peptides and amines ↓3E-012 ↓1E-07 NS ↑3E-012
Anions ↓9E-09 ↓7E-08 NS ↑3E-08
Carbohydrates, organic alcohols and acids NS ↓10E-035 ↓3E-08 ↑1E-012
Cations and iron carrying compounds NS ↓1E-03 NS ↑0.01
Nucleosides, purines and pyrimidines ↑3E-03 ↓0.02 NS ↑0.03
Other NS ↓2E-06 NS ↑4E-08
Unknown substrate ↑0.03 NS ↑1E-02 NS
Unknown function Enzymes of unknown specificity ↓2E-010 NS NS ↑0.04
General ↑0.04 NS NS NS
+Fatty acid and phospholipid metabolism.
*Biosynthesis and degradation of murein sacculus and peptidoglycan.
**Biosynthesis and degradation of surface polysaccharides and lipopolysaccharides.
***Degradation of proteins, peptides, and glycopeptides.
Supplementary Figure 1 Diversity analyses in CD+ (n=7) and CD- (n=15) samples. (A)Shannon index and (B) Chao 1 estimator of CD+ (F_16D, F_after,
G_before, G4_D, G_after, H_35D and H_38D) and CD- (patients A, B, C, D and E during AB) samples. Thickest line indicates the median.
Supplementary Figure 2 Relative abundance of the main functional roles of samples from patients F, G and H.
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4. GENERAL DISCUSSION
Nowadays, some aspects of the modern lifestyle as global mobility, Western diet, sanitation or medical therapies alter human-
microbe interactions that are the result of millions years of co-evolution. Some of the most influencing factors are an improved
hygiene and sanitation, as well as medical therapies, principally the antibiotic administration (Dethlefsen et al. 2007). Antibiotic
administration disrupt the normal gut microbiota, affecting the human-microbiota relationships and therefore the human
health. Among others consequences, antibiotic-induced perturbation leads to reduce the colonization resistance of the bacterial
community, allowing the overgrowth of opportunistic pathogens as C. difficile. Moreover, the potential spread and stabilization
of antibiotic resistance genes from gut bacteria to pathogens represents a major problem in public health (Cotter et al. 2012,
Jernberg et al. 2007, 2010; Macfarlane 2014, Salyers et al. 2004, Sommer et al. 2009). 
In this thesis, we focused on the consequences of antibiotic therapy on the structure, functions and stability of the
human gut microbiota, as well as on its role in the infection by the intestinal pathogen C. difficile. All the patients of the study
were part of the same European survey (ERA-NET project on C. difficile) and were recruited for the project at the Department
of  Internal Medicine of  the University Hospital Schleswig-Holstein in Kiel, Germany. We used faecal samples of  this set of
patients  to  perform an in-depth  follow-up analysis  of  antibiotic  effects  and  CDI on the  human intestinal  microbiota  by
analysing  different  molecular  markers  of  the  microbial  community  diversity  and  activity  (DNA,  RNA,  proteins  and
metabolites).
The general tools we applied consisted on 16S rRNA-based approaches, metagenomics and metatranscriptomics in
conjunction with pyrosequencing (Roche GS FLX sequencer and Titanium chemistry), as well as metaproteomics and meta-
metabolomics (these last two, in collaboration with the group of Manuel Ferrer at the Institute of Catalysis, Madrid, Spain). We
characterized the changes associated to different antibiotic therapies on the composition and diversity of the total and active
fraction of the human faecal microbiota, by the pyrosequencing of the 16S rDNA (total microbiota) and 16S rRNA (active
microbiota)  molecules,  respectively.  Shifts  on  the  potential  functions  of  the  intestinal  microbiome  related  to  antibiotic
administration were evaluated through pyrosequencing the total DNA of  the faecal microbial  community (metagenomes).
Moreover, the dynamics of the functions of the metabolically active faecal community under antibiotic stress was addressed by
analysing  the  total  mRNA  (metatranscriptomes),  proteins  (metaproteomes)  and  metabolites  (meta-metabolomes)  in  one
patient. 
Overall, we were able, for the first time, to obtain a general picture of the responses of the human gut microbiota to
antibiotic therapy and CDI, integrating the information of  different biological levels. Moreover, we identified bacteria and
functions probably involved in colonization resistance against C. difficile.
In Chapter 3.1 we performed a follow-up study of the gut microbiota of a hospitalized patient along a beta-lactam
antibiotic treatment. This study constitutes a proof of concept, since it was the first report about antibiotic-associated changes
of  the  gut  microbiota  based  on  the  application  of  multiple  "omics"  approaches.  This  multi-analysis  included  the
characterization  of  the  diversity  of  the  total  and  active  microbiota  (16S  rRNA  based  approaches),  the  gene  content
(metagenomics),  the  expressed  genes  (metatranscriptomics),  the  proteins  (metaproteomics)  and  the  metabolites  (meta-
metabolomics)  of  every  sample  before, during  and after  the  antibiotic  course.  This  work by  combining different  “omics”
provided an overview of the functional status of the gut ecosystem under antibiotic stress. 
In Chapter 3.2 we performed a follow-up study of the gut microbiota of four individuals under different antibiotic
therapies. Antibiotics administered to the patients presented bactericidal and bacteriostatic antimicrobial effects. Besides, the
antimicrobial agents presented different modes of actions that we grouped in three: cell replication inhibitor, protein synthesis
inhibitor  and cell  envelope synthesis  inhibitor. In this  work, through 16S rRNA-based approaches  and metagenomics, we
evaluated the effect of inherent properties of the antibiotics (the antimicrobial effect and mode of action) on the modelling of
the total and active gut microbiota and its genetic potential. We also analysed the functional changes and possible responses of
the microbiota associated to antibiotic stress, including the resistance gene reservoir evolution along antimicrobial therapies.
In Chapter 3.3 we carried out a follow-up study of three individuals under antibiotic therapy, similar to the previous
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works, but in this  case  the  three  patients  developed CDI. We also  used 16S rRNA gene and metagenomic approaches  to
characterize shifts on the structure and functions of the gut microbiota due to antibiotic treatment and CDI. In addition, we
performed a comparative analysis of this group of patients with the patients from the two previous studies (Chapters 3.1 and
3.2) that, as stated before, were also treated with broad spectrum antibiotics but that did not develop CDI. Specifically, we
performed three different statistical  comparisons  among the different samples of  the three studies that  allowed identifying
bacterial taxa and metabolic functions related with the infection process, as well as others that could be candidates to protect
against C. difficile. Moreover, we used Bayesian networks to identify other taxa and functions possibly involved in colonization
resistance based on their putative association (positive correlation) with the protective candidates.
Various studies  about antibiotic  effects  on the  gut microbiota  in animals  and humans, including our  own work,
described large variations in the relative abundance of bacterial taxa, a reduced diversity on the total gut microbiota during
antimicrobial  therapies,  as  well  as  an  almost  return  to  the  original  composition  several  weeks  after  treatment  cessation,
although with some unrecoverable minority taxa (Antonopoulos et al. 2009, Dethlefsen & Relman 2011, Dethlefsen et al. 2008,
Jernberg et al. 2007, Macfarlane 2014, Pérez-Cobas et al. 2013a,b). Similar to the non-infected patients, the microbial diversity
and the composition of the patients infected by C. difficile exhibited strong fluctuations as a consequence of the antibiotics, but
also due to the infection when the minimum values were reached (Pérez-Cobas et al. 2014). Moreover, our works were the first
studies to address the effects of antibiotics on the active fraction of the gut microbiota. Interestingly, we found that the active
fraction  during  treatment  showed  less  variations  (although  significant)  than  the  total  community, since  it  contained  the
resistant bacteria that continue growing and take longer to be affected by the antibiotic (Pérez-Cobas et al. 2013a,b).
In our studies about the effect of broad spectrum antibiotics on the human faecal microbiota, we observed that the
oscillatory dynamic in the microbial composition was in correspondence to the metabolism of the administered antibiotics, and
the abundance of the resistant microbial populations. For instance, during the first days of a beta-lactam treatment there was a
dominance of Firmicutes species (Gram-positive), then, a collapse of diversity occurred due to the continuing therapy leading
to a shift toward Bacteroidetes species (Gram-negative) that are considered as naturally resistant to beta-lactams and that also
remained more active during the antibiotic course  (Pérez-Cobas et al. 2013a).  In general, the use of  these broad-spectrum
antibiotics resulted in an increase in the relative abundance of Gram-negative bacteria as Bacteroidaceae or Enterobacteriaceae
families in the microbiota of the patients (Pérez-Cobas et al. 2013a,b). A similar increase in Gram-negative members has been
recently described in a cohort of 21 patients treated for a week with broad spectrum antibiotics, specifically beta-lactams and
fluoroquinolones (Panda et al. 2014).
In agreement with the high inter-individual variability previously described for the human gut microbiota, we found
that each patient exhibited a specific initial microbial assembly, and in consequence an individual response to therapy for both
groups, the infected and non-infected patients (Ahmed et al. 2007, Caporaso et al. 2011, Eckburg et al. 2005, Green et al. 2006) .
We also showed that the initial microbiota composition strongly influenced the shifts  on the intestinal  microbiota during
antibiotic therapy (Pérez-Cobas et al. 2013a,b, 2014). However, the selection of resistant microorganisms after similar antibiotic
treatment, led to microbial assemblies which share some features, regardless of the initial composition. Specifically, properties
of  the antibiotics as the antimicrobial effect and mode of  action influenced the gut microbial composition in a significant
manner. For instance, the clindamycin, which presents a bacteriostatic antimicrobial effect, led the microbiota of  a treated
patient to a  microbial  composition that  largely  differs  from that of  the  other  patients  that  were  treated with bactericidal
antibiotics. In addition, the effect of the mode of action was reflected on the gut microbiota composition, mainly of the active
fraction, since it contained those bacteria able to resist the treatment  (Pérez-Cobas et al. 2013b). A significant influence of
antibiotic mode of action on the modelling of the human gut microbiota was recently described in a cohort of elderly subjects
under antibiotic therapy (O’Sullivan et al. 2013).
The pattern of similarities between the samples of the infected patients showed an influence of the CDI, but also, as expected a
high inter-individual variability. The comparison of the microbiota structure of infected and non-infected patients showed a
lower (although not significant) diversity in the C. difficile positive samples. However, it was found a significant effect due to the
infection by the pathogen in terms of taxa presence and abundance, grouping the infected samples together, despite the large
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overall  variability  aforementioned. The  infected  samples  were  characterized  by  an  over-abundance  of  different  genera  as
Lactobacillus,  Bacteroides or  Enterococcus  and  a  low  representation  of  commensal  members  as  Roseburia,  Coprococcus,
Blautia among others (most of them from Firmicutes phyla).
On the other hand, the metagenomic analysis revealed that the variations caused by the antibiotics and the strength of
the signal due to the antimicrobial effect and mode of action were lower in the gene content than in the microbial structure
(Pérez-Cobas et al. 2013a,b, 2014). This result could be due to the high functional redundancy of the human gut microbiome
previously reported (Lozupone et al. 2012, Qin et al. 2010, The Human Microbiome Project Consortium 2012 Turnbaugh et al.
2010). 
However, the analysis of the metagenomes during the antibiotic courses showed individual responses of the microbiota
also  at  functional  level, for  infected and non-infected patients  (Pérez-Cobas et  al. 2013a,b, 2014). The functional  changes
associated to antibiotics depended on the strategies of the surviving bacteria and its dynamics along the course. For instance, a
patient treated with clindamycin, which had the most different taxonomic composition along the treatment respect  to the
others,  also  showed  a  clearly  distinct  functional  profile,  according  to  the  strategies  of  the  resistant  bacteria, in  this  case
opportunistic pathogens of Enterobacteriaceae family (Escherichia, Klebsiella  and Salmonella). In fact, the gut microbiota of
this  patient  exhibited  a  higher  abundance  of  genes  related  to  pathogenicity  and  others  involved  in  the  synthesis  of
lipopolysaccharides that constitute the main component of the outer membrane for Gram-negative bacteria, as it is the case of
Enterobacteriaceae  family  (Pérez-Cobas  et  al.  2013b).  The  outer  membrane  participates  in  nutrient  uptake  and  confers
resistance against antibiotics, taking advantage this bacterial group under adverse conditions (Doerrler 2006). A mechanism of
antibiotic  response that seems to be quite general  is  related to sugar transport, since a higher presence of  genes from the
phosphotransferase system (PTS) was described for most of the patients during the treatments (Pérez-Cobas et al. 2013b). The
PTS is the main sugar translocation system for bacteria and also participates in different stress responses (Deutscher et al. 2006).
Similarly, enrichment in genes involved in sugar metabolism was described on the gut phage community of antibiotic-treated
mice  as  well  as  on the  gut  microbiota  of  treated  pigs  (Looft  et  al.  2012, Modi  et  al.  2013). In  addition, in  one  of  our
collaborations, it  was  found that antibiotic-treated and obese  individuals  showed higher  and less  balanced sugar anabolic
capability respect to healthy and lean subjects (Hernández et al. 2013). Hence, the beneficial effect of this function may be due
to the role of sugar transporters in counteract osmotic stress, as well as to their participation in the energy metabolism of the
benefited bacteria, giving to them an advantage for survival and colonization on the gut, especially under unstable conditions.
Interestingly, the functional comparison between the metagenomes of  infected and non-infected patients revealed an over-
abundance of carbohydrate transport genes in the infected samples, showing an association of sugar metabolism and pathogen
infection, a point that has been previously described in mice studies (Ng et al. 2013, Theriot et al. 2014). The antibiotic-induced
alterations in the sugar availability and metabolism of the gut microbiota could explain the growing of some opportunistic
pathogens as  C. difficile that has been described as able of  metabolizing carbohydrates liberated by an antibiotic-disturbed
microbiota (Ng et al. 2013). In support to the role of carbohydrates in CDI, a different metabolic study described an increase in
sugar alcohols (as sorbitol, mannitol) in the gut metabolome of animals susceptible to infection (Theriot et al. 2014). 
The analysis of the resistome during antimicrobial treatments supported the claim that antibiotic usage increases the
abundance of resistance genes in microbial communities. Notably, after antibiotic therapy we found not only an increase on the
abundance of resistance genes against the administered antibiotic but also against others, as a side effect. Even more, it was
found a higher relative abundance on multidrug resistance genes, an issue that is concerning in hospital environments. It was
also  reported  a  cross-resistance  increase,  (including  multidrug-resistance  genes)  after  antibiotic  therapy  in  the  phage
community of  the mice gut and also in the swine intestinal microbiota  (Looft et al. 2012, Modi et al. 2013). The final gut
resistome after antibiotic therapy is a complex process principally determined by the initial microbial composition (the initial
resistance genes reservoir), the type of administered antibiotic and the dynamic of the surviving bacteria and the resistance
genes they carried, playing an important role the cross-resistance genes (Pérez-Cobas et al. 2013b).
We also studied the antibiotic-associated changes in the gene expression, protein production and metabolic activity of
the gut microbial community through metatranscriptomics, metaproteomics and meta-metabolomics approaches, respectively
(Pérez-Cobas et al. 2013a).
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The metatranscriptomic analysis of a beta-lactam treated patient showed that at the first days of treatment, the gut
microbial  community  responded  up-regulating  genes  involved  in  avoiding  the  antimicrobial  effects  (as  expressing  beta-
lactamases) and down-regulating genes of the CRISPR/Cas system, which could favour the acquisition of resistance genes, while
during the last days of treatment the up-regulated genes were related to renewal, maintenance and repair of essential molecules.
Besides  this, many of  the  genes  participating in antibiotic  responses  returned to  a  basal  level  after  cessation of  antibiotic
treatment, but the expression of genes of energetic metabolism, which was affected by the previous antibiotic administration,
was restored after therapy. It is important to highlight that after the suppression of the most abundant bacteria during antibiotic
therapies, specific bacterial groups, including minor community members, significantly contribute to the gene expression and
in consequence to the overall metabolism of the community (Pérez-Cobas et al. 2013a).
From  the  meta-metabolomic  analysis  it  is  worth  to  mention  that  not  only  bacterial,  but  also  some  metabolites
produced by the host and further processed by bacteria (derivatives of  bile acids, cholesterol, hormones), decreased during
antibiotic treatment and increased after it, showing how the antibiotics can alter the interplay between the liver/pancreas and
colonic  bacterial  enzymes, possibly  affecting  host  physiological  processes  (Pérez-Cobas  et  al.  2013a). A  similar  result  was
reported for a mouse-based study were antibiotics administration strongly disrupted the metabolic homeostasis of  the gut,
affecting negatively the hormone, bile acid and cholesterol metabolism  (Antunes et al. 2011). Also, during treatment, some
attenuated bacterial  pathways  as  glycolysis,  tricarboxylic  TCA cycle, glutamate  metabolism or  iron uptake, led  to  a  lower
amount of iron, sugars, branched amino acids, short organic acids and pyruvate in the gut environment. Similarly, a study of
rats treated with beta-lactam antibiotics showed a lower abundance of amino acids (mainly tryptophan), carbohydrates, SCFAs,
and TCA cycle metabolites (Zheng et al. 2011). 
The metaproteomic  approach, showed  a  notable  decrease  on protein  production  as  a  consequence  of  treatment.
Important metabolic pathways like glycolysis, tricarboxylic acid cycle, glutamate metabolism, metal uptake or vitamin synthesis
were affected, suggesting that antibiotics negatively influence the overall metabolic status of the gut ecosystem (Pérez-Cobas et
al. 2013a). A related metaproteomic study (in collaboration with our group) also showed that beta-lactam therapies alter the
digestion of  dietary sugars  by the  intestinal  microbiota, which has  detrimental  consequences  for the  metabolic  gut status
(Hernández et  al. 2013). Similar  to the gene expression profiles  during the course, an enrichment of  proteins  involved in
antibiotic responses like antimicrobial peptide transporters or multidrug efflux pumps was found and the proteins expression
seemed to recover after therapy. 
As we previously mentioned, antibiotics disrupt the human gut microbiota favouring infection by C. difficile, which is
the  leading  cause  of  antibiotic-associated diarrhea  and a current  problem in developed countries, since  its  incidence and
severity have increased during the last years. Besides this, the emergence of multidrug resistance strains reduced the efficiency of
the standard treatment, and consequently an increase in the probability of relapses  (Karadsheh & Sule 2013, Ley 2014). Taur
and collaborators suggested that using antibiotics to cure a condition caused by antibiotics is a conceptually incorrect strategy
and that it could be the reason for the high recurrence rates for CDI. In fact, the common treatments for relapse cases consist on
prolonged or pulsed antibiotic courses with low success (Kelly & LaMont 2008, Taur & Pamer 2014). 
Since a healthy gut microbiota is  able to maintain the  pathogen “out of  play” through its  colonization resistance
capacity, restoration of the gut microbiota seems to be the most promising approach to face CDI, especially for recurrent cases.
In this sense it has been proposed a therapy that consists in transferring faeces from a healthy donor to a patient, a process that
is known as faecal microbiota transplantation. The cure rates of faecal transplantation on recurrent CDI patients have been by
far higher than those of the patients treated with conventional antibiotic treatments (Borody et al. 2004, Petrof et al. 2013, Taur
& Pamer 2014, van Nood et al. 2013). However, the microbial ecosystem of faeces is complex, and many biological processes
which occur there remain unknown. This fact  introduces some concerns about faecal  microbial  transplantation, such as a
possible introduction of pathogens, or alterations of microbiota-host interactions that could trigger some microbiota-related
diseases as obesity or metabolic syndrome (Borody & Khoruts 2012, Kassam et al. 2013, Ley 2014, Taur & Pamer 2014). In this
regard, an alternative may be to identify the consortia  of  bacteria  involved in pathogen protection, so that, they could be
administered to patients in an easier and safety way such as probiotics  (Ley 2014, Taur & Pamer 2014). Some recent studies,
including our own work have focused on the identification of bacteria involved in resistance to CDI and its role in colonization
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resistance against this pathogen for both, mice and humans (Antharam et al. 2013, Lawley et al. 2012, Pérez-Cobas et al. 2014,
Petrof et al. 2013, Reeves et al. 2012, Shahinas et al. 2012). Some of the taxa we proposed as candidates to protect against CDI
have also been found in many of these studies, regardless of the methods and models used, suggesting that we are about to
obtain an optimal set of bacteria that can prevent the pathogen colonization. Members of the Clostridiales, principally species
from the families Ruminococcaceae and Lachnospiraceae have been the common factor of the conducted studies (Antharam et
al. 2013, Pérez-Cobas et al. 2014, Reeves et al., 2011, 2012; Vincent et al. 2013). For instance, a recent study showed that 33
strains of a healthy donor were able to cure two patients with recurrent CDI, being 11 strains from the Lachnospiraceae family
(Petrof et al. 2013). A mouse study showed that a strain of Lachnospiraceae was able to partially restore the gut microbiota after
CDI, but the total restoration was only possible when the cecal microbial community of a healthy donor was transferred to the
infected animals  (Reeves et al. 2012). Others genera belonging to these families, such as  Ruminococcus, Subdoligranulum
(Ruminococcaceae) and Roseburia, Coprococcus (Lachnospiraceae) could be involved in colonization resistance since they have
been also depleted in CDI samples from other human studies  (Antharam et al. 2013, Pérez-Cobas et al. 2014, Vincent et al.
2013). Interestingly, unclassified  OTUs  which  belong  to  these  families  have  also  appeared  as  possible  participants  of  the
colonization  resistance  response,  indicating  that  species  with  a  possible  key  role  in  protection  could  remain  undescribed
(Antharam et al. 2013, Pérez-Cobas et al. 2014, Reeves et al. 2012). Moreover, we propose to be tested as protectors against C.
difficile colonization  also  bacteria  from  other  phylum  as  Alistipes (Bacteroidetes),  Escherichia (Proteobacteria)  or
Coriobacteriaceae (Actinobacteria) (Pérez-Cobas et al. 2014).
Most of the bacteria candidates to be protectors have been described as producers of SCFAs, which are the main source
of  energy of  the gut epithelium and that also have anti-inflammatory effects  (Lawley & Walker 2013). In addition, SCFAs
stimulate  defence  barriers  by  increasing  antimicrobial  peptide  levels  and  mucin  production, as  well  as  participate  in  the
generation of a mucosal regulatory T cell subset as part of immune response  (Smith et al. 2013, Wong et al. 2006). Thus, a
proposed mechanism of colonization resistance for this group of bacteria is through the production of SCFAs and the positive
stimulation of the gut epithelial and immune system functions (Lawley & Walker 2013). In this sense, a study that compared
three groups of  individuals, healthy,  C. difficile negative with nosocomial diarrhea and  C. difficile positive with nosocomial
diarrhea, found a lower microbial diversity and abundance of SCFAs producers on the individuals with diarrhea, regardless of
the infection status  (Antharam et al. 2013). Hence, the depletion of  these organisms leads to an epithelial dysfunction and
diarrhea, reinforcing the role of these microbial products in a correct functioning of the gut. In contrast, some studies found
that SCFAs administration to infected mice did not reduce the CDI  (Reeves et al. 2012, Su et al. 1987). Therefore, it is still
unknown if the SCFAs play a leading or secondary role in avoiding the CDI, but it is clear that they contribute positively to
prevent  and  fight  pathogen  infection  through maintaining  and  restoring  the  gut  epithelium  equilibrium  and  stimulating
human defences. 
A different mechanism by which the microbiota could participate in colonization resistance to CDI is through its role
in bile acids transformation. Some  in vitro studies have shown that germination of  C. difficile spores can be stimulated by
primary bile acids produced by the liver and secreted in the small intestine (Sorg & Sonenshein 2008, Wilson 1983). In addition,
recently it has been identified a bile acid receptor of C. difficile required for germination and colonization, supporting the role
of bile metabolism in CDI (Francis et al. 2013). 
Moreover, a fraction of the gut microbiota is involved in the transformation of primary bile acids to secondary bile
acids (Britton & Young 2014, Ridlon et al. 2006, Sorg & Sonenshein 2008). Specifically, the action of the microbial enzyme 7-
dehydroxylase allows to transform the cholate (primary bile acid) into deoxycholate (secondary bile acid). In contrast to the
primary bile acids, the secondary ones, as deoxycholate, strongly inhibit the vegetative growth of the pathogen and reduce the
ability of C. difficile colonization (Britton & Young 2012, Howerton et al. 2013, Sorg & Sonenshein 2010, Taur & Pamer 2014).
Administration of antibiotics alters the bile acid equilibrium leading to higher levels of primary bile acids (cholate) and as a
consequence a higher rate of  C. difficile germination and overgrow  (Antunes et al. 2011, Giel et al. 2010, Pérez-Cobas et al.
2013a). In our meta-metabolomic survey, we also found an imbalance in the levels of bile acid derivatives of the gut microbiota
as consequence of beta-lactam antibiotics administration. Thus, the antimicrobial therapy probably altered the microbial pool
involved in bile  acid metabolism  (Pérez-Cobas et  al. 2013a). Additionally, Theriot  and colleagues  used a mouse  model  to
141
investigate CDI and found that the gut metabolome of animals susceptible to infection was characterized for relative increase in
primary bile acids and reduced level of secondary ones (Theriot et al. 2014). In this manner, Britton and collaborators suggested
that bacteria harbouring the enzyme responsible of  primary bile acid transformation (7-dehydroxylase), could be potential
probiotics against  C. difficile colonization and infection (Britton & Young 2012). Interestingly, the dehydrolase activity in the
gut has been described mainly for members of Clostridia as Clostridium and Eubacterium genera (Begley et al. 2006, Ridlon et
al. 2010). Since many of our identified candidate bacteria to protect against CDI belonged to Clostridia, it is a possibility that
their role in colonization resistance could be related to the metabolism of bile acids (Pérez-Cobas et al. 2014). However, it is so
far unknown, which gut microbial members contribute mostly to this function in vivo. Further studies should focus on testing
the activity of the different bacterial species regarding bile acids transformation. 
Since  the  gut  microbiota  forms  a  complex  metabolic  network  where  the  by-product  of  a  microorganism  is  the
substrate of other, competition for niches and nutrients has been proposed as a resistance mechanism against the establishment
of pathogenic bacteria (Britton & Young 2012, 2014; Lawley & Walker 2013). For instance, mucosal-associated bacteria act as an
extra barrier to pathogen penetration across the epithelium, since the invaders must compete with the microbiota for adhesion
receptors (niche competition) (Juge 2012). Moreover, studies with pathogenic E. coli strains showed that this bacteria compete
with commensal  E.coli strains for nutrients (i.e. sugars) and that commensal members are able to prevent the growth of the
pathogenic strains in the mouse intestine  (Leatham et al. 2009, Maltby et al. 2013).  In the case of  C. difficile, some studies
pointed to the competition for available resources, mainly carbohydratees, as a colonization resistance mechanism. 
In a preliminary study based on continuous flow-cultures it was found that components of the mucin (sialic acids, N-
acetylglucosamine, N-acetylneuraminic  acid)  are  required to  promote  the  expansion  of  intestinal  bacteria  able  to  supress
Clostridium (Wilson & Perini 1988). Recently, a transcriptomic study showed that  C. difficile, is able to use sialic acids as a
carbon source to reach high densities and colonize the mice intestine (Ng et al. 2013). The authors postulated that when the
normal gut microbiota is reduced by antibiotics, sialic acids are liberated for enough bacteria with sialidases but as there are less
sialic acids consumers (competitors) and C. difficile has a great chance for colonization. In this model, colonization resistance
by the gut microbiota works through competition for carbohydrates such as sialic acids, which are a source of energy, carbon
and nitrogen for many bacteria (Vimr et al. 2004). In our work, we found an over-representation of sugar transporters in the
metagenomes of CDI samples, indicating that an alteration of the carbohydrates metabolism of a disrupted microbiota could
favour the C. difficile expansion (Pérez-Cobas et al. 2014). Additionally, we found a candidate protector gene involved in the
metabolism of  N-acetylglucosamine to synthesize pseudaminic acid (sialic-acid-like sugar). The presence of  this compound
may promote the growth of bacterial groups that are better consumers than C. difficile, and therefore they are able of control
the  pathogen  growth.  Taking  into  account  that  the  candidate  bacteria  that  we  proposed  are  phylogenetically  related  to
Clostridium, they may share niche and compete for similar resources. This idea is supported by a study where a non-toxigenic
C. difficile strain was able to prevent the establishment of a toxigenic C. difficile since it was more successful at competing for
limiting resources (Merrigan et al. 2003, Sambol et al. 2002). 
A  direct  mechanism  of  colonization  resistance  by  the  gut  microbiota  against  CDI,  could  be  the  production  of
antimicrobials that inhibit the pathogen growth. Different antimicrobials produced by the gut microbiota (bacteriocins, toxins)
are capable of killing pathogens including C. difficile  (Britton & Young 2012, Lawley & Walker 2013). An intestinal strain of
Bacillus thuringensis produces a bacteriocin named Thuricin CD that has narrow activity against spore-forming Gram-positive
bacteria including C. difficile  (Rea et al. 2010). Although the activity of this bacteriocin has been only tested in  in vitro, this
capacity could represent a possible defence mechanism of  the gut microbiota. In our CDI study we did not found neither
members of  Bacillus genus nor specific antimicrobials as candidate genes against the pathogen colonization, although some
putative  protective  genes  were involved in the  endospore formation of  Bacillus species. Thus, we cannot  discard that  the
presence of Bacillus species may be important for the control of the pathogen. 
The  cross-talk  between  human  immune  system  and  gut  microbiota  could  be  an  indirect  (immune-mediated)
colonization resistance mechanism against CDI. The innate and adaptive immune responses of the host are important to reduce
the acute inflammation associated to CDI, as well as the recurrence of the disease (Hasegawa et al. 2011, 2012; Jarchum et al.
2012). Moreover, these immune-associated responses are at least in part dependent of  beneficial bacteria that stimulate the
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immune system, which in turn target the pathogen  (Buffie & Pamer 2013). However, antibiotic treatments reduce microbial
diversity  and suppress  the  innate  immune system, leading  the  host  to  an immunosupressed state, ideal  for  opportunistic
pathogens as  C. difficile  (Brandl et al. 2008, Lawley & Walker 2013). Commensal members of  Clostridia (as our protective
group) exert a strong influence in development of the host immune system (Atarashi et al. 2011, Bibbò et al. 2014, Francino
2013). It has been described that Clostridia species promote the development of  T-cell receptor intraepithelial lymphocytes
(IEL) and immunoglobulin A (IgA-). The stimulation of the immune system by this commensal group seems to work through a
gradient of SCFAs and secondary bile acids that are sensed by the epithelial cells, triggering the initiation of immunological
signalling (Lopetuso et al. 2013, Umesaki et al. 1999). In relation with the immune system stimulation and the gut epithelial
homeostasis,  we  described  the  products  of  some  metabolic  pathways  related  to  amino  acids  metabolism  (tryptophan  or
polyamines biosynthesis) as protective against CDI. Clostridium species are the most common amino acid fermenting bacteria
of the human gut (Dai et al. 2011). The amino acids catabolism is an important process that produces as a result, metabolites as
SCFAs,  organic  acids,  phenolic  and  indolic  compunds  and  amines,  which  have  a  strong  impact  on  the  gut  epithelium
physiology. Specifically, an  increase  in polyamine levels  is  associated with  a  major  growth of  intestinal  mucosal  cells  and
microorganisms, possibly  contributing to restoration of  the gut equilibrium during stress  conditions, as well  as they have
important anti-inflammatory effects (Dai et al. 2011, Kibe et al. 2014). In a recent collaboration of our group we found that C.
difficile-infected patients  showed a  deficiency  in  the  production  of  polyamines  respect  to  healty  controls,  supporting  the
possible protective role of these metabolites against CDI (Rojo et al. 2015 inpress). 
In summary, antibiotic treatments deplete members of the gut microbiota that through one or various colonization
resistance mechanisms (previously described) would be able to prevent CDI. These mechanisms are summarized in Figure 4.1. 
The gut environment under antibiotic stress is characterized by a low abundance of SCFAs, high abundance of primary
bile acids, high carbohydrate availability, a suppressed immune system and absence of competitors and inhibitors. All these
factors contribute to  C. difficile germination and growth. It is noteworthy that the biology of Clostridia members in the gut
greatly contributes to create an adverse environment for C. difficile germination and colonization. Clostridia class, which are
Gram-positive bacteria, constitutes a great part (10-40%) of the total bacteria of the gut (Hold et al. 2002, Manson et al. 2008).
In addition, it has been recently proposed that Clostridia dominate the more active fraction of the intestinal microbiota and
they are, as a consequence, more susceptible to antibiotic perturbations (Maurice et al. 2013). They populate a region in the
intestinal mucosa close to the epithelium and therefore have a strong influence in physiologic, metabolic and immunological
processes in the gut (Lopetuso et al. 2013, Nava et al. 2011). 
In particular, Clostridia members metabolize diet carbohydrates and produce SCFAs that have several benefits for the
host health, as a source of  energy and stimulating the immune system. This microbial group also participates in bile acids
metabolism, producing secondary metabolites with pathogenic inhibitory capability. Moreover, they would share the niche with
C. difficile  and compite  with  it.  Thus,  these  findings  support  that  species  of  Clostridiales  group  may  be  key  in  the  gut
equilibrium and specifically in colonization resistance against  C. difficile.  Interestingly, an  in vitro study about the effect of
some plant phenolic compounds and aromatic metabolites derived from their metabolization by intestinal bacteria, showed
that those products inhibit the growth of  pathogenic bacteria as  C. difficile, while they enhance the growth of  commensal
species of Clostridium genus (Lee at al. 2006). Further studies are required to test the influence on the gut microbiota of these
products  in vivo. If this could be confirmed, they may be potential candidates for prebiotics or specific dietary supplements
used for stimulating the growth of commensal gut bacteria, maintaining intestinal health and protecting against the pathogen
infection. 
It is very important to find out what is the exact colonization resistance mechanism(s) operating in the gut ecosystem
and which microbial members are implicated. Thereby, it would be possible to design specific diets, prebiotics or probiotics for
patients under antimicrobial therapies in order to prevent and fight CDI, especially recurrent cases.
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Figure 4.1. Possible mechanisms by which the gut microbiota can mediate colonization resistance
against  C. difficile. Direct inhibition can occur through competition for nutrients, the conversion of
nutrients or host metabolites to compounds that are inhibitory to C. difficile or by the production of
microbial  products that inhibit  C.  difficile. Indirect control of  C.  difficile can occur via interactions
between the microbiota and the host that results in the expression of host products that control C.
difficile colonization and growth.  Detection of  microbial-associated molecular  patterns (MAMPs)
can  trigger  the  host  immune  signaling  cascades  leading  to  the  production  of  innate  (e.g.
antimicrobial  peptides)  or  adaptive  (e.g.  IgA)  immune  effectors.  SCFA,  short-chain  fatty  acids
(Adapted from Britton & Young, 2012).
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5. CONCLUSIONS
1- Total  and active human gut bacterial  populations are strongly affected by broad-spectrum antibiotics, and the changes
during therapies are associated to the initial microbial composition and the pharmacodynamic and pharmacological properties
of the administered drug, together with the dynamics of the resistant microbial populations.
2- The use of these broad-spectrum antibiotics promotes drastic changes in the total microbiota with increase of Gram-negative
bacteria as Bacteroidaceae and Enterobacteriaceae families. On the other hand, the active microbiota shows less variations than
the total, since it contains the resistant bacteria, which take longer to be affected by the antibiotics. 
3-  Initial  responses  of  the  gut  microbiota  during  antibiotic  stress  are  directly  related to  avoid  the  antimicrobial  damage,
including high expression of antibiotic resistance genes. In contrast, later during treatment, the microbial responses are directed
towards the renewal, repairing and maintenance of essential cell components.
4- During antibiotic therapies human gut bacteria present an attenuated metabolic status with lower protein production, being
significantly altered the energy metabolism. Also, bacterial pathways related with the host physiology as the metabolism of bile
acid, cholesterol, hormones or vitamins are strongly affected by antibiotics, possibly affecting human health. Moreover, specific
bacterial groups can exert strong influence in the overall gut metabolic status and host interactions during antibiotic-associated
disturbances, highlighting the role of minority community members.
5- The antimicrobial  effect  and the mode of  action of  antibiotics have a significant influence on the evolution of  the gut
microbiota during therapies, despite other influential factors as the initial composition, the diet, or the host immune status.
6-  The survival strategies of the resistant bacteria during antibiotic therapies are reflected in the functional profile of the gut
microbiome. A general mechanism that could confer advantage to bacteria for surviving under antibiotics is related to sugar
metabolism, that counteracts the osmotic stress and favors the energy metabolism. 
7- The genetic composition of the gut resistome after antibiotic therapies is partially determined by the resistance genes carried
by the surviving bacteria and the type of administered antibiotic. Antibiotic use increases the abundance of resistance genes in
the gut environment, including genes unrelated with the class of the administered antibiotics, specially the multidrug resistance
genes.
8-  C. difficile significantly influences the structure of the human gut microbiota, with over-abundance of specific intestinal
genera (including opportunistic as  Enterococcus and Clostridium clusters XI and XIVa) and under-representation of various
commensal members (Ruminococcus, Roseburia, Subdoligranulum). 
9- The alteration of sugar metabolism in the gut due to antibiotic therapy, could favor the infection by opportunistic pathogens,
as C. difficile. 
10- Members of Clostridiales order, principally from Lachnospiraceae and Ruminococcaceae families, play a key role in the gut
ecosystem and seem to be involved in colonization resistance against C. difficile. The protectors members could avoid CDI by
creating an unfavorable environment for the pathogen germination and growth, and also by stimulating the immune system. 
11- Future studies focused on the colonization resistance mechanism(s) operating in the gut ecosystem and the responsible microorganisms, will
allow to design diets, prebiotics and probiotics for patients under antimicrobial therapies in order to prevent infection by pathogens as C. difficile.
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6. SHORT SPANISH VERSION
6.1. INTRODUCCIÓN
El cuerpo humano está poblado por complejas comunidades microbianas (definidas como microbiota) que han colonizado una
gran variedad de regiones como la piel, las vías respiratorias, los órganos reproductores o el tracto gastrointestinal, entre otras
(Charlson et al. 2011, Gao et al. 2007, Grice et al. 2009, Ma et al. 2012, Marchesi 2010, Ravel et al. 2011) . La mayor cantidad de
microorganismos y la diversidad más alta se encuentran en el tracto gastrointestinal donde el número total de microorganismos
supera  el  número total  de  células  humanas en  un orden de  magnitud  (Savage  1977). Dentro del  tracto, la  diversidad va
aumentando desde el estómago al recto, siendo el colon la región más densamente poblada (1013-1014 células) (Leser & Molbak
2009, Marchesi 2011, Whitman et al. 1998).
La mayoría de relaciones que se dan entre las comunidades microbianas y el hospedador son de tipo mutualista por lo
que  ambos  participantes  se  benefician  (Dethlefsen  et  al.  2007).  En  el  caso  de  la  microbiota  intestinal  humana,  los
microorganismos participan en una gran variedad de funciones que benefician al hospedador como la digestión de alimentos
de la dieta y obtención de energía, la síntesis de vitaminas y amino ácidos esenciales, el desarrollo y homeostasis del sistema
inmune, la proliferación, diferenciación y mantenimiento del epitelio intestinal y la protección contra patógenos, entre otras
(Backhed et al. 2004, Hattori & Taylor 2009, Hooper 2004, Leser & Molbak 2009, Montalto et al. 2009) . Los microorganismos
reciben por  su parte  condiciones  estables  de  crecimiento en  cuanto temperatura y  pH así  como una fuente  constante de
nutrientes (Savage 1977). 
La  mayor  cantidad de  microorganismos  del  intestino humano (en términos  de  biomasa), pertenecen al  dominio
bacteria,  sin  embargo  se  han  encontrado  principalmente  7  filos  diferentes  (Bacteroidetes,  Firmicutes,  Proteobacteria,
Actinobacteria, Fusobacteria, Verrucomicrobia  y  Cyanobacteria), perteneciendo un  95% de  las  bacterias  a  Bacteroidetes  y
Firmicutes (Eckburg et al. 2005). En contraste al bajo número de filos se encuentra una gran diversidad a niveles filogenéticos
más bajos, con más de 1000 especies descritas hasta el momento  (Blaser & Falkow 2009, Claesson et al. 2009, Eckburg et al.
2005, Ley et al. 2008b, Rajili -Stojanovi  et al. 2009)ć ć . Además, la composición de la comunidad intestinal presenta una gran
variabilidad  interindividual, lo  que  ha  impedido  definir  las  especies  que  conforman el  "core"  del  intestino  humano. Sin
embargo, dentro de un individuo, en ausencia de perturbaciones, hay una menor variabilidad en la composición microbiana lo
que indica que la microbiota intestinal es única y relativamente estable durante largos períodos de tiempo (Ahmed et al. 2007,
Durbán et al. 2012a, Eckburg et al. 2005, Green et al. 2006, Lozupone et al. 2012, Marchesi 2011, Robinson et al. 2010). 
La composición de la microbiota se ve influenciada por una serie de factores determinísticos como el genotipo del
hospedador, la dieta, la edad, las interacciones entre los miembros del ecosistema, así como por procesos estocásticos tales como
el orden inicial de colonización o el ataque de fagos. Todos estos factores contribuyen a explicar la gran diversidad y variabilidad
interindividual presente en la microbiota intestinal humana  (Claesson et al. 2011, David et al. 2013, Dethlefsen et al. 2006,
Filippo et al. 2010, Flint 2004, Koenig et al. 2011, McKnite et al. 2012, Palmer et al. 2007, Turnbaugh et al. 2008, Vallès et al.
2014).
Por otro lado, el conjunto de genes microbianos de este ecosistema se ha definido como microbioma intestinal y supera
el número total de genes del genoma humano en dos órdenes de magnitud (Yang et al. 2009). A diferencia de la ausencia de un
"core" de especies bacterianas en el intestino humano, la presencia de un gran número de genes compartidos entre individuos
ha permitido definir un "core" funcional. Precisamente, debido al gran número de genes compartidos entre distintas especies
intestinales existe una alta  redundancia funcional en el  microbioma intestinal  (Lozupone et  al. 2012, Qin et  al. 2010, The
Human Microbiome Project Consortium 2012, Turnbaugh et al. 2010). El estudio del microbioma ha permitido conocer que las
funciones más abundantes en los genomas de las bacterias del intestino son importantes para el mantenimiento del equilibro
microbiota-hospedador y que estas están relacionadas principalmente con el metabolismo de los carbohidratos, la producción
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de energía, o la síntesis de amino ácidos esenciales y vitaminas (Gill et al. 2006, Kurokawa et al. 2007, Qin et al. 2010). Una de las
funciones intrínseca de la microbiota consiste en proteger contra infecciones, conocida como capacidad de resistencia a la
colonización por patógenos (Servin 2004). Esta capacidad opera a través de diferentes niveles de defensa, que se clasifican en
dos tipos: directas e indirectas. Los mecanismos de protección directa funcionan a través de interacciones entre la microbiota y
el patógeno, tales como la competencia por nutrientes o nichos, la exclusión metabólica donde el metabolismo de las bacterias
intestinales crea condiciones desfavorables para el patógeno, o mediante la liberación de agentes antimicrobianos, como las
bacteriocinas  (Buffie & Pamer 2013, Lawley & Walker 2013, Lawley et  al. 2012, Stecher & Hardt 2011) . Por otro lado, los
mecanismos  de  protección  indirecta  funcionan  a  través  de  la  estimulación  y  mantenimiento  del  sistema  inmune  del
hospedador, así como controlando la respuesta inflamatoria (Buffie & Pamer 2013, Kamada & Núñez 2014, Kawai & Akira 2009,
Maslowski et al. 2009, Rakoff-Nahoum et al. 2004).
Algunos aspectos de la vida moderna, como el uso de medicamentos (fundamentalmente antibióticos), o las dietas
ricas en grasa, están interfiriendo negativamente con la relación beneficiosa que existe entre la microbiota y el hospedador, lo
que ha desencadenado un aumento en la incidencia de enfermedades asociadas a una microbiota alterada o disbiótica, como la
obesidad, la alergia o el asma, entre otras (Blaser 2011, Francino 2013). En el caso de los antibióticos, aunque algunos tienen
como diana patógenos específicos, la mayoría son de amplio espectro y son comúnmente usados para tratar la mayoría de
infecciones  (Nathan 2004). De esta manera, no sólo los patógenos sino también miembros comunes de la microbiota se ven
afectados por la terapia antimicrobiana, así  como los que están funcionalmente conectados a ellos, provocando una fuerte
perturbación en la comunidad microbiana intestinal y en consecuencia en las funciones que realizan. Uno de los principales
problemas del uso de antibióticos es que promueve la expansión de bacterias resistentes en el intestino, convirtiéndolo en un
reservorio de genes de resistencias que podrían ser transferidas a patógenos (Jernberg et al. 2010, Löfmark et al. 2006, Modi et
al. 2013, Sommer et al. 2009). Por otra parte, se ha comprobado que el uso de antibióticos afecta a funciones de la microbiota,
como la estimulación del sistema inmune, el metabolismo energético o la resistencia a la colonización por patógenos (Brandl et
al. 2008, Buffie et al. 2012, Dessein et al. 2009, Ng et al. 2013, Romick-Rosendale et al. 2009, Ubeda et al. 2013) . Esta última
función juega un papel esencial, ya que cuando la microbiota es suprimida por los antibióticos, patógenos oportunistas como
Salmonella spp., Klebsiella oxytoca o Clostridium difficile pueden causar graves infecciones intestinales (Walk & Young 2008).
C. difficile es el causante más común de la diarrea nosocomial y constituye actualmente un serio problema en salud pública. Su
principal factor de riesgo es la terapia con antibióticos, especialmente la de amplio espectro (Denève et al. 2009, Kuijper et al.
2007). Además, la incidencia y virulencia de la enfermedad han aumentado drásticamente en los últimos años con la aparición
de una cepa hipervirulenta  (McFarland et al. 2002, Wilcox 1998). Por otra parte, la infección por  C. difficile  presenta una
elevada tasa de recurrencia, y las actuales terapias basadas principalmente en la administración de antibióticos tienen un bajo
éxito  (Kelly & LaMont 2008, McFarland et al. 2002, Taur & Pamer 2014, Wilcox 1998). Esto indica una necesidad de nuevos
enfoques que se dirijan hacia una búsqueda de terapias alternativas eficaces para la eliminación del patógeno.
En los últimos años el desarrollo de técnicas moleculares, como la secuenciación del gen que codifica para el  16S
rRNA, las aproximaciones meta-"omicas" (metagenómica, metatranscriptómica, metaproteómica, etc) y la secuenciación de alto
rendimiento, ha incrementado el conocimiento sobre la estructura, funciones y ecología de la microbiota intestinal, así como su
papel en la salud y en la enfermedad (Andersson et al. 2008, Arumugam et al. 2011, Gill et al. 2006, Gosalbes et al. 2011, 2012;
Kurokawa et al. 2007, Marchesi 2010, Qin et al. 2010, Verberkmoes et al. 2009). En el marco de esta nueva tecnología, se ha
comenzado a  estudiar  recientemente  con gran interés  la  interacción de  los  antibióticos  con la  microbiota  intestinal, y  su
repercusión en la salud humana. 
6.2. OBJETIVOS
El objetivo general de esta tesis consistió en caracterizar el efecto de la terapia con antibióticos en la microbiota intestinal
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humana, así como los efectos de la infección del patógeno oportunista Clostridium difficile. 
El  primer objetivo específico consistió en analizar en profundidad, mediante diferentes aproximaciones ómicas, la
evolución de la microbiota fecal de un individuo durante un tratamiento con antibióticos beta-lactámicos. La idea era evaluar
los cambios estructurales (diversidad y composición de la microbiota total y activa) y funcionales (genes, RNAm, proteínas y
metabolitos) del ecosistema microbiano como respuesta al estrés inducido por los antibióticos. Los principales resultados de
este estudio se encuentran publicados en el artículo científico: "Gut microbiota disturbance during antibiotic therapy: a multi-
omic approach" (capitulo 3.1).
El segundo objetivo específico de este proyecto consistió en estudiar el efecto de diferentes clases de antibióticos en la
microbiota intestinal humana. Específicamente, queríamos comprobar si las diferencias en cuanto espectro, modo de acción y
efecto antimicrobiano que presentaban los antibióticos utilizados, se reflejaban en los cambios asociados de la microbiota total,
activa y en el contenido génico, de manera significativa. Además queríamos estudiar la evolución de los genes de resistencia
(resistoma) y su relación con el tipo de antibióticos. Los principales resultados de este estudio se publicaron en el artículo
"Differential effects of antibiotic therapy on the structure and function of human gut microbiota" (capítulo 3.2).
El  tercer  objetivo  consistió  en estudiar  efecto  de  la  infección por  C. difficile  en  una microbiota  alterada  por  los
antibióticos. En primer lugar, se querían evaluar los cambios de la microbiota intestinal (estructurales y funcionales) debido a la
infección por  el  patógeno. Por  otra  parte, se  querían  identificar  microorganismos  y  funciones  metabólicas  asociadas  a  la
infección, así como otras bacterias y funciones que podrían estar implicadas en la protección contra la colonización por este
patógeno. Este trabajo se encuentra publicado en el artículo "Structural and functional changes in the gut microbiota associated
to Clostridium difficile infection" (capítulo 3.3).
6.3. METODOLOGÍA
El  total  de pacientes incluidos en los  estudios  de esta  tesis  provienen del  Departamento de Medicina Interna del  hospital
universitario Shleswig-Holstein en Kiel, Alemania, enmarcados en un proyecto europeo sobre la microbiota intestinal humana,
el uso de antibióticos y la infección por C. difficile (ERA-NET project on C. difficile). Todos los pacientes recibieron terapia con
antibióticos de amplio espectro durante su estancia en el hospital, pero no en los seis meses previos a su entrada. Todos los
pacientes fueron sometidos a la detección de C. difficile mediante reacción en cadena de la polimerasa (en inglés, PCR) de los
genes que codifican las toxinas  tcdA  y tcdB, así como el gen que codifica la triosa fosfato isomerasa (tpi) del patógeno. Se
tomaron  muestras  de  heces  de  cada  uno  de  los  pacientes  antes,  durante  y  después  de  la  terapia  con  antibióticos  y  se
mantuvieron congelados en tubos estériles a -80º hasta su procesamiento. Dentro del capítulo 3.3 en la tabla 1 se encuentra
resumida la información referente a los pacientes de todos los estudios que comprende esta tesis.
En los diferentes estudios utilizamos dos tipos de aproximaciones, las basadas en el gen que codifica para el RNA
ribosomal 16S y las “meta-omicas”, seguidas por la pirosecuenciación del material obtenido con un secuenciador Roche GS FLX
y química de Titanium (excepto para la metabolómica y metaproteómica).
Para caracterizar los cambios asociados a las terapias con antibióticos en la composición y diversidad de la microbiota
total y la fracción activa, nos basamos en el gen del RNA ribosomal 16S (16S rDNA) y en el transcrito de dicho gen (16S rRNA),
respectivamente. Para estudiar la microbiota total se extrajo el DNA total de las heces y se realizaron “PCRs” del gen que codifica
para el  16S rRNA. En el caso de la fracción activa de la microbiota se realizó una extracción del RNA total de las heces, se
procedió a su retrotranscripción, obtención de cDNA y posterior secuenciación. Las secuencias resultantes de ambos grupos se
analizaron bioinformáticamente y se clasificaron taxonómicamente con la base de datos Ribosomal Database Project (RDP)
(Cole  et  al.  2009). Para  ambos  grupos  se  realizaron  varios  análisis  ecológicos, así  como estadísticos  (especificados  en  los
materiales y métodos de los capítulos 3.1, 3.2 y 3.3).  La mayoría de análisis se realizaron utilizando los programas QIIME
(Caporaso et al. 2010) y R (R Development Core Team, 2011).
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 La caracterización del contenido génico de las muestras (metagenomas) se realizó mediante la extracción del  DNA
total y secuenciación directa de éste, lo que nos permitió describir el total de genes, y como cambian las funciones metabólicas
para las que codifican durante las terapias antimicrobianas.
Por  otro  lado,  el  análisis  de  la  expresión  total  de  los  genes  en  la  comunidad  microbiana  de  las  muestras
(metatranscriptómica), se basó en la extracción del RNA total, seguida de la eliminación del RNA ribosomal y purificación del
RNA mensajero, a partir del que se obtuvo el correspondiente cDNA que fue secuenciado. 
Para la obtención de los metaproteomas, se extrajeron de las muestras de heces las proteínas totales y se sometieron a
una cromatografía de líquidos de ultra alta eficacia acoplada a un intrumento Orbitrap MS 2  (UPLC-LTQ Orbitrap-MS/MS)
para  la  identificación  de  las  proteínas. Finalmente, los  meta-metabolomas  se  obtuvieron a  través  de  la  extracción  de  los
metabolitos  totales  y  se  identificaron posteriormente  mediante  la  aplicación de  una cromatografía  líquida  de  alta  eficacia
acoplada a un espectómetro de masas ESI-QTOF. Estas últimas dos aproximaciones ómicas se llevaron a cabo  en diferentes
laboratorios con los que colaboramos.
Las  secuencias  obtenidas  para  los  metagenomas,  metatranscriptomas  y  metaproteomas  se  procesaron
bioinformáticamente y se anotaron funcionalmente contra la base de datos TIGRFAM, mientras que la información de los
metabolitos fue también procesada y se clasificaron usando la base de datos MELTIN (Haft et al. 2003, Smith et al. 2005). Los
metatranscriptomas y metaproteomas fueron mapeados sobre los metagenomas con los que comparten su anotación funcional.
Se realizaron una serie de análisis bioinformáticos, ecológicos y estadísticos con los datos funcionales obtenidos a través de estas
técnicas, utilizando, en la  mayoría de los casos  paquetes del  programa R (R Development Core Team, 2011). Los detalles
específicos  de  análisis  de  los  metagenomas  se  encuentran  en  los  capítulos  3.1,  3.2  y  3.3,  mientras  que  los  de  los
metatranscriptomas, metaproteomas y meta-metabolomas se encuentran en el capítulo 3.1. 
Las secuencias procedentes de los diferentes estudios fueron depositadas en la base de datos pública “European Bioinformatics
Institute database”.
6.4. RESULTADOS Y CONCLUSIONES
En el capítulo 3.1 realizamos un seguimiento de la microbiota intestinal de un único paciente bajo terapia de antibióticos beta-
lactámicos  a  través  de  la  integración  de  diferentes  herramientas  moleculares  (basadas  en  el  16S  rRNA,  metagenómica,
metatranscriptómica, metaproteómica  y  meta-metabolómica), constituyendo  así,  el  primer  estudio  multi-ómico  donde  se
evaluó la respuesta de la microbiota al daño ocasionado por los antibióticos a varios niveles biológicos  (Pérez-Cobas et al.
2013a). 
A  consecuencia  de  esta  investigación  llegamos  a  la  conclusión  de  que  la  aplicación  conjunta  de  esta  serie  de
aproximaciones  moleculares  constituye  una poderosa  herramienta  para  una  caracterización en detalle  de  la  composición,
diversidad, funcionalidad y ecología de la comunidad microbiana intestinal, así como su respuesta a perturbaciones como son
las inducidas por el estrés antibiótico.
En primer lugar, describimos como los cambios en la composición de la microbiota intestinal debido al tratamiento se
corresponden con el metabolismo de la droga y con la dinámica de crecimiento de las poblaciones bacterianas resistentes.
Por  otro  lado,  encontramos  que  la  respuesta  inicial  de  la  microbiota  intestinal  al  estrés  inducido  por  los  beta-
lactámicos está enfocada a evitar el efecto dañino directo de los antimicrobianos, con una alta expresión de genes codificantes
de resistencias, como por ejemplo bombas exportadoras de drogas. Por el contrario, tras varios días de tratamiento la respuesta
de la microbiota está más dirigida a la renovación, reparación y mantenimiento de componentes celulares esenciales. 
Además,  observamos  que  durante  los  tratamientos  con  antibióticos  las  bacterias  intestinales  presentan  un
metabolismo atenuado con una producción de proteínas más baja que en condiciones de normalidad, afectando a procesos
biológicos  tales  como  el  metabolismo  energético.  No  sólo  se  ven  afectadas  rutas  metabólicas  importantes  para  los
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microorganismos sino también para la fisiología del hospedador, tales como el metabolismo de los ácidos biliares, el colesterol y
las hormonas, al igual que la síntesis de vitaminas, lo que puede tener consecuencias negativas en la salud humana. 
Una  observación  relevante  de  este  trabajo  fue  el  hecho  de  que  algunos  miembros  específicos  de  la  microbiota
intestinal, especialmente grupos minoritarios pueden jugar un papel importante en el estado metabólico global del intestino y
su equilibrio, cuando miembros mayoritarios de la microbiota han sido afectados por los antibióticos. 
En el capítulo 3.2 realizamos seguimientos de la microbiota intestinal de cuatro individuos que estaban siendo tratados
con  antibióticos  de  diferentes  clases.  Los  antibióticos  presentaban  los  dos  tipos  de  efecto  antimicrobiano:  bactericidas  y
bacterioestáticos. Además, también presentaban diferentes modos de acción: inhibidores de la replicación celular, inhibidores de
la síntesis de proteínas e inhibidores de la síntesis de la pared celular. En este trabajo, a través del uso de aproximaciones basadas
en el  16S rRNA y metagenómica evaluamos el efecto de estas propiedades en el modelado de la microbiota total, la fracción
activa  y  en  el  contenido  genético  total  (potencial  funcional)  de  la  microbiota.  Además,  analizamos  posibles  respuestas
funcionales de la microbiota al estrés con antibióticos, incluyendo la evolución de los genes de resistencia a lo largo de los
tratamientos (Pérez-Cobas et al. 2013b). 
En  este  trabajo  observamos  que  el  carácter  único  de  la  microbiota  intestinal  humana  se  refleja  en  los  cambios
asociados a antibióticos, encontrándose grandes diferencias entre individuos en cuanto a la diversidad, composición y potencial
genético de la comunidad microbiana intestinal durante terapias similares. 
Por otro lado, las propiedades de los antibióticos como el efecto antimicrobiano (bactericida o bacteriostático) y el
modo de acción también resultaron ejercer una influencia significativa en la composición de la fracción total y activa de la
microbiota. Así, a pesar de que una gran variabilidad es introducida por factores como la composición inicial de la microbiota,
la dieta o el estado de salud del hospedador, tratamientos con antibióticos similares moldean la microbiota de una manera
similar, dirigiendo el ecosistema intestinal hacia una estructura final donde comparten ciertas características. 
En cuanto a las respuestas funcionales al estrés antibiótico destacan el transporte y metabolismo de azúcares, que
podrían conferir ventaja a las bacterias para sobrevivir en condiciones adversas, como la que generan los antibióticos. Este
efecto beneficioso puede deberse al papel de los transportadores de azúcares en contrarrestar el estrés osmótico, así como en
favorecer el metabolismo energético de estas bacterias, lo que lleva a un mayor crecimiento poblacional. Además, los cambios en
el perfil funcional del microbioma intestinal en respuesta a los antibióticos, se corresponden con las estrategias de supervivencia
de las bacterias resistentes al tratamiento. Por ejemplo, un incremento en miembros de la familia  Enterobacteriaceae durante
una de las terapias con antibióticos, se correspondió con un aumento en la abundancia relativa de genes que participan en la
síntesis de la membrana externa de bacterias Gram-negativas, como las pertenecientes a esta familia. La membrana externa es
importante  para la  obtención de  nutrientes  y  confiere resistencia contra los  antibióticos, dándole  ventaja  a  este  grupo de
bacterias durante condiciones de estrés.
En cuanto al análisis del resistoma observamos que la toma de antibióticos provoca un aumento en la abundancia
relativa de los genes de resistencia. El incremento ocurre no sólo en aquellos genes que confieren resistencia contra el antibiótico
administrado sino también en genes de resistencias a otros antibióticos como parte de un efecto colateral. El ejemplo más claro
que encontramos de este efecto, fue el aumento en abundancia de genes que confieren resistencia a múltiples antibióticos. Con
respecto  a la  composición genética del  resistoma intestinal  después de terapias con antibióticos, vimos que es un proceso
complejo definido principalmente por los genes de resistencia de las bacterias que sobreviven, así como de las propiedades del
antibiótico administrado. 
En el capítulo 3.3 de una manera similar a los dos estudios previos realizamos un estudio de seguimiento de tres individuos
tratados  con antibióticos  de  amplio  espectro, pero  en  este  caso  los  pacientes  presentaron  una  infección  por  el  patógeno
intestinal C. difficile. También usamos la pirosecuenciación del gen 16S rRNA y la metagenómica para caracterizar los cambios
estructurales y funcionales debidos al tratamiento con antibióticos pero fundamentalmente a la infección por C. difficile. Por
otra parte, realizamos un análisis comparativo de este grupo de pacientes infectados con los pacientes de los dos estudios
previos, que a pesar de haber recibido tratamiento con antibióticos no desarrollaron infección (Capítulos 3.1 y 3.2). Estas
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comparaciones estadísticas nos permitieron identificar bacterias y funciones posiblemente relacionadas con la infección por C.
difficile  y otras implicadas en la protección contra la infección por el patógeno. Además, hicimos uso de redes bayesianas de
correlación  para  identificar  otras  bacterias  y  genes  también  posiblemente  implicados  en  la  resistencia  a  la  colonización,
basándonos en una asociación (correlación positiva) con las bacterias y genes previamente identificados como candidatos a ser
protectores (Pérez-Cobas et al. 2014).
En esta investigación encontramos una influencia significativa de la infección por  C. difficile  en la estructura de la
microbiota  intestinal  con  una  alta  representación  de  géneros  bacterianos  específicos  (generalmente  microorganismos
oportunistas como algunos del género Enterococcus y los grupos Clostridium XI y XIVa) y una baja abundancia de miembros
comensales como Ruminococcus, Roseburia, Subdoligranulum, Blautia o Coprococcus.
El  análisis  de los  metagenomas indicó que los  antibióticos  introducen un desequilibrio en el  metabolismo de los
azúcares de la dieta por parte de la microbiota intestinal y que esta alteración podría favorecer la infección por C. difficile.
Tras la identificación de bacterias protectoras en el análisis comparativo y la aplicación de redes bayesianas se encontró
que miembros del orden filogenético Clostridiales, principalmente de las familias Lachnospiraceae y Ruminococcaceae, que
juegan un papel esencial en el ecosistema intestinal, podrían estar implicadas en la resistencia a la colonización por C. difficile.
La identificación de rutas metabólicas candidatas a participar en la resistencia a la colonización por C. difficile sugiere
que  los  miembros  protectores  de  la  microbiota  podrían  crear  (como  parte  de  su  metabolismo  y  funciones  naturales)
condiciones desfavorables para la germinación y crecimiento del patógeno y además podrían participar en la estimulación del
sistema inmune del hospedador, evitando así la infección. 
Finalmente,  es  de  destacar  que  las  redes  bayesianas  de  correlación  que  han  sido  poco  utilizadas  en  este  campo
constituyen unas herramientas prometedoras en la exploración de asociaciones ecológicas en la comunidad microbiana del
intestino.  En nuestro estudio fueron utilizadas para ampliar  el  grupo de bacterias y genes candidatos a proteger contra la
infección por C. difficile.
En  conclusión,  los  antibióticos  ejercen  una  gran  influencia  negativa  en  el  ecosistema  intestinal,  viéndose  afectada  la
composición,  diversidad  y  actividad  de  la  microbiota,  y  como  consecuencia  las  funciones  beneficiosas  que  las  bacterias
intestinales aportan al hospedador. Este es el caso de la capacidad de resistencia a la colonización por patógenos como  C.
difficile, una función que se ve debilitada durante las terapias antimicrobianas. Los antibióticos causan grandes variaciones en la
abundancia relativa de microorganismos clave en el ecosistema intestinal, viéndose afectado el estado metabólico global del
intestino  y  en  consecuencia  la  fisiología  del  hospedador.  Además,  son  frecuentes  drásticas  reducciones  en  la  diversidad
microbiana  durante  los  tratamientos,  incluyendo  una  pérdida  definitiva  de  algunas  especies.  La  ausencia  de  bacterias
protectoras  favorece  la  germinación y el  crecimiento de patógenos oportunistas  como  C. difficile. Así, en  nuestro estudio
proponemos un grupo de microorganismos y funciones que podrían estar implicadas en evitar la infección de este patógeno.
Futuros estudios permitirán clarificar si los taxones identificados están realmente implicados en la resistencia a la colonización y
a través de qué mecanismo biológico. De esta manera será posible diseñar dietas, prebióticos y probióticos para pacientes bajo
terapia antibiótica con el fin de prevenir y tratar la infección por C. difficile, especialmente los casos recurrentes.
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METATRANSCRIPTOMIC APPROACH TO ANALYZE THE FUNCTIONAL HUMAN GUT MICROBIOTA. 
Gosalbes MJ, Durbán A, Pignatelli M, Abellan JJ, Jiménez-Hernández N, Pérez-Cobas AE, Latorre A, Moya A. 
PLoS One. 6(3):e17447. 2011. 
ABSTRACT
The human gut is  the natural habitat for a large and dynamic bacterial  community that has a great  relevance for health.
Metagenomics is increasing our knowledge of gene content as well as of functional and genetic variability in this microbiome.
However,  little  is  known  about  the  active  bacteria  and  their  function(s)  in  the  gastrointestinal  tract.  We  performed  a
metatranscriptomic  study  on  ten  healthy  volunteers  to  elucidate  the  active  members  of  the  gut  microbiome  and  their
functionality under conditions of  health. First, the microbial cDNAs obtained from each sample were sequenced using 454
technology.  The  analysis  of  16S  transcripts  showed  the  phylogenetic  structure  of  the  active  microbial  community.
Lachnospiraceae, Ruminococcaceae, Bacteroidaceae, Prevotellaceae, and Rickenellaceae were the predominant families detected
in the active microbiota. The characterization of mRNAs revealed a uniform functional pattern in healthy individuals. The main
functional roles of the gut microbiota were carbohydrate metabolism, energy production and synthesis of cellular components.
In contrast, housekeeping activities such as amino acid and lipid metabolism were underrepresented in the metatranscriptome.
Our results provide new insights into the functionality of the complex gut microbiota in healthy individuals. In this RNA-based
survey, we also detected small RNAs, which are important regulatory elements in prokaryotic physiology and pathogenicity. 
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METAGENOMICS OF HUMAN MICROBIOME: BEYOND 16S rDNA.  
Gosalbes MJ, Abellan JJ, Durbán A, Pérez-Cobas AE, Latorre A, Moya A. 
Clinical Microbiology and Infection.18 Suppl 4:47-9. 2012. 
ABSTRACT
The gut microbiota presents a symbiotic relationship with the human host playing a beneficial role in human health. Since its
establishment, the bacterial community is subjected to the influence of many different factors that shape its composition within
each individual. However, an important convergence is observed at functional level in the gut microbiota. A metatranscriptomic
study  of  healthy  individuals  showed  homogeneity  in  the  composition  of  the  active  microbiota  that  increased  further  at
functional level. 
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FUNCTIONAL  CONSEQUENCES  OF  MICROBIAL  SHIFTS  IN  THE  HUMAN  GASTROINTESTINAL  TRACT
LINKED TO ANTIBIOTIC TREATMENT AND OBESITY.
Hernández E, Bargiela R, Diez MS, Friedrichs A, Pérez-Cobas AE, Gosalbes MJ, Knecht H, Martínez-Martínez M, Seifert J, von
Bergen M, Artacho A, Ruiz A, Campoy C, Latorre A, Ott SJ, Moya A, Suárez A, Martins dos Santos VA, Ferrer M. 
Gut Microbes. 4(4):306-15. 2013. 
ABSTRACT
The microbiomes in the gastrointestinal tract (GIT) of individuals receiving antibiotics and those in obese subjects undergo
compositional shifts, the metabolic effects and linkages of which are not clearly understood. Herein, we set to gain insight into
these effects, particularly with regard to carbohydrate metabolism, and to contribute to unravel the underlying mechanisms and
consequences for health conditions. We measured the activity level of  GIT carbohydrate-active enzymes toward 23 distinct
sugars in adults patients (n = 2) receiving 14-d -lactam therapy and in obese (n = 7) and lean (n = 5) adolescents. We observedβ
that  both 14 d antibiotic-treated and obese subjects showed higher and less balanced sugar anabolic capacities, with 40%
carbohydrates being preferentially processed as compared with non-treated and lean patients. Metaproteome-wide metabolic
reconstructions confirmed that the impaired utilization of sugars propagated throughout the pentose phosphate metabolism,
which had adverse consequences for the metabolic  status of  the GIT microbiota. The results point to an age-independent
positive association between GIT glycosidase activity and the body mass index, fasting blood glucose and insulin resistance (r
( 2)  0.95). Moreover, antibiotics altered the active fraction of enzymes controlling the thickness, composition and consistency≥
of the mucin glycans. Our data and analyses provide biochemical insights into the effects of antibiotic usage on the dynamics of
the GIT microbiota and pin-point presumptive links to obesity. The knowledge and the hypotheses generated herein lay a
foundation for  subsequent, systematic  research  that  will  be  paramount  for  the  design of  "smart"  dietary  and therapeutic
interventions to modulate host-microbe metabolic co-regulation in intestinal homeostasis. 
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CLOSTRIDIUM  DIFFICILE HETEROGENEOUSLY  IMPACTS  INTESTINAL  COMMUNITY  ARCHITECTURE
BUT DRIVES STABLE METABOLOME RESPONSES. 
Rojo D, Gosalbes MJ, Ferrari R, Pérez-Cobas AE, Hernández E, Oltra R, Buesa J, Latorre A, Barbas C, Ferrer M, Moya A. 
ISME Journal (in press). 2015.
ABSTRACT
Clostridium difficile-associated diarrhoea (CDAD) is caused by C. difficile toxins A and B and represents a serious emerging
health problem. Yet, its progression and functional consequences are unclear. We hypothesised that C. difficile can drive major
measurable metabolic changes in the gut microbiota and that a relationship with the production or absence of toxins may be
established. We tested this hypothesis by performing metabolic profiling on the gut microbiota of patients with C. difficile that
produced (n=6) or did not produce (n=4) toxins and on non-colonised control patients (n=6), all of whom were experiencing
diarrhoea.  We  report  a  statistically  significant  separation  (p-value<0.05)  among  the  three  groups,  regardless  of  patient
characteristics, duration of the disease, antibiotic therapy, and medical history. This classification is associated with differences
in the production of distinct molecules with presumptive global importance in the gut environment, disease progression and
inflammation. Moreover, while severe impaired metabolite production and biological deficits were associated with the carriage
of C.  difficile that  did  not  produce  toxins,  only  previously  unrecognised  selective  features,  namely,  choline-  and
acetylputrescine-deficient  gut  environments,  characterised  the  carriage  of  toxin-producing  C.  difficile.  Additional  results
demonstrated that the changes induced by C. difficile become marked at the highest level of the functional hierarchy, namely
the metabolic activity exemplified by the gut microbial metabolome regardless of heterogeneities that commonly appear below
the functional level (gut bacterial composition). We discuss possible explanations for this effect and suggest that the changes
imposed by CDAD are much more defined and predictable than previously thought.
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METAGENÓMICA DEL MICROBIOMA INTESTINAL HUMANO.
Pérez-Cobas AE, Gosalbes MJ, Latorre A, Moya A.
Revista de la Sociedad Española de Microbiología. Número 54. Especial “Taxonomía, Filogenia y Diversidad”. 2012. 
RESUMEN
A lo  largo  de  la  evolución  los  mamíferos  han  establecido  simbiosis  con  microorganismos  que  han  colonizado  diferentes
regiones del cuerpo humano tales como la piel, las mucosas, el tracto gastrointestinal, etc. Al conjunto de ellos se le denomina
«microbiota». La mayor densidad de microorganismos se concentra en el tracto gastrointestinal, constituyendo de hecho uno de
los ecosistemas más complejos de toda la biosfera. La microbiota gastrointestinal participa en una serie de funciones esenciales
para el  hospedador, como la  digestión de polisacáridos de  la  dieta, el  metabolismo de las  grasas, la  síntesis  de  vitaminas
esenciales, la renovación del epitelio intestinal, el desarrollo del sistema inmune y la protección contra patógenos. Debido a su
importancia,  alteraciones  en  la  microbiota  tienen  una  gran  repercusión  en  la  salud  humana,  estando  relacionados  con
enfermedades de gran impacto, como la obesidad, la colitis o el cáncer, por citar algunas. La metagenómica estudia los genomas
de los microorganismos de un determinado hábitat sin necesidad de aislarlos y cultivarlos. El uso de esta técnica combinada con
las nuevas tecnologías de secuenciación masiva ha permitido un gran avance en el estudio de la ecología y la diversidad de las
comunidades microbianas de prácticamente cualquier ambiente.
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SUCCESSION OF THE GUT MICROBIOTA IN THE COCKROACH BLATTELLA GERMANICA.
Carrasco P, Pérez-Cobas AE, van de P, Baixeras J, Moya A, Latorre A. 
International Microbiology. 17:99-109. 2014. 
ABSTRACT
The cockroach gut harbors a wide variety of microorganisms that, among other functions, collaborate in digestion and act as a
barrier against pathogen colonization. Blattabacterium, a primary endosymbiont, lives in the fat body inside bacteriocytes and
plays an important role in nitrogen recycling. Little is known about the mode of acquisition of gut bacteria or their ecological
succession throughout the insect life cycle. Here we report on the bacterial taxa isolated from different developmental instars of
the cockroach Blattella germanica. The bacterial load in the gut increased two orders of magnitude from the first to the second
nymphal  stage,  coinciding  with  the  incorporation  of  the  majority  of  bacterial  taxa,  but  remained  similar  thereafter.
Pyrosequencing of the hypervariable regions V1–V3 of the 16S rRNA genes showed that the microbial composition differed
significantly between adults and nymphs. Specifically, a succession was observed in which  Fusobacterium accumulated with
aging, while  Bacteroides decreased.  Blattabacterium was the only symbiont found in the ootheca, which makes the vertical
transmission of gut bacteria an unlikely mode of acquisition. Scanning electron microscopy disclosed a rich bacterial biofilm in
third instar nymphs, while filamentous structures were found exclusively in adults. 
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DIET SHAPES THE GUT MICROBIOTA OF THE OMNIVOROUS COCKROACH BLATELLA GERMANICA. 
Pérez-Cobas AE, Maiques E, Angelova A, Carrasco P, Moya A, Latorre A. 
FEMS Microbiology Ecology (in press). 2015. 
ABSTRACT
The gut microbiota of insects contributes positively to the physiology of  its host mainly by participating in food digestion,
protecting against pathogens, or provisioning vitamins or amino acids, but the dynamics of this complex ecosystem is not well
understood so far. In this study, we have characterized the gut microbiota of the omnivorous cockroach Blattella germanica by
pyrosequencing the hypervariable regions V1–V3 of the 16S rRNA gene of the whole bacterial community. Three diets differing
in the protein content (0, 24 and 50%) were tested at two time points in lab-reared individuals. In addition, the gut microbiota
of wild adult cockroaches was also analyzed. In contrast to the high microbial richness described on the studied samples, only
few species are shared by wild and lab-reared cockroaches, constituting the bacterial core in the gut of B. germanica. Overall, we
found that the gut microbiota of B. germanica is highly dynamic as the bacterial composition was reassembled in a diet-specific
manner over a short time span, with no-protein diet promoting high diversity, although the highest diversity was found in the
wild cockroaches analyzed. We discuss how the flexibility of the gut microbiota is probably due to its omnivorous life style and
varied diets.
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